CA2539731A1 - Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases - Google Patents
Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases Download PDFInfo
- Publication number
- CA2539731A1 CA2539731A1 CA002539731A CA2539731A CA2539731A1 CA 2539731 A1 CA2539731 A1 CA 2539731A1 CA 002539731 A CA002539731 A CA 002539731A CA 2539731 A CA2539731 A CA 2539731A CA 2539731 A1 CA2539731 A1 CA 2539731A1
- Authority
- CA
- Canada
- Prior art keywords
- het ring
- alkyl
- substituted
- unsubstituted
- once
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002253 acid Substances 0.000 title claims description 25
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title abstract description 20
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title abstract description 20
- 239000003112 inhibitor Substances 0.000 title description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 89
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 10
- 230000006378 damage Effects 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 208000014674 injury Diseases 0.000 claims abstract description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 5
- 206010003246 arthritis Diseases 0.000 claims abstract description 5
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- 210000002808 connective tissue Anatomy 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 208000036487 Arthropathies Diseases 0.000 claims abstract description 3
- 206010006895 Cachexia Diseases 0.000 claims abstract description 3
- 208000017667 Chronic Disease Diseases 0.000 claims abstract description 3
- 208000012659 Joint disease Diseases 0.000 claims abstract description 3
- 208000000112 Myalgia Diseases 0.000 claims abstract description 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims abstract description 3
- 206010040070 Septic Shock Diseases 0.000 claims abstract description 3
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims abstract description 3
- 208000025865 Ulcer Diseases 0.000 claims abstract description 3
- 230000001154 acute effect Effects 0.000 claims abstract description 3
- 208000022531 anorexia Diseases 0.000 claims abstract description 3
- 230000004097 bone metabolism Effects 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims abstract description 3
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 3
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 3
- 230000003137 locomotive effect Effects 0.000 claims abstract description 3
- 210000004417 patella Anatomy 0.000 claims abstract description 3
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 3
- 230000036303 septic shock Effects 0.000 claims abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 3
- 230000036269 ulceration Effects 0.000 claims abstract description 3
- -1 benzimidazalinyl Chemical group 0.000 claims description 144
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 89
- 125000000217 alkyl group Chemical group 0.000 claims description 73
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 62
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 150000003857 carboxamides Chemical class 0.000 claims description 28
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 25
- 125000004076 pyridyl group Chemical group 0.000 claims description 23
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 23
- 125000001544 thienyl group Chemical group 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 208000002991 Ring chromosome 4 syndrome Diseases 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 208000032826 Ring chromosome 3 syndrome Diseases 0.000 claims description 18
- 125000002541 furyl group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 17
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 17
- 208000032825 Ring chromosome 2 syndrome Diseases 0.000 claims description 16
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 16
- 125000000335 thiazolyl group Chemical group 0.000 claims description 16
- 208000035217 Ring chromosome 1 syndrome Diseases 0.000 claims description 15
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 229910052717 sulfur Chemical group 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 13
- 125000002757 morpholinyl group Chemical group 0.000 claims description 13
- 125000001624 naphthyl group Chemical group 0.000 claims description 13
- 125000004193 piperazinyl group Chemical group 0.000 claims description 13
- 125000003386 piperidinyl group Chemical group 0.000 claims description 13
- 125000004434 sulfur atom Chemical group 0.000 claims description 12
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 11
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 9
- 125000005509 dibenzothiophenyl group Chemical group 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- VVWUWTAURHNLGY-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinolin-2-ium-1-carboxylate Chemical compound C1CCCC2C(C(=O)O)NCCC21 VVWUWTAURHNLGY-UHFFFAOYSA-N 0.000 claims description 7
- APNFMEVVIUSJSX-UHFFFAOYSA-N 2-(2-methylphenyl)phenol Chemical compound CC1=CC=CC=C1C1=CC=CC=C1O APNFMEVVIUSJSX-UHFFFAOYSA-N 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 6
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 6
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 claims description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 6
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 6
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 6
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 5
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims description 5
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 5
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 5
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 5
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 5
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 5
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 claims description 5
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 5
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 5
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 5
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 230000005526 G1 to G0 transition Effects 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 125000002785 azepinyl group Chemical group 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 125000004069 aziridinyl group Chemical group 0.000 claims description 5
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 5
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 5
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 5
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 5
- 125000004623 carbolinyl group Chemical group 0.000 claims description 5
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 claims description 5
- 238000001212 derivatisation Methods 0.000 claims description 5
- 125000000532 dioxanyl group Chemical group 0.000 claims description 5
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 5
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000003838 furazanyl group Chemical group 0.000 claims description 5
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 5
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 5
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 5
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 5
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims description 5
- 125000005438 isoindazolyl group Chemical group 0.000 claims description 5
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 5
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 5
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 5
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims description 5
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 claims description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 5
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 5
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 claims description 5
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 claims description 5
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims description 5
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 5
- 125000005954 phenoxathiinyl group Chemical group 0.000 claims description 5
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims description 5
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 5
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 5
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 5
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 5
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 5
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 5
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 claims description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 5
- 125000004306 triazinyl group Chemical group 0.000 claims description 5
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 5
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- PNMYVXTZMXEHSF-UHFFFAOYSA-N 2-(4-phenylphenyl)sulfonyl-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound OC(=O)C1C2CCCCC2CCN1S(=O)(=O)C(C=C1)=CC=C1C1=CC=CC=C1 PNMYVXTZMXEHSF-UHFFFAOYSA-N 0.000 claims description 2
- LGUCBZPKIJKLPG-UHFFFAOYSA-N 2-(4-pyridin-4-yloxyphenyl)sulfonyl-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound OC(=O)C1C2CCCCC2CCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 LGUCBZPKIJKLPG-UHFFFAOYSA-N 0.000 claims description 2
- LQQNUOBJNUFKPS-UHFFFAOYSA-N 2-(6-phenoxypyridin-3-yl)sulfonyl-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound OC(=O)C1C2CCCCC2CCN1S(=O)(=O)C(C=N1)=CC=C1OC1=CC=CC=C1 LQQNUOBJNUFKPS-UHFFFAOYSA-N 0.000 claims description 2
- RWASSSHRLXGXGD-UHFFFAOYSA-N 2-[2-[4-(4-chlorophenyl)phenyl]ethylsulfonyl]-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound OC(=O)C1C2CCCCC2CCN1S(=O)(=O)CCC(C=C1)=CC=C1C1=CC=C(Cl)C=C1 RWASSSHRLXGXGD-UHFFFAOYSA-N 0.000 claims description 2
- JAEMOUPODCBVBR-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)phenyl]sulfonyl-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound OC(=O)C1C2CCCCC2CCN1S(=O)(=O)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 JAEMOUPODCBVBR-UHFFFAOYSA-N 0.000 claims description 2
- MVQFCOWDGSSHPB-UHFFFAOYSA-N 2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(S(=O)(=O)N2C(C3CCCCC3CC2)C(O)=O)C=C1 MVQFCOWDGSSHPB-UHFFFAOYSA-N 0.000 claims description 2
- HYEZWGJIZYEVRP-UHFFFAOYSA-N 2-[4-[4-(2,2,2-trifluoroethoxy)phenoxy]phenyl]sulfonyl-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound OC(=O)C1C2CCCCC2CCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(OCC(F)(F)F)C=C1 HYEZWGJIZYEVRP-UHFFFAOYSA-N 0.000 claims description 2
- WGSYGRYQMLRQAH-UHFFFAOYSA-N 2-dibenzofuran-2-ylsulfonyl-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)N4CCC5CCCCC5C4C(=O)O)=CC=C3OC2=C1 WGSYGRYQMLRQAH-UHFFFAOYSA-N 0.000 claims description 2
- YEVUDYGNIFKWJD-UHFFFAOYSA-N C1=CC(C(=O)NC(C)C)=CC=C1C1=CC=C(S(=O)(=O)N2C(C3CCCCC3CC2)C(=O)NO)C=C1 Chemical compound C1=CC(C(=O)NC(C)C)=CC=C1C1=CC=C(S(=O)(=O)N2C(C3CCCCC3CC2)C(=O)NO)C=C1 YEVUDYGNIFKWJD-UHFFFAOYSA-N 0.000 claims description 2
- 206010058112 Chondrolysis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010065433 Ligament rupture Diseases 0.000 claims description 2
- 206010072970 Meniscus injury Diseases 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000012024 dehydrating agents Substances 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 238000006884 silylation reaction Methods 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 2
- 125000004185 ester group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 239000003814 drug Substances 0.000 abstract description 6
- 230000035876 healing Effects 0.000 abstract description 2
- 208000027932 Collagen disease Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000026816 acute arthritis Diseases 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000003041 ligament Anatomy 0.000 abstract 1
- 230000005499 meniscus Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 208000005801 spondylosis Diseases 0.000 abstract 1
- 230000036262 stenosis Effects 0.000 abstract 1
- 208000037804 stenosis Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 48
- 108090000790 Enzymes Proteins 0.000 description 48
- 229940088598 enzyme Drugs 0.000 description 48
- 239000000243 solution Substances 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 40
- 150000003254 radicals Chemical class 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 230000008033 biological extinction Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 108010062466 Enzyme Precursors Proteins 0.000 description 12
- 102000010911 Enzyme Precursors Human genes 0.000 description 12
- 239000007983 Tris buffer Substances 0.000 description 12
- 239000000758 substrate Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000008366 buffered solution Substances 0.000 description 9
- 229940125532 enzyme inhibitor Drugs 0.000 description 9
- 239000002532 enzyme inhibitor Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000005984 hydrogenation reaction Methods 0.000 description 8
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 5
- 102100030411 Neutrophil collagenase Human genes 0.000 description 5
- 101710118230 Neutrophil collagenase Proteins 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 102100030416 Stromelysin-1 Human genes 0.000 description 5
- 101710108790 Stromelysin-1 Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 238000001506 fluorescence spectroscopy Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- XAAKCCMYRKZRAK-UHFFFAOYSA-N isoquinoline-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NC=CC2=C1 XAAKCCMYRKZRAK-UHFFFAOYSA-N 0.000 description 5
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 5
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 5
- NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 102100027995 Collagenase 3 Human genes 0.000 description 4
- 108050005238 Collagenase 3 Proteins 0.000 description 4
- 229940124761 MMP inhibitor Drugs 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- OXFGRWIKQDSSLY-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-2-ium-1-carboxylate Chemical compound C1=CC=C2C(C(=O)O)NCCC2=C1 OXFGRWIKQDSSLY-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
- XCOBLONWWXQEBS-KPKJPENVSA-N N,O-bis(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)O\C(C(F)(F)F)=N\[Si](C)(C)C XCOBLONWWXQEBS-KPKJPENVSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000408939 Atalopedes campestris Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical class ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- AEKHNNJSMVVESS-UHFFFAOYSA-N o-trimethylsilylhydroxylamine Chemical compound C[Si](C)(C)ON AEKHNNJSMVVESS-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 125000006410 propenylene group Chemical group 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical class C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- RZYHXKLKJRGJGP-UHFFFAOYSA-N 2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)N([Si](C)(C)C)C(=O)C(F)(F)F RZYHXKLKJRGJGP-UHFFFAOYSA-N 0.000 description 1
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 1
- PGYDBHAYJMYOAC-UHFFFAOYSA-N 2-(5-chloro-2-phenylphenyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCC1=CC(Cl)=CC=C1C1=CC=CC=C1 PGYDBHAYJMYOAC-UHFFFAOYSA-N 0.000 description 1
- WDZYWTRLDQGBJQ-UHFFFAOYSA-N 2-[4-[4-(2,2,2-trifluoroethoxy)phenyl]phenyl]sulfonyl-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound OC(=O)C1C2CCCCC2CCN1S(=O)(=O)C(C=C1)=CC=C1C1=CC=C(OCC(F)(F)F)C=C1 WDZYWTRLDQGBJQ-UHFFFAOYSA-N 0.000 description 1
- JYUPDDDFZIYLQR-UHFFFAOYSA-N 2-[4-[4-(propan-2-yloxycarbonylamino)phenyl]phenyl]sulfonyl-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1=CC(NC(=O)OC(C)C)=CC=C1C1=CC=C(S(=O)(=O)N2C(C3CCCCC3CC2)C(O)=O)C=C1 JYUPDDDFZIYLQR-UHFFFAOYSA-N 0.000 description 1
- KUCJKFJSZWYGMF-UHFFFAOYSA-N 2-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-1-carboxylic acid Chemical compound OC(=O)C1C2CCCCC2CCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1 KUCJKFJSZWYGMF-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 238000012584 2D NMR experiment Methods 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- RJSZSPDURMYOEK-UHFFFAOYSA-N 5-chloro-2-phenylbenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC(Cl)=CC=C1C1=CC=CC=C1 RJSZSPDURMYOEK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102100040550 FXYD domain-containing ion transport regulator 4 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101150014058 MMP1 gene Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- TYBWABJIIOVYOR-UHFFFAOYSA-N OCC(C(O)=O)OP(=O)=O Chemical compound OCC(C(O)=O)OP(=O)=O TYBWABJIIOVYOR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- PVYPHUYXKVVURH-UHFFFAOYSA-N boron;2-methylpropan-2-amine Chemical compound [B].CC(C)(C)N PVYPHUYXKVVURH-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 125000005622 butynylene group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 108700004333 collagenase 1 Proteins 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 108010070092 corticosteroid hormone-induced factor Proteins 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006841 cyclic skeleton Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical class 0.000 description 1
- 102000053150 human MMP2 Human genes 0.000 description 1
- 102000054439 human MMP9 Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- RBVFKMBFVHRPCU-UHFFFAOYSA-N n-trimethylsilylhydroxylamine Chemical compound C[Si](C)(C)NO RBVFKMBFVHRPCU-UHFFFAOYSA-N 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- ODSGJAOAEGSRGK-UHFFFAOYSA-N pentachloro-lambda5-phosphane hydrochloride Chemical compound P(Cl)(Cl)(Cl)(Cl)Cl.Cl ODSGJAOAEGSRGK-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000007154 radical cyclization reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940101201 ringl Drugs 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000034365 zymogen activation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to compounds of formula (I) which are suitable for the production of medicaments for the prophylaxis and therapy of diseases, whereby the course thereof involves the increased activity of matrix-metalloproteinases. Diseases belonging thereto are degenerative joint diseases, for example, osteo-arthrosis, spondylosis, chondroporosis after articulation injury or a long duration of articulation immobilisation after meniscus or patella injury or torn ligaments, or a disease of the connective tissue, such as collagenosis, periodontal diseases, problems with healing wounds, or a chronic disease of the locomotor system, such as inflammatory, immunological or metabolic-related acute or chronic arthritis, arthropathy, myalgies or troubles of the bone metabolism or ulceration, atherosclerosis or stenosis or an inflammatory disease or cancer, a metastatic tumour, cachexia, anorexia or septic shock.
Description
Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases The invention relates to novel derivatives of saturated bicyclic imino acids, such as, in particular, decahydroisoquinoline-1-carboxylic acid, to methods for preparing them, and to the use thereof as pharmaceuticals.
In diseases such as osteoarthritis and rheumatism, destruction of the joint takes place, with this destruction being caused, in particular, by the proteolytic breakdown of collagen due to collagenases. Collagenases belong to the metalloproteinase (MP) or matrix metalloproteinase (MMP) supen'amily. The MMPs form a group of Zn-dependent enzymes which are involved in the biological breakdown of the extracellular matrix (D. Yip et al.
in Investigational New Drugs 17 (1999), 387-399 and Michaelides et al. in Current Pharmaceutical Design 5 (1999) 787 - 819). These MMPs are, in particular, able to break down fibrillar and nonfibrillar collagen and also proteoglycans, both of which are important matrix constituents. MMPs are involved in processes of wound healing, tumor invasion and metastasis migration, and also in angiogenesis, multiple sclerosis and heart failure (Michaelides, page 788; see above). In particular, they play an important role in the breakdown of the joint matrix in arthrosis and arthritis, whether this be osteoarthrosis, osteoarthritis or rheumatoid arthritis.
The activity of the MMPs is furthermore essential for many of the processes which play a role in atherosclerotic plaque formation, such as the infiltration of inflammatory cells and smooth muscle cell migration, as well as proliferation and angiogenesis (S.J. George, Exp. Opin. Invest. Drugs (2000), 9 (5), 993-1007). Furthermore, the degradation of matrix by MMPs can cause anything from plaque instabilities through to ruptures, with these conditions being able to give rise to the clinical symptoms of atherosclerosis, unstable angina pectoris, myocardial infarction or stroke (E.J.M. Creemers et al., Circulation Res. 89, 201-210 (2001 )). All in all, the MMP family as a whole is able to break down all the components of the extracellular matrix of the blood vessels; in normal blood vessels, therefore, their activity is to a very great degree subject to regulatory mechanisms.
The increase in MMP activity during plaque formation and plaque instability is caused by an increase in cytokine-stimulated and growth factor-stimulated gene transcription, an increase in zymogen activation and an imbalance in the MMPITIMP (tissue inhibitors of metalloproteases) ratio. It therefore seems plausible that an MMP inhibition or the reattainment of the MMP-TIMP balance, would be helpful in treating atherosclerotic diseases. It is likewise becoming ever more clear that an increase in MMP activity is at least partially responsible for other cardiovascular diseases in addition to atherosclerosis, such as restenosis, dilated cardiomyopathy and the previously mentioned myocardial infarction. It has been shown that administering synthetic inhibitors to experimental animal models of these diseases is able to achieve marked improvements, for example in regard to the formation of atherosclerotic lesions, neointima formation, left ventricular remodeling, pump performance malfunction or infarction healing. In various preclinical studies using MMP inhibitors, detailed tissue analyses indicated a reduction in collagen damage, an improvement in extracellular matrix remodeling and an improvement in the structure and function of cardiac muscle and blood vessels. Among these processes, matrix remodeling processes and MMP-regulated fibroses, in particular, are regarded as being important components in the progression of heart diseases (infarction) (Drugs 61, 1239-1252 (2001 )).
Under physiological conditions, MMPs cleave matrix proteins such as collagen, laminin, proteoglycans, elastin or gelatine, and also process (i.e.
activate or inactivate), by means of cleavage, a large number of other proteins and enzymes, which means that they play an important role in the entire body, with this role being particularly significant in the connective tissue and bones.
A large number of different MMP inhibitors are known (EP 0 606 046; WO
94/28889; WO 96/27583; cf. reviews such as Current Medicinal Chemistry 8, 425-74 (2001 ) as welt). Following the first clinical studies in humans, it has now been found that MMPs give rise to side-effects. The side-effects to be mentioned are musculoskeletal pain or anthralgias. The prior art makes it clear that it is expected that more selective inhibitors would be able to reduce these side-effects (Yip, page 387, see above). Specificity towards MMP-1 is particularly to be emphasized in this connection since these unwanted side-effects evidently appear to an increased extent when MMP-1 is inhibited.
A disadvantage of the known MMP inhibitors is therefore that they frequently lack specificity. Most MMP inhibitors inhibit many MMPs simultaneously because the catalytic domains of the MMPs possess similar structures. As a consequence, the inhibitors also undesirably affect the enzymes which have a vital function (Massova I, et al., The FASEB Journal (1998) 12, 1075-1095).
In the endeavor to find effective compounds for treating connective tissue diseases, it has now been found that the derivatives which are employed in accordance with the invention are powerful inhibitors of the matrix metalloproteinases MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13 while only having a weak inhibitory effect on MMP-1.
The invention therefore relates to a compound of the formula I
n1 0 n2 R2 N,S A-ring-B ' ring2 D-ring3 E-ring4 R5 ~ R1 R3 X (I) andlor to all the stereoisomeric forms of the compound of the formula I
and/or to mixtures of these forms in any ratio, and/or to a physiologically tolerated salt of the compound of the formula I, wherein A is -(Co-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(Co-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)~-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m , in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1 ) -C(O)-2) -(C2-C4)-alkenylene, 3) -S(O)o , where o is the integers zero, 1 or 2, 4) -N(R6)-, in which R6 is hydrogen atom, methyl or ethyl, 5) -N(R6)-C(Y)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 6) -C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 7) -N(R6)-S02-, in which R6 is defined as above, 8) -SOZ-N(R6)-, in which R6 is defined as above, 9) -N(R6)-S02-N(R6)-, in which R6 is defined as above, 10) -N(R6)-C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 11 ) -O-C(O)-N(R6)-, 12) -NH-C(O)-O-, 13) -O-, 14) -C(O)-O-, 15) -O-C(O)-, 16) -O-C(O)-O-, 17) -O-CH2-C(O)-, 18) -O-CH2-C(O)-O-, 19) -O-CH2-C(O)-N(R6)-, in which R6 is defined as above, 20) -C(O)-CHZ-O-, 21 ) -O-C(O)-CH2-O-, 22) -N(R6)-C(O)-CH2-O-, in which R6 is defined as above, 23) -O-(CH2)"-O-, in which n is the integer 2 or 3, or 24) -O-(CHZ)m-N(R6)-, in which m is the integer 2 or 3 and R6 is defined as above, 25) -N(R6)-(CH2)m-O-, in which m is the integer 2 or 3 and R6 is defined as above, 26) -N(R6)-N(R6)-, in which R6 is defined as above, 27) -N=N-, 28) -N(R6)-CH=N-, in which R6 is defined as above, 29) -N=CH-N(R6)-, in which R6 is defined as above, 30) -N(R6)-C(R7)=N-, in which R6 is defined as above and R7 is -N H-R6, 31 ) -N=C(R7)-N(R6)-, in which R6 is defined as above and R7 is -NH-R6, or 32) -(CZ-C6)-alkynylene, ring1, and ring3 are identical or different and are, ring2 independently of each other, 1 ) covalent bond, 2) -(C6-C~4)-aryl, in which aryl is unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) 4- to 15-membered Het ring, in which Het ring is unsubstituted or substituted, independently of each other, once, twice or three times, by G, ring4 is 5 1 ) -(C6-C~4)-aryl, in which aryl is unsubstituted or substituted, independently of each other, once, twice or three times, by G, 2) 4- to 15-membered Het ring, in which the Het ring is unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) is one of the following radicals O N O O N O
H H
and these radicals are unsubstituted or substituted once by G, G is 1 ) hydrogen atom, 2) halogen, 3) =O, 4) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, 5) -(Cs-C,a)-aryl, 6) Het ring, 7) -C(O)-O-R10, in which R10 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(CZ-C6)-alkynyl, -(Cs-C~4)-aryl or Het ring, or b) -(C6-C~4)-aryl or Het ring, 8) -C(S)-O-R10, in which R10 is defined as above, 9) -C(O)-NH-R11, in which R11 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C6-C,4)-aryl or Het ring, or b) -(C6-C~4)-aryl or Het ring, 10) -C(S)-NH-R11, in which R11 is defined as above, 11 ) -O-R12, in which R12 is a) hydrogen atom, b) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, (Cs-Cia)-aryl or Het ring, c) -(Cs-C,a)-aryl, d) Het ring, e) -C(O)-O-R13, in which R13 is e)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(CZ-Cs) alkynyl, -(C6-C~4)-aryl, or Het ring, or e)2) -(C6-C~4)-aryl or Het ring, f) -C(S)-O-R13, in which R13 is defined as above, g) -C(O)-NH-R14, in which R14 is g)1 ) -(C~-Cs)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(CZ-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, or g)2) -(C6-C~4)-aryl or Het ring, or h) -C(S)-NH-R14, in which R14 is defined as above, 12) -C(O)-R10, in which R10 is defined as above, 13) -S(O)p R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 14) -N02, 15) -CN, or 16) -N(R15)-R12, in which R15 is 16)1 ) hydrogen atom, 16)2) -(C~-C6)-alkyl, or 16)3) -S02-(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(CZ-C6)-alkynyl, -(C6-C1a)-aryl or Het ring, and R12 is defined as above, or 17) -S02-N(R12)-R1, in which R12 is defined as above and R1 is defined as below, X is -OH or -NH-OH, n1 is the integer zero, 1, 2 or 3, n2 is the integer zero, 1, 2, 3 or 4, with the proviso that the sum of n1 and n2 amounts to 1, 2, 3, 4, 5, 6 or 7, R1, R2, R3, R4 and R5 are identical or different and are, independently of each other, 1 ) hydrogen atom, 2) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-Cs)-alkynyl, -(C6-C~a)-aryl or Het ring, 3. -C(O)-O-R8, in which R8 is 3)1 ) hydrogen atom, 3)2) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, or substituted once to five times, by fluorine, or 3)3) -(C6-C~4)-aryl or Het ring, 4) -O-R8, in which R8 has the abovementioned meaning, or 5) -(C3-C6)-cycloalkyl.
The invention also relates to the compound of the formula I where A is -(Co-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(Co-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CHZ)~-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1 ) -C(O)-2) -(CZ-C4)-alkenylene, 3) -S(O)o-, where o is the integers zero, 1 or 2, 4) -N(R6)-, in which R6 is hydrogen atom, methyl or ethyl, 5) -N(R6)-C(Y)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 6) -C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 7) -N(R6)-S02-, in which R6 is defined as above, - 8) -SOz-N(R6)-, in which R6 is defined as above, 9) -N(R6)-S02-N(R6)-, in which R6 is defined as above, 10) -N(R6)-C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 11 ) -O-C(O)-N(R6)-, 12) -NH-C(O)-O-, 13) -O-, 14) -C(O)-O-, 15) -O-C(O)-, 16) -O-C(O)-O-, 17) -O-CH2-C(O)-, 18) -O-CH2-C(O)-O-, 19) -O-CH2-C(O)-N(R6)-, in which R6 is defined as above, 20) -C(O)-CHZ-O-, 21 ) -O-C(O)-CH2-O-, 22) -N(R6)-C(O)-CH2-O-, in which R6 is defined as above, 23) -O-(CH2)~-O-, in which n is the integer 2 or 3, or 24) -O-(CH2)m-N(R6)-, in which m is the integer 2 or 3 and R6 is defined as above, 25) -N(R6)-(CH2)m-O-, in which m is the integer 2 or 3 and R6 is defined as above, 26) -N(R6)-N(R6)-, in which R6 is defined as above, 27) -N=N-, 28) -N(R6)-CH=N-, in which R6 is defined as above, 29) -N=CH-N(R6)-, in which R6 is defined as above, 30) -N(R6)-C(R7)=N-, in which R6 is defined as above and R7 is -N H-R6, 31 ) -N=C(R7)-N(R6)-, in which R6 is defined as above and R7 is -NH-R6, or 32) -(C2-C6)-alkynylene, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1 ) covalent bond, 2) phenyl or naphthyl and are unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) 4- to 15-membered Het ring, in which the Het ring is a radical from the series acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, deca-hydroquinolinyl, dibenzofuranyl, dibenzothiophenyl, dihydrofuran[2,3-b]tetrahydrofuranyl, dihydrofuranyl, dioxolyl, dioxanyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1 H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxothiolanyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydro-pyridinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thia-diazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, and these radicals are unsubstituted or substituted, independently of each other, once, twice or three times, by G, ring4 is 1 ) -(C6-C~4)-aryl, in which aryl is a radical from the series phenyl, naphthyl, 1-naphthyl, 2-naphthyl, anthryl and fluorenyl, and these radicals are unsubstituted or substituted, independently of each other, once, twice or three times, by G, 2) 4- to 15-membered Het ring, in which the Het ring is a radical from the series acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, deca-hydroquinolinyl, dibenzofuranyl, dibenzothiophenyl, dihydrofuran[2,3-b]tetrahydrofuranyl, dihydrofuranyl, dioxolyl, dioxanyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1 H-indazolyl, indolinyl, 5 indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolinyl, 2'-methylbiphenyl-2-0l, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, 10 oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxothiolanyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydro-pyridinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thia-diazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, . and are unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) is one of the following radicals O N O O N O
H H
and these radicals are unsubstituted or substituted once by G, G is 1 ) hydrogen atom, 2) halogen, 3) =O, 4) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, 5) -(C6-C~4)-aryl, where aryl is defined as above, 6) Het ring, where Het ring is defined as above, 7) -C(O)-O-R10, in which R10 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, or b) -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, 8) -C(S)-O-R10, where R10 is defined as above, 9) -C(O)-NH-R11, in which R11 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, or b) -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, 10) -C(S)-NH-R11, in which R11 is defined as above, 11 ) -O-R12, in which R12 is a) hydrogen atom, b) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-Cs)-alkynyl, -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, c) -(C6-C~4)-aryl, where aryl is defined as above, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~a)-aryl, or Het ring, where aryl and Het ring are defined as above, or e)2) -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, f) -C(S)-O-R13, in which R13 is defined as above, g) -C(O)-NH-R14, in which R14 is g)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, or g)2) -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, or h) -C(S)-NH-R14, in which R14 is defined as above, 12) -C(O)-R10, in which R10 is defined as above, 13) -S(O)p-R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 14) -N02, 15) -CN, or 16) -N(R15)-R12, in which R15 is 16)1 ) hydrogen atom, or 16.2) -(C~-C6)-alkyl and R12 is defined as above, 16.3) -S02-(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, 17) -SOZ-N(R12)-R1, in which R12 is defined as above and R1 is defined as below, X is -OH or -NH-OH, n1 is the integer 1 or 2, n2 is the integer 2 or 3, R1, R2, R3, R4 and R5 are identical or different and are, independently of each other, 1 ) hydrogen atom, 2) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(CZ-C6)-alkynyl, -(C6-C,4)-aryl or Het ring, 3) -C(O)-O-R8, in which R8 is 3)1 ) hydrogen atom, 3)2) -(C~-Cs)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, or is substituted once to five times by fluorine, or 3)3) -(C6-C~a)-aryl or Het ring, 4) -O-R8, in which R8 has the abovementioned meaning, or 5) -(C3-C6)-cycloalkyl.
The invention furthermore relates to the compound of the formula I wherein A is -(Co-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(Co-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)~ , in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1 ) -(Co-C2)-alkylene, 2) ethenylene, 3) ethynylene, 4) -C(O)-5) -N(R6)-C(O)-, in which R6 is hydrogen atom, methyl or ethyl, 6) -C(O)-N(R6)-, in which R6 is defined as above, 7) -O-, or 8) _S_, ring1, and ring3 are identical or different and are, ring2 independently of each other, 1 ) covalent bond, 2) phenyl or naphthyl and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series dihydrofuranyl, furanyl, pyridinyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl or thiophenyl, and the radicals are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1 ) phenyl or naphthyl and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dihydrofuranyl, dibenzofuranyl, dibenzothiophenyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical O N O
and this radical is unsubstituted or substituted once by G, G is 1 ) hydrogen atom, 2) Br, CI or F, 3) -(C~-C4)-alkyl, in which alkyl is unsubstituted or substituted once or twice by F, phenyl, -C3-cycloalkyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH-R11, in which R11 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, f) -C(S)-O-R13, in which R13 is defined as above, or 5 g) -C(O)-NH-R14, in which R14 is g)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by phenyl or Het ring, where Het ring is defined as above, or 10 g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 10) -S(O)p-R12, in which R12 is defined as above and p is the integers 1 or 2, 15 11 ) -N 02, 12) -CN, or 13) -N(R15)-R12, in which R15 is 13)1 ) hydrogen atom, or 13)2) -(C1-Cs)-alkyl and R12 is defined as above, X is -OH or -NH-OH, n1 is the integer 1 or 2, n2 is the integer 2 or 3, R1, R2 and R3 are in each case hydrogen atom, R4 and R5 are identical or different and are, independently of each other, 1 ) hydrogen atom, 2) methyl, 3) ethyl, or 4) -OH.
The invention furthermore relates to the compound of the formula I wherein A is -(Co-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(Co-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)~-, in which n is the integer zero, 1 or 2, B3 is -(CHZ)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1 ) -(Co-C2)-alkylene, 2) ethenylene, or 3) ethynylene, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1 ) covalent bond, 2) phenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series dihydrofuranyl, furanyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolyl, thiazolyl or thiophenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1 ) phenyl, and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dihydrofuranyl, dibenzofuranyl, dibenzothiophenyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical O N O
and this radical is unsubstituted or substituted once by G, G is 1 ) hydrogen atom, 2) Br, CI or F, 3) -(C~-C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times, by Br, CI, F, -C3-cycloalkyl, phenyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C,-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH -R11, in which R11 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl or naphthyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl, naphthyl, or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, f) -C(S)-O-R13, in which R13 is defined as above, or g) -C(O)-NH-R14, in which R14 is g)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by phenyl or Het ring, where Het ring is defined as above, or g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 10) -S(O)P-R12, in which R12 is defined as above and p is the integers 1 or 2, 11 ) -N02, 12) -CN, or 13) -N(R15)-R12, in which R15 is 13)1 ) hydrogen atom, or 13)2) -(C~-C6)-alkyl and R12 is defined as above, X is -OH or -NH-OH, n1 is the integer 2, n2 is the integer 3, R1, R2, R3, R4 and R5 are in each case hydrogen atom.
The invention furthermore relates to the compound of the formula I wherein A is a covalent bond or -CH2-CH2-, B, D and E are identical or different and are, independently of each other, -(Co-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)"-, in which n is the integer zero, 1 or 2, B3 is -(CHZ)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1 ) -C(O)-2) -(C2-C4)-alkynylene, 3) -S(O)o-, where o is the integers zero or 1, 4) -N(R6)-C(Y)-, in which Y is oxygen atom and R6 is hydrogen atom, 5) -C(Y)-N(R6)-, in which Y is oxygen atom and R6 is hydrogen atom, or 6 ) -O-, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1 ) covalent bond, 2) phenyl and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series furanyl, pyridinyl, pyrimidinyl or thiophenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1 ) phenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dibenzofuranyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical o~o s and this radical is unsubstituted or substituted once by G, G is 1 ) hydrogen atom, 2) Br, CI or F, 3) -(C~-C4)-alkyl, in which alkyl is unsubstituted or once, twice or three times, by Br, CI, F, -C3-cycloalkyl, phenyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH-R11, in which R11 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, 5 f) -C(S)-O-R13, in which R13 is defined as above, or g) -C(O)-NH-R14, in which R14 is g)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or 10 twice, by phenyl or Het ring, where Het ring is defined as above, or g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 15 10) -S(O)p-R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 11 ) -N02, 12) -CN, or 13) -N(R15)-R12, in which R15 is 20 13)1 ) hydrogen atom, or 13)2) -(C~-C6)-alkyl and R12 is defined as above, X is -NH-OH, n1 is the integer 2, n2 is the integer 3, and R1, R2, R3, R4 and R5 are in each case hydrogen atom.
The invention also relates to the compound of the formula I from the series 2-(4'-nitrobiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(4'-chlorobiphenyl-4-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-(4'-chlorobiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)-carboxamide, 2-(6-phenoxypyridine-3-sulfonyl)decahydroisoquinoline-1-carboxylic acid;
trifluoroacetate, 2-(6-phenoxypyridine-3-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)-carboxamide; trifluoroacetate, 2-[2-(4'-chlorobiphenyl-4-yl)ethanesulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-[2-(4'-chlorobiphenyl-4-yl)ethanesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(pyridin-4-yloxy)benzenesulfonyl]decahydroisoquinoline-1-carboxylic acid; trifluoroacetate, 2-[4-(pyridin-4-yloxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)-carboxamide; trifluoroacetate, 2-[4-(4-methoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-[4-(4-methoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-{4-[4-(2,2,2-trifluoroethoxy)phenoxy]benzenesulfonyl}decahydro-isoquinoline-1-carboxylic acid, 2-{4-[4-(2,2,2-trifluoroethoxy)phenoxy]benzenesulfonyl}decahydro-isoquinoline-1-(N-hydroxy)carboxamide, 2-[4'-(2,2,2-trifluoroethoxy)biphenyl-4-sulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-(4'-isopropoxycarbonylaminobiphenyl-4-sulfonyl)decahydroisoquinoline-1- carboxylic acid, [4'-(1-hydroxycarbamoyloctahydroisoquinoline-2-sulfonyl)biphenyl-4-yl]carboxamide isopropyl ester, 2-[4'-(2,2,2-trifluoroethoxy)biphenyl-4-sulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(4'-trifluoromethoxybiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-fluorophenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-trifluoromethoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-trifluoromethoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-(biphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(biphenyl-4-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-[4-(4-cyanophenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(dibenzofuran-2-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-(dibenzofuran-2-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, or 2-[4-(4-fluorophenoxy)benzenesulfonyl]-6-methoxydecahydroisoquinoline-1-(N-hydroxy)carboxamide, and also all the isomeric forms of the abovementioned compounds.
The term "(C~-C6)alkyl" is understood as meaning hydrocarbon radicals whose carbon chain is straight-chain or branched and contains from 1 to 6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, isopentyl, neopentyl, hexyl, 2,3-dimethylbutane or neohexyl.
The term "-(Co-C4)alkylene" is understood as meaning hydrocarbon radicals whose carbon chain is straight-chain or branched and contains from 1 to 4 carbon atoms, for example methylene, ethylene, propylene, isopropylene, isobutylene, butylene or tertiary butylene. "-Co-Alkylene" is a covalent bond.
The term "-(CH2)~-, in which n is the integer zero, 1 or 2" is understood as meaning a covalent bond, where n is zero, the radical methylene, where n is 1 and the radical ethylene where n is 2.
The term "-(C2-C4)-alkenylene" is understood as meaning hydrocarbon radicals whose carbon chain is straight-chain or branched and contains from 2 to 4 carbon atoms and which, depending on chain length, possess one or two double bonds, for example ethenylene, propenylene, isopropenylene, isobutenylene or butenylene; insofar as the possibility exists in principle, the substituents at the double bond can be arranged in the E position or Z position.
The term "-(C2-C6)-alkynylene" is understood as meaning hydrocarbon radicals whose carbon chain is straight-chain or branched and contains from 2 to 6 carbon atoms and which, depending on chain length, possess one or two triple bonds, for example ethynylene, propenylene, isopropynylene, isobutynyl, butynylene, pentynylene or isomers of pentynylene, or hexynyl or isomers of hexynylene.
The term "(C3-C6)-cycloalkyl" is understood as meaning radicals such as compounds which are derived from 3- to 6-membered monocycles such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
The radicals n2 n1 or are in each case understood as meaning -CH2- radicals in the ring of the formula I, where the variables n1 or n2 in each case specify the number of the -CH2- radicals in the ring of the formula I. When n1 has the value zero, a covalent bond ensues and the resulting part ring has a total of 4 ring atoms. When n2 has the value zero, a covalent bond ensues and the resulting part ring has a total of 3 ring atoms. When n1 has the value 1, a -CH2- radical ensues and the resulting part ring has a total of 5 ring atoms.
When n1 has the value 2, a -CH2-CH2- radical ensues and the resulting part ring has a total of 6 ring atoms. When n1 has the value 3, a -CH2-CHZ-CH2- radical ensues and the resulting part ring has a total of 7 ring atoms.
Corresponding part rings ensue in the case of n2.
The term "-(C6-C~4)-aryl" is understood as meaning aromatic hydrocarbon radicals having from 6 to 14 carbon atoms in the ring. -(C6-C~4)-Aryl radicals are, for example, phenyl, naphthyl, for example 1-naphthyl or 2 naphthyl, anthryl or fluorenyl. Naphthyl radicals and, in particular, phenyl radicals are preferred aryl radicals.
The term "4- to 15-membered Het ring" or "Het ring" is understood as meaning ring systems which have from 4 to 15 carbon atoms, which are present in one, two or three ring systems which are linked to each other, and which contain one, two, three or four identical or different heteroatoms from the series oxygen, nitrogen or sulfur. Examples of these ring systems are the radicals acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, dibenzofuranyl, dibenzothiophenyl, dihydrofuran[2,3-b]tetrahydrofuranyl, dihydrofuranyl, dioxolyl, dioxanyl, 2H, 6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1 H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolinyl, 2'-methylbiphenyl-2-o1, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxothiolanyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydropyridinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl.
Preferred Het rings are the radicals benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, 1,3-benzodioxolyl, quinazolinyl, quinolinyl, quinoxalinyl, chromanyl, cinnolinyl, furanyl such as 2-furanyl and 3-furanyl; imidazolyl, indolyl, indazolyl, isoquinolinyl, isochromanyl, isoindolyi, isothiazolyi, isoxazolyl, 2'-methyibiphenyl-2-ol, oxazolyl, phthalazinyl, pteridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridyl; such as 2-pyridyl, 3-pyridyl or 4-pyridyl; pyrimidinyl, pyrrolyl; such as 2-pyrrolyl and pyrrolyl; purinyl, thiazolyl, tetrazolyl or thienyl; such as 2-thienyl and 3-thienyl.
The term "halogen" is understood as meaning fluorine, chlorine, bromine or iodine.
The invention furthermore relates to a process for preparing the compound of the formula I andlor a stereoisomeric form of the compound of formula I
and/or a physiologically tolerated salt of the compound of the formula I, which comprises a) reacting a compound of the formula IV, O
n2 R2 ,Re ~O
NH (IV) in which Re is a hydrogen atom or an ester-protecting group, with a compound of the formula V, Rz-S- A -rings- B ring2 D ring3 E-ring4 (V) in which A, B, D, E and ring1, ring2, ring3 and ring4 are defined as in formula I, and in which Rz is chlorine atom, imidazoyl or OH, 10 in the presence of a base or following silylation with a suitable silylating agent, or using a suitable dehydrating agent when Rz = OH, to give a compound of the formula VI, n2 O
R2 ,Re ~O
R5 R3 N\S O A-ring-B-ringZ D-ring3 E-ring4 (vp O
in which A, B, D, E, Re and ringl , ring2, ring3 and ring4 are defined as above, and b) when Re = ester reacting a compound of the formula VI prepared as described in a) with a solution of alkali such as NaOH or LiOH, and then treating the product with acid, to give the carboxylic acid according to the invention of the formula I, in which X = OH
(corresponding to VII), with modifications in one of the side chains of the rings ring1-ring4 also having previously been made, where appropriate; or converting said ester, by treating it with a mineral acid, such as hydrochloric acid, into the free carboxylic acid VII
n2 O
'OH
N~ %O (VII) R5 R3 S-A-ring-B-ringZ D-ring3 E-ringa O
and then converting this into the hydroxamic acid according to the invention, in which X = NH-OH, of the formula I, c) using salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases, or derivatization with chiral, enantiomerically pure compounds such as amino acids, separation of the resulting diastereomers and elimination of the chiral auxiliary groups, to separate a compound of formula I prepared as described in procedure a), or a suitable precursor of the formula I, which arises in enantiomeric forms due to its chemical structure, into the pure enantiomers, or d) either isolating the compound of the formula I prepared as described in procedures b) or c) in free form, or, when acid or basic groups are present, converting it into physiologically tolerated salts.
Compounds of the formula IV to VII type are compounds which are only presented by way of example; in accordance with formula I, it is also possible to adduce four-membered rings, six-membered rings and seven-membered rings instead of the five-membered ring.
Compounds of the formula IV type can be prepared using known protocols.
For example, compounds in which n~ = 1 and n2 = 0 (methanoprolines) can be prepared using a number of known methods. The description of a recent synthesis can be found, for example, in Tetrahedron 53, 14773-92 (1997).
For example, the bicyclic skeletons of the formula IV in which n~ = 2 and n2 - 3 in accordance with formula I can be prepared by hydrogenation of isoquinoline-1-carboxylic acid or suitable derivatives of isoquinoline-1 carboxylic acid, such as methyl ester or ethyl ester. This hydrogenation is described, for example, in US 5430023, US 5726159 and EP 643073.
In the same way, it is possible to use 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid and its derivatives to prepare these compounds by hydrogenation. This procedure has the advantage that it is possible to use a broad range of methods for synthesizing the 1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acids. For example, Pictet-Spengler-type cyclizations, such as described in US 4902695, are particularly well known and broadly applicable. Depending on the nature of the starting compounds employed, such methods can be used, for example, to obtain substituted compounds, i.e. compounds in which the substituents R1, R4 and R5 are not H atoms. A novel example of ring-substituted compounds can be found in WO 2003041641. Innumerable examples of R1 and/or R4 and R5 not being H exist and are readily available to the skilled person.
Other possible methods for preparing the cyclic skeletons use free radical cyclization reactions, for example, and are described in Tetrahedron 48, 4659-76 (1992).
Other methods can be used for synthesizing compounds of the IV type when n~ = 1 and n3 = 3. For example, described syntheses are to be found in Tetrahedron 55, 8025 (1999) and Tetrahedron Lett. 24, 5339 (1983) or in the laid-open specifications DE 3322530 and DE 3211676.
Methods for synthesizing compounds of the IV type in which n~ = 1 and n2 - 2 are likewise to be found in Tetrahedron 55, 8025 (1999) and DE 3322530 or DE 3211676.
Methods for synthesizing the skeletons of related compounds, for example in which n~ = 1 and n2 = 4, are also described. For example, J. Org. Chem.
61, 7125 (1996) describes syntheses of (3-lactams which contain said skeleton. The substituted basic structures in analogy with formula IV can also be prepared from these compounds by opening the (i-lactam.
Methods for synthesizing the skeletons in which n~ = 2 and n2 = 4 are likewise known and well described, for example in EP 0672665 and the abovementioned references.
The groups used as protecting groups for esters in "Protective Groups in Organic Synthesis", T.H. Greene, P.G.M. Wuts, Wiley-Interscience, 1999, can be used as the ester-protecting group Re. Examples of preferred ester-protecting groups are methyl, ethyl, isopropyl, tert-butyl and benzyl.
Under certain conditions, it can be useful to employ compounds of the IV
type in the N-protected state. For example, it is easier to purify compounds which are protected in this way than it is to purify the free imino acids; in the same way, these protected compounds can sometimes also be more readily used for preparing the enantiomerically pure or diastereomerically pure compounds. The groups described in "Protective Groups in Organic Synthesis", T.H. Greene, P.G.M. Wuts, Wiley-Interscience, 1999, can be employed as protecting groups for the amino group. Examples of preferred amino-protecting or imino-protecting groups are Z, Boc, Fmoc, Aloc, acetyl, trifluoroacetyl, benzoyl, benzyl and the like.
The starting compounds and reagents employed can either be prepared using known methods or obtained commercially.
The reactions are carried out as described, for example, in WO 97/18194.
The reaction as described in procedural step a) takes place in the presence of a base, such as KOH, NaOH, LiOH, N-methylmorpholine (NMM), N-ethylmorpholine (NEM), triethylamine (TEA), diisopropylethylamine (DIPEA), pyridine, collidin, imidazole or sodium carbonate, in solvents such as tetrahydrofuran (THF), dimethylformamide (DMF), dimethylacetamide, dioxane, acetonitrile, toluene, chloroform or methylene chloride, or else in the presence of water. If the reaction is being carried out using silylating agents, N,O-bis(trimethylsilyl)acetamide (BSA) or N,O-bis(trimethylsilyl)-trifluoroacetamide (BSTFA) is used, for example, for silylating the imino acid in order to subsequently carry out the sulfonamide formation.
Modifications in the side chain F mean that, for example, a nitro group is hydrogenated using the metal catalyst Pd/C, or reacted with SnCl2 or Zn under standard conditions, and the resulting amino group can then be subjected to further modification, for example by reacting it with carbonyl chlorides, sulfonyl chlorides, chloroformic esters, isocyanates, isothiocyanates or other reactive or activatable reagents in order to arrive at the precursors of the compounds of formula I according to the invention.
In this case, it is frequently advantageous for Re in compound VI to be an ester since side reactions can be expected when the carboxylic acid is unprotected.
In procedural step c), the compound of the formula I is separated, insofar as it arises as a mixture of diastereomers or enantiomers, or accrues in the chosen synthesis as their mixtures, into the pure stereoisomers, either by means of chromatography on a support material, which is chiral where appropriate, or, provided the racemic compound of formula I is capable of salt formation, by means of fractional crystallization of the diastereomeric salts which are formed with an optically active base or acid used as auxiliary substance. Examples of chiral stationary phases which are suitable for separating enantiomers by means of thin layer chromatography or column chromatography are modified silica gel supports (what are termed Pirkle phases) and also high molecular weight carbohydrates such as triacetylcellulose. For analytical purposes, it is also possible, following appropriate derivatization known to the skilled person, to use gas-chromatographic methods on chiral stationary phases. In order to resolve the racemic carboxylic acids into their enantiomers, an optically active base, which is as a rule commercially available, such as (-)-nicotine, (+)-and (-)-phenylethylamine, quinine bases, L-lysine or L- and D-arginine, are used to form the differently soluble diastereomeric salts, the more difficulty soluble component is isolated as a solid, the more readily soluble diastereomer is removed from the mother liquor, and the pure enantiomers are obtained from the diastereomeric salts which have thus been isolated.
In what is in principle the same way, the racemic compounds of the formula I which contain a basic group such as an amino group can be converted into the pure enantiomers using optically active acids, such as (+)-camphor-10-sulfonic acid, D- and L-tartaric acid, D- and L-lactic acid and also (+)- and (-)-mandelic acid. It is also possible to convert chiral compounds which contain alcohol or amine functions into the corresponding esters or amides using appropriately activated and, where appropriate, N-protected enantiomerically pure amino acids or, vice versa, to convert chiral carboxylic acids into the amides using carboxyl-protected enantiomerically pure amino acids or to convert them into the corresponding chiral esters using enantiomerically pure hydroxycarboxylic acids such as lactic acid. The chirality of the amino acid radical or alcohol radical which has been introduced in enantiomerically pure form can then be used for separating the isomers by carrying out a separation of the diastereomers, which are now present, by means of crystallization or by means of chromatography on suitable stationary phases and, after that, using suitable methods to once again eliminate the entrained chiral molecule moiety.
In addition, the possibility arises, in the case of some of the compounds 5 according to the invention, of using diastereomerically pure or enantiomerically pure starting compounds for preparing the skeletal structures. This then makes it possible, where appropriate, to also use other methods, or simplified methods, for purifying the end products. These starting compounds were prepared beforehand in enantiomerically pure 10 form or diastereomerically pure form using methods known from the literature. For example, it is possible, as mentioned and cited above, to use isoquinoline-1-carboxylic acid either directly in the method for preparing decahydroisoquinoline-1-carboxylic acid. As a result of 3 heterocenters being present, it is possible, in this case, to form a maximum of 8 15 stereoisomers (4 enantiomeric diastereomer pairs). However, the nature of the preparation, for example hydrogenation, strongly favors certain stereoisomers. Thus, it should be possible, as described in the literature, to achieve strong preference for hydrogen attachment at the positions of the ring linkage, for example, by selecting the hydrogenation conditions 20 (catalyst, pressure, solvent and temperature) appropriately. Thus, it is possible, under the specified conditions, to achieve formation of the cis-linked rings. It would then consequently only remain a matter of determining the position of the carboxylic acid since the number of possible stereoisomers would already be restricted to 4. As a result of the nature of 25 the hydrogenation mechanism, it is particularly easy to attach the hydrogens on the same side as that of the bridgehead hydrogens, i.e. a further restriction in the possibility of isomer formation is thereby to be expected. It would consequently be possible, in the most favorable case, to assume that only one enantiomer pair would be formed. It ought then to be 30 possible to use the abovementioned methods to resolve this pair into the enantiomers. However, in connection with these considerations, it has also to be assumed that complete stereoselection will never take place and that, on the contrary, varying proportions of the other isomers will virtually always also be formed or will be detectable, even in very small quantities, when suitable methods are used.
When enantiomerically pure 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid derivatives are used, it would be expected that, if the reaction conditions were identical or similar to those used during the hydrogenation of isoquinoline-1-carboxylic acid, analogous considerations would apply and it would once again to a large extent only be preferred stereoisomers which were formed; in this said case, there should be strong preference for only one single enantiomer since, when carrying out the hydrogenation process under conditions which were analogous to those which lead to the cis ring linkage when hydrogenating isoquinoline-1-carboxylic acid, the H
atoms can once again only be attached from the one side and, as a consequence, analogous products will be formed. The identity of the structures can be established by means of suitable 2D NMR experiments, X ray methods such as cocrystallization and others, as well as reference analysis or chemical derivatization and suitable analysis or chemical derivatization which leads to known and described isomers.
Another possibility for synthesizing enantiomerically pure or diastereomerically pure compounds is that of using suitably chirally substituted starting compounds in order, by means of the chiral substituent, to achieve induction of chirality at other chiral centers. For example, chiral glyoxylic esters could be used in Pictet-Spengler cyclizations in order to obtain chiral Tic derivatives and then to hydrogenate these derivatives, as already mentioned above.
Acid or basic products of the compound of formula I can be present in the form of their salts or in free form. Preference is given to pharmacologically tolerated salts, for example alkali metal or alkaline earth metal salts, or hydrochlorides, hydrobromides, sulfates, hemisulfates and all possible phosphates, as well as salts of the amino acids, natural bases or carboxylic acids. Physiologically tolerated salts are prepared in a manner known per se, in accordance with procedural step d), from compounds of formula I, including their stereoisomeric forms, which are capable of salt formation.
The compounds of formula I form stable alkali metal salts, alkaline earth metal salts, or optionally substituted ammonium salts, with basic reagents such as hydroxides, carbonates, hydrogen carbonates or alkoxides, as well as ammonia or organic bases, for example trimethylamine, triethylamine, ethanolamine, diethanolamine, triethanolamine or trometamol, or else basic amino acids, for example lysine, ornithine or arginine. Provided the compounds of formula I possess basic groups, it is also possible to prepare stable acid addition salts using strong acids. Both inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, hemisulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 4-bromobenzenesulfonic acid, cyclohexylamidosulfonic acid, trifluoromethylsulfonic acid, 2-hydroxyethanesulfonic acid, acetic acid, oxalic acid, tartaric acid, succinic acid, phosphoglyceric acid, lactic acid, malic acid, adipic acid, citric acid, fumaric acid, malefic acid, gluconic acid, glucuronic acid, palmitic acid or trifluoroacetic acid are suitable for this purpose.
The invention also relates to pharmaceuticals which are characterized by an effective content of at least one compound of the formula I and/or a physiologically tolerated salt of the compound of formula I and/or an optionally stereoisomeric form of the compound of formula I, together with a pharmaceutically suitable and physiologically tolerated carrier substance, additive and/or other active compounds and auxiliary substances.
On account of their pharmacological properties, the compounds according to the invention are suitable for the selective prophylaxis and therapy of all those diseases whose course involves an increase in the activity of the metalloproteinases. These diseases include degenerative joint diseases such as osteoarthroses, spondyloses and chondrolysis following joint trauma or a relatively long period of joint immobilization following meniscus injuries or patella injuries or ligament ruptures. They furthermore also include diseases of the connective tissue such as collagenoses, periodontal diseases, wound healing disturbances and chronic diseases of the locomotory apparatus such as inflammatory, immunologically determined or metabolism-determined acute and chronic arthritides, arthropathies, myalgias and disturbances of bone metabolism. The compounds of the formula I are furthermore suitable for the treatment of ulceration, atherosclerosis and stenoses. In addition, the compounds of the formula I are suitable for the treatment of inflammations, cancer diseases, tumor metastases formation, cachexia, anorexia, heart failure and septic shock. The compounds are also suitable for the prophylaxis of myocardial and cerebral infarctions.
The pharmaceuticals according to the invention can be administered by means of oral, inhalative, rectal or transdermal administration or by means of subcutaneous, intraarticular, intraperitoneal or intravenous injection.
Oral administration is preferred.
The invention also relates to a process for producing a pharmaceutical, which comprises bringing at least one compound of the formula I, together with a pharmaceutically suitable and physiologically tolerated excipient and, where appropriate, other suitable active compounds, additives or auxiliary substances, in a suitable form of administration.
Examples of suitable solid or galenic preparation forms are granules, powders, sugar-coated tablets, tablets, (micro)capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions, as well as preparations giving a protracted release of active compound, the production of which makes use of customary adjuvants such as carrier substances, disintegrants, binders, coating agents, swelling agents, glidants, lubricants, flavorings, sweeteners and solubilizers. Frequently employed auxiliary substances which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils, such as cod liver oil, sunflower oil, groundnut oil or sesame oil, polyethylene glycol and solvents such as sterile water and monohydric or polyhydric alcohols, such as glycerol.
The pharmaceutical preparations are preferably produced and administered in dosage units, with each unit containing, as the active constituent, a defined dose of the compound of the formula I according to the invention. This dose can be up to about 1000 mg, preferably, however, from about 50 to 300 mg, in the case of solid dosage units, such as tablets, capsules, sugar-coated tablets or suppositories, and be up to about 300 mg, preferably, however, from about 10 to 100 mg, in the case of injection solutions in ampoule form.
Daily doses of from about 2 mg to 1000 mg of active compound, preferably of from 50 mg to 500 mg, are indicated, in dependence on the activity of the compound of the formula I, for treating an adult patient weighing about 70 kg. However, higher or lower daily doses may sometimes also be appropriate. The daily dose can be administered either by means of a once-only administration in the form of a single dosage unit or of several smaller dosage units or else by means of the multiple administration of subdivided doses at defined intervals.
End products are as a rule determined by means of mass-spectroscopic methods (FAB-MS and ESI-MS) and'H-NMR (400 MHz, in DMSO-D6); the main peak or the two main peaks are given in each case. Temperatures are given in degrees centigrade, RT denotes room temperature (21 °C to 24°C). The abbreviations employed are either explained or in conformity with the customary conventions. The invention is clarified below with the aid of examples.
General protocol 1: Sulfonamide from sulfonyl chloride and carboxylic acid The carboxylic acid (6.45 mmol) was dissolved in 20 ml of dimethylform-amide (DMF), and 3 equivalents of a 3N solution of NaOH (6.45 ml) were added at 0°C. After 10 min, a solution of the arylsulfonyl chloride (1.1 equivalents, 7.1 mmol) in from 10 to 15 ml of DMF was slowly added dropwise; after room temperature (RT) has been reached, the mixture continues to be stirred for a maximum of 12 hours (h) at temperatures between 20°C and 80°C. The precise time depends on when conversion is complete, with this being established by mass spectroscopy. After that, the solvent was removed under reduced pressure. Aqueous working-up (extracting by shaking with 1 N HCI and a saturated solution of NaCI, drying of the organic phase such as ethyl acetate, methylene chloride or chloroform with magnesium sulfate or sodium sulfate, and after that concentrating) subsequently took place. The crude product was either subjected directly to further reaction or purified by chromatography.
General protocol 2: Sulfonamide from sulfonyl chloride and carboxylic acid The carboxylic acid was dissolved in 0.5-2 molar NaOH, where appropriate in the added presence of 10-50% tetrahydrofuran (THF) or DMF. Acid chloride (1-1.2 equivalents, preferably 1.1 ) was dissolved in THF
(concentration, from 0.05 to 1 M) and this solution was slowly added dropwise. 2 N NaOH was automatically added at RT, using an autotitrator, for the purpose of maintaining a constant pH. The set pH was: from 8 to 12, preferably from 9 to 11. After the termination of the reaction, recognizable by no further NaOH being consumed, the organic cosolvent was removed on a rotary evaporator and the aqueous solution or suspension was treated with ethyl acetate and acidified with 1 N HCI. After the organic phase had been separated off, and the aqueous phase had been extracted once again with ethyl acetate, the organic phases were combined and dried over sodium sulfate; the solvent was subsequently removed under reduced pressure. The crude product was either subjected directly to further reaction or purified by chromatography.
General protocol 3: Sulfonamide from sulfonyl chloride and carboxylic acid.
This protocol is particularly suitable for the reaction of biphenylethylsulfonyl chloride with iminocarboxylic acids (see Example 6 and Example 7) or 5 similar, more hydrolysis-labile sulfonyl chlorides.
8 mmol of the imino acid were dissolved or suspended in 30 ml of acetonitrile. 2.3 g (9 mmol) of BSTFA (bis(trimethylsilyl)trifluoroacetamide) were added at RT and under an inert gas (N2) and the mixture was heated 10 for 2 h under reflux. 2.84 g (9 mmol) of 4-chlorobiphenylethanesulfonyl chloride, dissolved in 30 ml of acetonitrile, were added to this solution and the whole was once again heated for 3 h under reflux conditions. After the reaction mixture had cooled down, aqueous 1 N HCI was added and the mixture was stirred for 1 h; the solvent was then removed under reduced 15 pressure on a rotary evaporator, after which ethyl acetate or chloroform was added; the organic phase was then separated off, extracted with a saturated solution of NaCI, dried over sodium sulfate and concentrated under reduced pressure. Depending on its purity, it was either possible to subject the reaction product directly to further reaction or necessary to 20 previously chromatograph it through silica gel.
General protocol 4: Preparing the hydroxamic acid from carboxylic acid by way of chloroformate activation 25 The sulfonated carboxylic acid was dissolved in 10 ml of DMF after which 1.1 equivalents of ethyl chloroformate, 2.2 equivalents of N-ethylmorpholine and, after a preactivation time of from 30 min to 1 h, 3 equivalents of trimethylsilylhydroxylamine were added at 0°C. After the mixture had been heated at 80°C for at least 4 h, the solvent was removed under reduced 30 pressure and the crude product purified using chromatographic methods.
General protocol 5: Preparing the hydroxamic acid by way of the corresponding carbonyl chloride 35 The sulfonated carboxylic acid was initially introduced in dry chloroform (ethanol-free) (about 5 ml for 0.5 mmol) and 3 equivalents of oxalyl chloride were added at RT. The mixture was then heated at 45°C for about 30 min.
In order to monitor the chloride formation, a small sample was removed from the reaction flask and treated with a little benzylamine in THF. It was possible to ascertain when the reaction was complete by the quantitative formation of benzylamide; it was no longer possible to detect the carboxylic acid (monitoring by HPLC-MS). It may be necessary to heat for a longer period or to heat under reflux conditions. The solvent was then distilled off under reduced pressure, after which the residue was taken up repeatedly in dry toluene and once again subjected to rotary evaporation. The acid chloride was now once again taken up in chloroform (10 ml per 0.5 mmol) and this mixture was treated, at RT, with 3 equivalents of O-trimethylsilylhydroxylamine. After a reaction period of at least 30 min (reaction monitored by HPLC-MS), the reaction mixture was evaporated under reduced pressure and the residue was purified directly by chromatography.
Special protocols 4-Chlorobiphenyiethanesulfonyl chloride (intermediate for Example 7) Step 1: 1-(2-Bromoethenone)-4-(4-chlorophenyl)benzene 4-Chlorobiphenyl (23.6 g, 0.125 mol) was introduced, in portions and at 0°C, into a stirred suspension of AICl3 (34.7 g, 0.26 mol) and bromoacetyl bromide (25.2 g, 0.125 mol) in 400 ml of CS2 and the reaction mixture was then heated under reflux for 3 h. After that, it was slowly poured onto ice and subsequently extracted with ethyl acetate; the organic phase was then washed with an aqueous solution of NaHC03 and with water. )t was then dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue which remained was recrystallized from dichloromethane.
Yield: 24.2 g (62% of theory). m.p.: 127 -128°C
'H-NMR: (300 MHz) 5.0 (s, 2H, CH2); 7.5-8.1 (4 d, 8H, ar) MS: 311.1 (M+H) Step 2: 4-Chlorobiphenylethane bromide tert-Butylamineborane (27.5 g, 0.31 mol) was added, at 0°C, to a stirred suspension of AICI3 (20.0 g, 0.15 mol) in dichloromethane (500 ml). After the mixture had been stirred at 0°C for 15 min, a solution of the bromoketone from step 1 (16.0 g, 50 mmol) in dichloromethane (150 mi) was added and the mixture was stirred at 0°C for a further 4 h. Cold dilute HCI (1 N, 30 ml) was added dropwise, after which the mixture was extracted several times with ethyl acetate. The combined organic phases were washed first with dilute HCI and then with a saturated solution of sodium chloride, after which they were evaporated. An oily compound, which was purified by flash chromatography on silica gel, was obtained.
Yield: 15 g (quantitative), m.p.: 142°C
'H-NMR: (300 MHz) 3.2; 3.78 (2t, 4H, CH2); 7.4-7.7 (4 d, 8H, ar) MS: 296.2 (M+H) Step 3: Sodium salt of the 4-chlorobiphenylethanesulfonic acid The compound from step 2 (14.8 g, 50 mmol) was dissolved in a mixture of ethanol and water (1:1, 200 ml). Sodium sulfite (9.5 g, 75 mmol) and tetrabutylammonium iodide (1.8 g, 5 mmol) were added and the mixture was heated under reflux for 16 h. After that, the liquid reaction mixture was decanted off from a small quantity of a solid and the volume of this mixture was reduced by partially evaporating the mixture under reduced pressure.
Then the mixture was cooled, the product crystallized out and was subsequently filtered off and recrystallized from MeOH/H20. It was then dried under reduced pressure.
Yield: 13.9 g (94% of theory).
'H-NMR: (300 MHz) 2.6; 2.95 (2 m, 4 H, CH2); 7.3-7.7 (4 d, 8H, ar) Step 4: 4-Chlorobiphenylethanesulfonyl chloride Phosphorus pentachloride (3.2 g, 15 mmol) was added to a suspension of the compound from step 3 (4.8 g, 15 mmol) in phosphorus oxychloride (50 ml). The mixture was heated at 60°C for 6 h and was subsequently poured onto ice after methylene chloride had been added. This mixture was neutralized with a saturated solution of sodium hydrogen carbonate and the organic phase was separated off, dried and evaporated under reduced pressure.
Yield: 5 g (quantitative) 'H-NMR: (300 MHz) 2.9 (m, 4H, CH2); 7.3-7.7 (4 d, 8H, ar) Using chiral high pressure liquid chromatography (HPLC) to separate the enantiomers of preparation example 3:
Column employed: Chiralpak ADR, 250 x 4.6 mm, 30°C, running time: 30 min, injection volume: 5 NI, flow rate: 1 ml/min, solvent MeOH/EtOH 1:1 isocratic, detection at 277 nm.
In diseases such as osteoarthritis and rheumatism, destruction of the joint takes place, with this destruction being caused, in particular, by the proteolytic breakdown of collagen due to collagenases. Collagenases belong to the metalloproteinase (MP) or matrix metalloproteinase (MMP) supen'amily. The MMPs form a group of Zn-dependent enzymes which are involved in the biological breakdown of the extracellular matrix (D. Yip et al.
in Investigational New Drugs 17 (1999), 387-399 and Michaelides et al. in Current Pharmaceutical Design 5 (1999) 787 - 819). These MMPs are, in particular, able to break down fibrillar and nonfibrillar collagen and also proteoglycans, both of which are important matrix constituents. MMPs are involved in processes of wound healing, tumor invasion and metastasis migration, and also in angiogenesis, multiple sclerosis and heart failure (Michaelides, page 788; see above). In particular, they play an important role in the breakdown of the joint matrix in arthrosis and arthritis, whether this be osteoarthrosis, osteoarthritis or rheumatoid arthritis.
The activity of the MMPs is furthermore essential for many of the processes which play a role in atherosclerotic plaque formation, such as the infiltration of inflammatory cells and smooth muscle cell migration, as well as proliferation and angiogenesis (S.J. George, Exp. Opin. Invest. Drugs (2000), 9 (5), 993-1007). Furthermore, the degradation of matrix by MMPs can cause anything from plaque instabilities through to ruptures, with these conditions being able to give rise to the clinical symptoms of atherosclerosis, unstable angina pectoris, myocardial infarction or stroke (E.J.M. Creemers et al., Circulation Res. 89, 201-210 (2001 )). All in all, the MMP family as a whole is able to break down all the components of the extracellular matrix of the blood vessels; in normal blood vessels, therefore, their activity is to a very great degree subject to regulatory mechanisms.
The increase in MMP activity during plaque formation and plaque instability is caused by an increase in cytokine-stimulated and growth factor-stimulated gene transcription, an increase in zymogen activation and an imbalance in the MMPITIMP (tissue inhibitors of metalloproteases) ratio. It therefore seems plausible that an MMP inhibition or the reattainment of the MMP-TIMP balance, would be helpful in treating atherosclerotic diseases. It is likewise becoming ever more clear that an increase in MMP activity is at least partially responsible for other cardiovascular diseases in addition to atherosclerosis, such as restenosis, dilated cardiomyopathy and the previously mentioned myocardial infarction. It has been shown that administering synthetic inhibitors to experimental animal models of these diseases is able to achieve marked improvements, for example in regard to the formation of atherosclerotic lesions, neointima formation, left ventricular remodeling, pump performance malfunction or infarction healing. In various preclinical studies using MMP inhibitors, detailed tissue analyses indicated a reduction in collagen damage, an improvement in extracellular matrix remodeling and an improvement in the structure and function of cardiac muscle and blood vessels. Among these processes, matrix remodeling processes and MMP-regulated fibroses, in particular, are regarded as being important components in the progression of heart diseases (infarction) (Drugs 61, 1239-1252 (2001 )).
Under physiological conditions, MMPs cleave matrix proteins such as collagen, laminin, proteoglycans, elastin or gelatine, and also process (i.e.
activate or inactivate), by means of cleavage, a large number of other proteins and enzymes, which means that they play an important role in the entire body, with this role being particularly significant in the connective tissue and bones.
A large number of different MMP inhibitors are known (EP 0 606 046; WO
94/28889; WO 96/27583; cf. reviews such as Current Medicinal Chemistry 8, 425-74 (2001 ) as welt). Following the first clinical studies in humans, it has now been found that MMPs give rise to side-effects. The side-effects to be mentioned are musculoskeletal pain or anthralgias. The prior art makes it clear that it is expected that more selective inhibitors would be able to reduce these side-effects (Yip, page 387, see above). Specificity towards MMP-1 is particularly to be emphasized in this connection since these unwanted side-effects evidently appear to an increased extent when MMP-1 is inhibited.
A disadvantage of the known MMP inhibitors is therefore that they frequently lack specificity. Most MMP inhibitors inhibit many MMPs simultaneously because the catalytic domains of the MMPs possess similar structures. As a consequence, the inhibitors also undesirably affect the enzymes which have a vital function (Massova I, et al., The FASEB Journal (1998) 12, 1075-1095).
In the endeavor to find effective compounds for treating connective tissue diseases, it has now been found that the derivatives which are employed in accordance with the invention are powerful inhibitors of the matrix metalloproteinases MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13 while only having a weak inhibitory effect on MMP-1.
The invention therefore relates to a compound of the formula I
n1 0 n2 R2 N,S A-ring-B ' ring2 D-ring3 E-ring4 R5 ~ R1 R3 X (I) andlor to all the stereoisomeric forms of the compound of the formula I
and/or to mixtures of these forms in any ratio, and/or to a physiologically tolerated salt of the compound of the formula I, wherein A is -(Co-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(Co-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)~-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m , in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1 ) -C(O)-2) -(C2-C4)-alkenylene, 3) -S(O)o , where o is the integers zero, 1 or 2, 4) -N(R6)-, in which R6 is hydrogen atom, methyl or ethyl, 5) -N(R6)-C(Y)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 6) -C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 7) -N(R6)-S02-, in which R6 is defined as above, 8) -SOZ-N(R6)-, in which R6 is defined as above, 9) -N(R6)-S02-N(R6)-, in which R6 is defined as above, 10) -N(R6)-C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 11 ) -O-C(O)-N(R6)-, 12) -NH-C(O)-O-, 13) -O-, 14) -C(O)-O-, 15) -O-C(O)-, 16) -O-C(O)-O-, 17) -O-CH2-C(O)-, 18) -O-CH2-C(O)-O-, 19) -O-CH2-C(O)-N(R6)-, in which R6 is defined as above, 20) -C(O)-CHZ-O-, 21 ) -O-C(O)-CH2-O-, 22) -N(R6)-C(O)-CH2-O-, in which R6 is defined as above, 23) -O-(CH2)"-O-, in which n is the integer 2 or 3, or 24) -O-(CHZ)m-N(R6)-, in which m is the integer 2 or 3 and R6 is defined as above, 25) -N(R6)-(CH2)m-O-, in which m is the integer 2 or 3 and R6 is defined as above, 26) -N(R6)-N(R6)-, in which R6 is defined as above, 27) -N=N-, 28) -N(R6)-CH=N-, in which R6 is defined as above, 29) -N=CH-N(R6)-, in which R6 is defined as above, 30) -N(R6)-C(R7)=N-, in which R6 is defined as above and R7 is -N H-R6, 31 ) -N=C(R7)-N(R6)-, in which R6 is defined as above and R7 is -NH-R6, or 32) -(CZ-C6)-alkynylene, ring1, and ring3 are identical or different and are, ring2 independently of each other, 1 ) covalent bond, 2) -(C6-C~4)-aryl, in which aryl is unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) 4- to 15-membered Het ring, in which Het ring is unsubstituted or substituted, independently of each other, once, twice or three times, by G, ring4 is 5 1 ) -(C6-C~4)-aryl, in which aryl is unsubstituted or substituted, independently of each other, once, twice or three times, by G, 2) 4- to 15-membered Het ring, in which the Het ring is unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) is one of the following radicals O N O O N O
H H
and these radicals are unsubstituted or substituted once by G, G is 1 ) hydrogen atom, 2) halogen, 3) =O, 4) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, 5) -(Cs-C,a)-aryl, 6) Het ring, 7) -C(O)-O-R10, in which R10 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(CZ-C6)-alkynyl, -(Cs-C~4)-aryl or Het ring, or b) -(C6-C~4)-aryl or Het ring, 8) -C(S)-O-R10, in which R10 is defined as above, 9) -C(O)-NH-R11, in which R11 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C6-C,4)-aryl or Het ring, or b) -(C6-C~4)-aryl or Het ring, 10) -C(S)-NH-R11, in which R11 is defined as above, 11 ) -O-R12, in which R12 is a) hydrogen atom, b) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, (Cs-Cia)-aryl or Het ring, c) -(Cs-C,a)-aryl, d) Het ring, e) -C(O)-O-R13, in which R13 is e)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(CZ-Cs) alkynyl, -(C6-C~4)-aryl, or Het ring, or e)2) -(C6-C~4)-aryl or Het ring, f) -C(S)-O-R13, in which R13 is defined as above, g) -C(O)-NH-R14, in which R14 is g)1 ) -(C~-Cs)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(CZ-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, or g)2) -(C6-C~4)-aryl or Het ring, or h) -C(S)-NH-R14, in which R14 is defined as above, 12) -C(O)-R10, in which R10 is defined as above, 13) -S(O)p R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 14) -N02, 15) -CN, or 16) -N(R15)-R12, in which R15 is 16)1 ) hydrogen atom, 16)2) -(C~-C6)-alkyl, or 16)3) -S02-(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(CZ-C6)-alkynyl, -(C6-C1a)-aryl or Het ring, and R12 is defined as above, or 17) -S02-N(R12)-R1, in which R12 is defined as above and R1 is defined as below, X is -OH or -NH-OH, n1 is the integer zero, 1, 2 or 3, n2 is the integer zero, 1, 2, 3 or 4, with the proviso that the sum of n1 and n2 amounts to 1, 2, 3, 4, 5, 6 or 7, R1, R2, R3, R4 and R5 are identical or different and are, independently of each other, 1 ) hydrogen atom, 2) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-Cs)-alkynyl, -(C6-C~a)-aryl or Het ring, 3. -C(O)-O-R8, in which R8 is 3)1 ) hydrogen atom, 3)2) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, or substituted once to five times, by fluorine, or 3)3) -(C6-C~4)-aryl or Het ring, 4) -O-R8, in which R8 has the abovementioned meaning, or 5) -(C3-C6)-cycloalkyl.
The invention also relates to the compound of the formula I where A is -(Co-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(Co-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CHZ)~-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1 ) -C(O)-2) -(CZ-C4)-alkenylene, 3) -S(O)o-, where o is the integers zero, 1 or 2, 4) -N(R6)-, in which R6 is hydrogen atom, methyl or ethyl, 5) -N(R6)-C(Y)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 6) -C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 7) -N(R6)-S02-, in which R6 is defined as above, - 8) -SOz-N(R6)-, in which R6 is defined as above, 9) -N(R6)-S02-N(R6)-, in which R6 is defined as above, 10) -N(R6)-C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 11 ) -O-C(O)-N(R6)-, 12) -NH-C(O)-O-, 13) -O-, 14) -C(O)-O-, 15) -O-C(O)-, 16) -O-C(O)-O-, 17) -O-CH2-C(O)-, 18) -O-CH2-C(O)-O-, 19) -O-CH2-C(O)-N(R6)-, in which R6 is defined as above, 20) -C(O)-CHZ-O-, 21 ) -O-C(O)-CH2-O-, 22) -N(R6)-C(O)-CH2-O-, in which R6 is defined as above, 23) -O-(CH2)~-O-, in which n is the integer 2 or 3, or 24) -O-(CH2)m-N(R6)-, in which m is the integer 2 or 3 and R6 is defined as above, 25) -N(R6)-(CH2)m-O-, in which m is the integer 2 or 3 and R6 is defined as above, 26) -N(R6)-N(R6)-, in which R6 is defined as above, 27) -N=N-, 28) -N(R6)-CH=N-, in which R6 is defined as above, 29) -N=CH-N(R6)-, in which R6 is defined as above, 30) -N(R6)-C(R7)=N-, in which R6 is defined as above and R7 is -N H-R6, 31 ) -N=C(R7)-N(R6)-, in which R6 is defined as above and R7 is -NH-R6, or 32) -(C2-C6)-alkynylene, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1 ) covalent bond, 2) phenyl or naphthyl and are unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) 4- to 15-membered Het ring, in which the Het ring is a radical from the series acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, deca-hydroquinolinyl, dibenzofuranyl, dibenzothiophenyl, dihydrofuran[2,3-b]tetrahydrofuranyl, dihydrofuranyl, dioxolyl, dioxanyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1 H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxothiolanyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydro-pyridinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thia-diazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, and these radicals are unsubstituted or substituted, independently of each other, once, twice or three times, by G, ring4 is 1 ) -(C6-C~4)-aryl, in which aryl is a radical from the series phenyl, naphthyl, 1-naphthyl, 2-naphthyl, anthryl and fluorenyl, and these radicals are unsubstituted or substituted, independently of each other, once, twice or three times, by G, 2) 4- to 15-membered Het ring, in which the Het ring is a radical from the series acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, deca-hydroquinolinyl, dibenzofuranyl, dibenzothiophenyl, dihydrofuran[2,3-b]tetrahydrofuranyl, dihydrofuranyl, dioxolyl, dioxanyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1 H-indazolyl, indolinyl, 5 indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolinyl, 2'-methylbiphenyl-2-0l, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, 10 oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxothiolanyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydro-pyridinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thia-diazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, . and are unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) is one of the following radicals O N O O N O
H H
and these radicals are unsubstituted or substituted once by G, G is 1 ) hydrogen atom, 2) halogen, 3) =O, 4) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, 5) -(C6-C~4)-aryl, where aryl is defined as above, 6) Het ring, where Het ring is defined as above, 7) -C(O)-O-R10, in which R10 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, or b) -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, 8) -C(S)-O-R10, where R10 is defined as above, 9) -C(O)-NH-R11, in which R11 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, or b) -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, 10) -C(S)-NH-R11, in which R11 is defined as above, 11 ) -O-R12, in which R12 is a) hydrogen atom, b) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-Cs)-alkynyl, -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, c) -(C6-C~4)-aryl, where aryl is defined as above, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~a)-aryl, or Het ring, where aryl and Het ring are defined as above, or e)2) -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, f) -C(S)-O-R13, in which R13 is defined as above, g) -C(O)-NH-R14, in which R14 is g)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, or g)2) -(C6-C~4)-aryl or Het ring, where aryl and Het ring are defined as above, or h) -C(S)-NH-R14, in which R14 is defined as above, 12) -C(O)-R10, in which R10 is defined as above, 13) -S(O)p-R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 14) -N02, 15) -CN, or 16) -N(R15)-R12, in which R15 is 16)1 ) hydrogen atom, or 16.2) -(C~-C6)-alkyl and R12 is defined as above, 16.3) -S02-(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, 17) -SOZ-N(R12)-R1, in which R12 is defined as above and R1 is defined as below, X is -OH or -NH-OH, n1 is the integer 1 or 2, n2 is the integer 2 or 3, R1, R2, R3, R4 and R5 are identical or different and are, independently of each other, 1 ) hydrogen atom, 2) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(CZ-C6)-alkynyl, -(C6-C,4)-aryl or Het ring, 3) -C(O)-O-R8, in which R8 is 3)1 ) hydrogen atom, 3)2) -(C~-Cs)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C~4)-aryl or Het ring, or is substituted once to five times by fluorine, or 3)3) -(C6-C~a)-aryl or Het ring, 4) -O-R8, in which R8 has the abovementioned meaning, or 5) -(C3-C6)-cycloalkyl.
The invention furthermore relates to the compound of the formula I wherein A is -(Co-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(Co-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)~ , in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1 ) -(Co-C2)-alkylene, 2) ethenylene, 3) ethynylene, 4) -C(O)-5) -N(R6)-C(O)-, in which R6 is hydrogen atom, methyl or ethyl, 6) -C(O)-N(R6)-, in which R6 is defined as above, 7) -O-, or 8) _S_, ring1, and ring3 are identical or different and are, ring2 independently of each other, 1 ) covalent bond, 2) phenyl or naphthyl and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series dihydrofuranyl, furanyl, pyridinyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl or thiophenyl, and the radicals are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1 ) phenyl or naphthyl and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dihydrofuranyl, dibenzofuranyl, dibenzothiophenyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical O N O
and this radical is unsubstituted or substituted once by G, G is 1 ) hydrogen atom, 2) Br, CI or F, 3) -(C~-C4)-alkyl, in which alkyl is unsubstituted or substituted once or twice by F, phenyl, -C3-cycloalkyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH-R11, in which R11 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, f) -C(S)-O-R13, in which R13 is defined as above, or 5 g) -C(O)-NH-R14, in which R14 is g)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by phenyl or Het ring, where Het ring is defined as above, or 10 g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 10) -S(O)p-R12, in which R12 is defined as above and p is the integers 1 or 2, 15 11 ) -N 02, 12) -CN, or 13) -N(R15)-R12, in which R15 is 13)1 ) hydrogen atom, or 13)2) -(C1-Cs)-alkyl and R12 is defined as above, X is -OH or -NH-OH, n1 is the integer 1 or 2, n2 is the integer 2 or 3, R1, R2 and R3 are in each case hydrogen atom, R4 and R5 are identical or different and are, independently of each other, 1 ) hydrogen atom, 2) methyl, 3) ethyl, or 4) -OH.
The invention furthermore relates to the compound of the formula I wherein A is -(Co-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(Co-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)~-, in which n is the integer zero, 1 or 2, B3 is -(CHZ)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1 ) -(Co-C2)-alkylene, 2) ethenylene, or 3) ethynylene, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1 ) covalent bond, 2) phenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series dihydrofuranyl, furanyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolyl, thiazolyl or thiophenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1 ) phenyl, and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dihydrofuranyl, dibenzofuranyl, dibenzothiophenyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical O N O
and this radical is unsubstituted or substituted once by G, G is 1 ) hydrogen atom, 2) Br, CI or F, 3) -(C~-C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times, by Br, CI, F, -C3-cycloalkyl, phenyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C,-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH -R11, in which R11 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl or naphthyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl, naphthyl, or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, f) -C(S)-O-R13, in which R13 is defined as above, or g) -C(O)-NH-R14, in which R14 is g)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by phenyl or Het ring, where Het ring is defined as above, or g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 10) -S(O)P-R12, in which R12 is defined as above and p is the integers 1 or 2, 11 ) -N02, 12) -CN, or 13) -N(R15)-R12, in which R15 is 13)1 ) hydrogen atom, or 13)2) -(C~-C6)-alkyl and R12 is defined as above, X is -OH or -NH-OH, n1 is the integer 2, n2 is the integer 3, R1, R2, R3, R4 and R5 are in each case hydrogen atom.
The invention furthermore relates to the compound of the formula I wherein A is a covalent bond or -CH2-CH2-, B, D and E are identical or different and are, independently of each other, -(Co-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)"-, in which n is the integer zero, 1 or 2, B3 is -(CHZ)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1 ) -C(O)-2) -(C2-C4)-alkynylene, 3) -S(O)o-, where o is the integers zero or 1, 4) -N(R6)-C(Y)-, in which Y is oxygen atom and R6 is hydrogen atom, 5) -C(Y)-N(R6)-, in which Y is oxygen atom and R6 is hydrogen atom, or 6 ) -O-, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1 ) covalent bond, 2) phenyl and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series furanyl, pyridinyl, pyrimidinyl or thiophenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1 ) phenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dibenzofuranyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical o~o s and this radical is unsubstituted or substituted once by G, G is 1 ) hydrogen atom, 2) Br, CI or F, 3) -(C~-C4)-alkyl, in which alkyl is unsubstituted or once, twice or three times, by Br, CI, F, -C3-cycloalkyl, phenyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH-R11, in which R11 is a) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, 5 f) -C(S)-O-R13, in which R13 is defined as above, or g) -C(O)-NH-R14, in which R14 is g)1 ) -(C~-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or 10 twice, by phenyl or Het ring, where Het ring is defined as above, or g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 15 10) -S(O)p-R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 11 ) -N02, 12) -CN, or 13) -N(R15)-R12, in which R15 is 20 13)1 ) hydrogen atom, or 13)2) -(C~-C6)-alkyl and R12 is defined as above, X is -NH-OH, n1 is the integer 2, n2 is the integer 3, and R1, R2, R3, R4 and R5 are in each case hydrogen atom.
The invention also relates to the compound of the formula I from the series 2-(4'-nitrobiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(4'-chlorobiphenyl-4-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-(4'-chlorobiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)-carboxamide, 2-(6-phenoxypyridine-3-sulfonyl)decahydroisoquinoline-1-carboxylic acid;
trifluoroacetate, 2-(6-phenoxypyridine-3-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)-carboxamide; trifluoroacetate, 2-[2-(4'-chlorobiphenyl-4-yl)ethanesulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-[2-(4'-chlorobiphenyl-4-yl)ethanesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(pyridin-4-yloxy)benzenesulfonyl]decahydroisoquinoline-1-carboxylic acid; trifluoroacetate, 2-[4-(pyridin-4-yloxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)-carboxamide; trifluoroacetate, 2-[4-(4-methoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-[4-(4-methoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-{4-[4-(2,2,2-trifluoroethoxy)phenoxy]benzenesulfonyl}decahydro-isoquinoline-1-carboxylic acid, 2-{4-[4-(2,2,2-trifluoroethoxy)phenoxy]benzenesulfonyl}decahydro-isoquinoline-1-(N-hydroxy)carboxamide, 2-[4'-(2,2,2-trifluoroethoxy)biphenyl-4-sulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-(4'-isopropoxycarbonylaminobiphenyl-4-sulfonyl)decahydroisoquinoline-1- carboxylic acid, [4'-(1-hydroxycarbamoyloctahydroisoquinoline-2-sulfonyl)biphenyl-4-yl]carboxamide isopropyl ester, 2-[4'-(2,2,2-trifluoroethoxy)biphenyl-4-sulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(4'-trifluoromethoxybiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-fluorophenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-trifluoromethoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-trifluoromethoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-(biphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(biphenyl-4-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-[4-(4-cyanophenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(dibenzofuran-2-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-(dibenzofuran-2-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, or 2-[4-(4-fluorophenoxy)benzenesulfonyl]-6-methoxydecahydroisoquinoline-1-(N-hydroxy)carboxamide, and also all the isomeric forms of the abovementioned compounds.
The term "(C~-C6)alkyl" is understood as meaning hydrocarbon radicals whose carbon chain is straight-chain or branched and contains from 1 to 6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, isopentyl, neopentyl, hexyl, 2,3-dimethylbutane or neohexyl.
The term "-(Co-C4)alkylene" is understood as meaning hydrocarbon radicals whose carbon chain is straight-chain or branched and contains from 1 to 4 carbon atoms, for example methylene, ethylene, propylene, isopropylene, isobutylene, butylene or tertiary butylene. "-Co-Alkylene" is a covalent bond.
The term "-(CH2)~-, in which n is the integer zero, 1 or 2" is understood as meaning a covalent bond, where n is zero, the radical methylene, where n is 1 and the radical ethylene where n is 2.
The term "-(C2-C4)-alkenylene" is understood as meaning hydrocarbon radicals whose carbon chain is straight-chain or branched and contains from 2 to 4 carbon atoms and which, depending on chain length, possess one or two double bonds, for example ethenylene, propenylene, isopropenylene, isobutenylene or butenylene; insofar as the possibility exists in principle, the substituents at the double bond can be arranged in the E position or Z position.
The term "-(C2-C6)-alkynylene" is understood as meaning hydrocarbon radicals whose carbon chain is straight-chain or branched and contains from 2 to 6 carbon atoms and which, depending on chain length, possess one or two triple bonds, for example ethynylene, propenylene, isopropynylene, isobutynyl, butynylene, pentynylene or isomers of pentynylene, or hexynyl or isomers of hexynylene.
The term "(C3-C6)-cycloalkyl" is understood as meaning radicals such as compounds which are derived from 3- to 6-membered monocycles such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
The radicals n2 n1 or are in each case understood as meaning -CH2- radicals in the ring of the formula I, where the variables n1 or n2 in each case specify the number of the -CH2- radicals in the ring of the formula I. When n1 has the value zero, a covalent bond ensues and the resulting part ring has a total of 4 ring atoms. When n2 has the value zero, a covalent bond ensues and the resulting part ring has a total of 3 ring atoms. When n1 has the value 1, a -CH2- radical ensues and the resulting part ring has a total of 5 ring atoms.
When n1 has the value 2, a -CH2-CH2- radical ensues and the resulting part ring has a total of 6 ring atoms. When n1 has the value 3, a -CH2-CHZ-CH2- radical ensues and the resulting part ring has a total of 7 ring atoms.
Corresponding part rings ensue in the case of n2.
The term "-(C6-C~4)-aryl" is understood as meaning aromatic hydrocarbon radicals having from 6 to 14 carbon atoms in the ring. -(C6-C~4)-Aryl radicals are, for example, phenyl, naphthyl, for example 1-naphthyl or 2 naphthyl, anthryl or fluorenyl. Naphthyl radicals and, in particular, phenyl radicals are preferred aryl radicals.
The term "4- to 15-membered Het ring" or "Het ring" is understood as meaning ring systems which have from 4 to 15 carbon atoms, which are present in one, two or three ring systems which are linked to each other, and which contain one, two, three or four identical or different heteroatoms from the series oxygen, nitrogen or sulfur. Examples of these ring systems are the radicals acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, dibenzofuranyl, dibenzothiophenyl, dihydrofuran[2,3-b]tetrahydrofuranyl, dihydrofuranyl, dioxolyl, dioxanyl, 2H, 6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1 H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolinyl, 2'-methylbiphenyl-2-o1, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxothiolanyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydropyridinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl.
Preferred Het rings are the radicals benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, 1,3-benzodioxolyl, quinazolinyl, quinolinyl, quinoxalinyl, chromanyl, cinnolinyl, furanyl such as 2-furanyl and 3-furanyl; imidazolyl, indolyl, indazolyl, isoquinolinyl, isochromanyl, isoindolyi, isothiazolyi, isoxazolyl, 2'-methyibiphenyl-2-ol, oxazolyl, phthalazinyl, pteridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridyl; such as 2-pyridyl, 3-pyridyl or 4-pyridyl; pyrimidinyl, pyrrolyl; such as 2-pyrrolyl and pyrrolyl; purinyl, thiazolyl, tetrazolyl or thienyl; such as 2-thienyl and 3-thienyl.
The term "halogen" is understood as meaning fluorine, chlorine, bromine or iodine.
The invention furthermore relates to a process for preparing the compound of the formula I andlor a stereoisomeric form of the compound of formula I
and/or a physiologically tolerated salt of the compound of the formula I, which comprises a) reacting a compound of the formula IV, O
n2 R2 ,Re ~O
NH (IV) in which Re is a hydrogen atom or an ester-protecting group, with a compound of the formula V, Rz-S- A -rings- B ring2 D ring3 E-ring4 (V) in which A, B, D, E and ring1, ring2, ring3 and ring4 are defined as in formula I, and in which Rz is chlorine atom, imidazoyl or OH, 10 in the presence of a base or following silylation with a suitable silylating agent, or using a suitable dehydrating agent when Rz = OH, to give a compound of the formula VI, n2 O
R2 ,Re ~O
R5 R3 N\S O A-ring-B-ringZ D-ring3 E-ring4 (vp O
in which A, B, D, E, Re and ringl , ring2, ring3 and ring4 are defined as above, and b) when Re = ester reacting a compound of the formula VI prepared as described in a) with a solution of alkali such as NaOH or LiOH, and then treating the product with acid, to give the carboxylic acid according to the invention of the formula I, in which X = OH
(corresponding to VII), with modifications in one of the side chains of the rings ring1-ring4 also having previously been made, where appropriate; or converting said ester, by treating it with a mineral acid, such as hydrochloric acid, into the free carboxylic acid VII
n2 O
'OH
N~ %O (VII) R5 R3 S-A-ring-B-ringZ D-ring3 E-ringa O
and then converting this into the hydroxamic acid according to the invention, in which X = NH-OH, of the formula I, c) using salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases, or derivatization with chiral, enantiomerically pure compounds such as amino acids, separation of the resulting diastereomers and elimination of the chiral auxiliary groups, to separate a compound of formula I prepared as described in procedure a), or a suitable precursor of the formula I, which arises in enantiomeric forms due to its chemical structure, into the pure enantiomers, or d) either isolating the compound of the formula I prepared as described in procedures b) or c) in free form, or, when acid or basic groups are present, converting it into physiologically tolerated salts.
Compounds of the formula IV to VII type are compounds which are only presented by way of example; in accordance with formula I, it is also possible to adduce four-membered rings, six-membered rings and seven-membered rings instead of the five-membered ring.
Compounds of the formula IV type can be prepared using known protocols.
For example, compounds in which n~ = 1 and n2 = 0 (methanoprolines) can be prepared using a number of known methods. The description of a recent synthesis can be found, for example, in Tetrahedron 53, 14773-92 (1997).
For example, the bicyclic skeletons of the formula IV in which n~ = 2 and n2 - 3 in accordance with formula I can be prepared by hydrogenation of isoquinoline-1-carboxylic acid or suitable derivatives of isoquinoline-1 carboxylic acid, such as methyl ester or ethyl ester. This hydrogenation is described, for example, in US 5430023, US 5726159 and EP 643073.
In the same way, it is possible to use 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid and its derivatives to prepare these compounds by hydrogenation. This procedure has the advantage that it is possible to use a broad range of methods for synthesizing the 1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acids. For example, Pictet-Spengler-type cyclizations, such as described in US 4902695, are particularly well known and broadly applicable. Depending on the nature of the starting compounds employed, such methods can be used, for example, to obtain substituted compounds, i.e. compounds in which the substituents R1, R4 and R5 are not H atoms. A novel example of ring-substituted compounds can be found in WO 2003041641. Innumerable examples of R1 and/or R4 and R5 not being H exist and are readily available to the skilled person.
Other possible methods for preparing the cyclic skeletons use free radical cyclization reactions, for example, and are described in Tetrahedron 48, 4659-76 (1992).
Other methods can be used for synthesizing compounds of the IV type when n~ = 1 and n3 = 3. For example, described syntheses are to be found in Tetrahedron 55, 8025 (1999) and Tetrahedron Lett. 24, 5339 (1983) or in the laid-open specifications DE 3322530 and DE 3211676.
Methods for synthesizing compounds of the IV type in which n~ = 1 and n2 - 2 are likewise to be found in Tetrahedron 55, 8025 (1999) and DE 3322530 or DE 3211676.
Methods for synthesizing the skeletons of related compounds, for example in which n~ = 1 and n2 = 4, are also described. For example, J. Org. Chem.
61, 7125 (1996) describes syntheses of (3-lactams which contain said skeleton. The substituted basic structures in analogy with formula IV can also be prepared from these compounds by opening the (i-lactam.
Methods for synthesizing the skeletons in which n~ = 2 and n2 = 4 are likewise known and well described, for example in EP 0672665 and the abovementioned references.
The groups used as protecting groups for esters in "Protective Groups in Organic Synthesis", T.H. Greene, P.G.M. Wuts, Wiley-Interscience, 1999, can be used as the ester-protecting group Re. Examples of preferred ester-protecting groups are methyl, ethyl, isopropyl, tert-butyl and benzyl.
Under certain conditions, it can be useful to employ compounds of the IV
type in the N-protected state. For example, it is easier to purify compounds which are protected in this way than it is to purify the free imino acids; in the same way, these protected compounds can sometimes also be more readily used for preparing the enantiomerically pure or diastereomerically pure compounds. The groups described in "Protective Groups in Organic Synthesis", T.H. Greene, P.G.M. Wuts, Wiley-Interscience, 1999, can be employed as protecting groups for the amino group. Examples of preferred amino-protecting or imino-protecting groups are Z, Boc, Fmoc, Aloc, acetyl, trifluoroacetyl, benzoyl, benzyl and the like.
The starting compounds and reagents employed can either be prepared using known methods or obtained commercially.
The reactions are carried out as described, for example, in WO 97/18194.
The reaction as described in procedural step a) takes place in the presence of a base, such as KOH, NaOH, LiOH, N-methylmorpholine (NMM), N-ethylmorpholine (NEM), triethylamine (TEA), diisopropylethylamine (DIPEA), pyridine, collidin, imidazole or sodium carbonate, in solvents such as tetrahydrofuran (THF), dimethylformamide (DMF), dimethylacetamide, dioxane, acetonitrile, toluene, chloroform or methylene chloride, or else in the presence of water. If the reaction is being carried out using silylating agents, N,O-bis(trimethylsilyl)acetamide (BSA) or N,O-bis(trimethylsilyl)-trifluoroacetamide (BSTFA) is used, for example, for silylating the imino acid in order to subsequently carry out the sulfonamide formation.
Modifications in the side chain F mean that, for example, a nitro group is hydrogenated using the metal catalyst Pd/C, or reacted with SnCl2 or Zn under standard conditions, and the resulting amino group can then be subjected to further modification, for example by reacting it with carbonyl chlorides, sulfonyl chlorides, chloroformic esters, isocyanates, isothiocyanates or other reactive or activatable reagents in order to arrive at the precursors of the compounds of formula I according to the invention.
In this case, it is frequently advantageous for Re in compound VI to be an ester since side reactions can be expected when the carboxylic acid is unprotected.
In procedural step c), the compound of the formula I is separated, insofar as it arises as a mixture of diastereomers or enantiomers, or accrues in the chosen synthesis as their mixtures, into the pure stereoisomers, either by means of chromatography on a support material, which is chiral where appropriate, or, provided the racemic compound of formula I is capable of salt formation, by means of fractional crystallization of the diastereomeric salts which are formed with an optically active base or acid used as auxiliary substance. Examples of chiral stationary phases which are suitable for separating enantiomers by means of thin layer chromatography or column chromatography are modified silica gel supports (what are termed Pirkle phases) and also high molecular weight carbohydrates such as triacetylcellulose. For analytical purposes, it is also possible, following appropriate derivatization known to the skilled person, to use gas-chromatographic methods on chiral stationary phases. In order to resolve the racemic carboxylic acids into their enantiomers, an optically active base, which is as a rule commercially available, such as (-)-nicotine, (+)-and (-)-phenylethylamine, quinine bases, L-lysine or L- and D-arginine, are used to form the differently soluble diastereomeric salts, the more difficulty soluble component is isolated as a solid, the more readily soluble diastereomer is removed from the mother liquor, and the pure enantiomers are obtained from the diastereomeric salts which have thus been isolated.
In what is in principle the same way, the racemic compounds of the formula I which contain a basic group such as an amino group can be converted into the pure enantiomers using optically active acids, such as (+)-camphor-10-sulfonic acid, D- and L-tartaric acid, D- and L-lactic acid and also (+)- and (-)-mandelic acid. It is also possible to convert chiral compounds which contain alcohol or amine functions into the corresponding esters or amides using appropriately activated and, where appropriate, N-protected enantiomerically pure amino acids or, vice versa, to convert chiral carboxylic acids into the amides using carboxyl-protected enantiomerically pure amino acids or to convert them into the corresponding chiral esters using enantiomerically pure hydroxycarboxylic acids such as lactic acid. The chirality of the amino acid radical or alcohol radical which has been introduced in enantiomerically pure form can then be used for separating the isomers by carrying out a separation of the diastereomers, which are now present, by means of crystallization or by means of chromatography on suitable stationary phases and, after that, using suitable methods to once again eliminate the entrained chiral molecule moiety.
In addition, the possibility arises, in the case of some of the compounds 5 according to the invention, of using diastereomerically pure or enantiomerically pure starting compounds for preparing the skeletal structures. This then makes it possible, where appropriate, to also use other methods, or simplified methods, for purifying the end products. These starting compounds were prepared beforehand in enantiomerically pure 10 form or diastereomerically pure form using methods known from the literature. For example, it is possible, as mentioned and cited above, to use isoquinoline-1-carboxylic acid either directly in the method for preparing decahydroisoquinoline-1-carboxylic acid. As a result of 3 heterocenters being present, it is possible, in this case, to form a maximum of 8 15 stereoisomers (4 enantiomeric diastereomer pairs). However, the nature of the preparation, for example hydrogenation, strongly favors certain stereoisomers. Thus, it should be possible, as described in the literature, to achieve strong preference for hydrogen attachment at the positions of the ring linkage, for example, by selecting the hydrogenation conditions 20 (catalyst, pressure, solvent and temperature) appropriately. Thus, it is possible, under the specified conditions, to achieve formation of the cis-linked rings. It would then consequently only remain a matter of determining the position of the carboxylic acid since the number of possible stereoisomers would already be restricted to 4. As a result of the nature of 25 the hydrogenation mechanism, it is particularly easy to attach the hydrogens on the same side as that of the bridgehead hydrogens, i.e. a further restriction in the possibility of isomer formation is thereby to be expected. It would consequently be possible, in the most favorable case, to assume that only one enantiomer pair would be formed. It ought then to be 30 possible to use the abovementioned methods to resolve this pair into the enantiomers. However, in connection with these considerations, it has also to be assumed that complete stereoselection will never take place and that, on the contrary, varying proportions of the other isomers will virtually always also be formed or will be detectable, even in very small quantities, when suitable methods are used.
When enantiomerically pure 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid derivatives are used, it would be expected that, if the reaction conditions were identical or similar to those used during the hydrogenation of isoquinoline-1-carboxylic acid, analogous considerations would apply and it would once again to a large extent only be preferred stereoisomers which were formed; in this said case, there should be strong preference for only one single enantiomer since, when carrying out the hydrogenation process under conditions which were analogous to those which lead to the cis ring linkage when hydrogenating isoquinoline-1-carboxylic acid, the H
atoms can once again only be attached from the one side and, as a consequence, analogous products will be formed. The identity of the structures can be established by means of suitable 2D NMR experiments, X ray methods such as cocrystallization and others, as well as reference analysis or chemical derivatization and suitable analysis or chemical derivatization which leads to known and described isomers.
Another possibility for synthesizing enantiomerically pure or diastereomerically pure compounds is that of using suitably chirally substituted starting compounds in order, by means of the chiral substituent, to achieve induction of chirality at other chiral centers. For example, chiral glyoxylic esters could be used in Pictet-Spengler cyclizations in order to obtain chiral Tic derivatives and then to hydrogenate these derivatives, as already mentioned above.
Acid or basic products of the compound of formula I can be present in the form of their salts or in free form. Preference is given to pharmacologically tolerated salts, for example alkali metal or alkaline earth metal salts, or hydrochlorides, hydrobromides, sulfates, hemisulfates and all possible phosphates, as well as salts of the amino acids, natural bases or carboxylic acids. Physiologically tolerated salts are prepared in a manner known per se, in accordance with procedural step d), from compounds of formula I, including their stereoisomeric forms, which are capable of salt formation.
The compounds of formula I form stable alkali metal salts, alkaline earth metal salts, or optionally substituted ammonium salts, with basic reagents such as hydroxides, carbonates, hydrogen carbonates or alkoxides, as well as ammonia or organic bases, for example trimethylamine, triethylamine, ethanolamine, diethanolamine, triethanolamine or trometamol, or else basic amino acids, for example lysine, ornithine or arginine. Provided the compounds of formula I possess basic groups, it is also possible to prepare stable acid addition salts using strong acids. Both inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, hemisulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 4-bromobenzenesulfonic acid, cyclohexylamidosulfonic acid, trifluoromethylsulfonic acid, 2-hydroxyethanesulfonic acid, acetic acid, oxalic acid, tartaric acid, succinic acid, phosphoglyceric acid, lactic acid, malic acid, adipic acid, citric acid, fumaric acid, malefic acid, gluconic acid, glucuronic acid, palmitic acid or trifluoroacetic acid are suitable for this purpose.
The invention also relates to pharmaceuticals which are characterized by an effective content of at least one compound of the formula I and/or a physiologically tolerated salt of the compound of formula I and/or an optionally stereoisomeric form of the compound of formula I, together with a pharmaceutically suitable and physiologically tolerated carrier substance, additive and/or other active compounds and auxiliary substances.
On account of their pharmacological properties, the compounds according to the invention are suitable for the selective prophylaxis and therapy of all those diseases whose course involves an increase in the activity of the metalloproteinases. These diseases include degenerative joint diseases such as osteoarthroses, spondyloses and chondrolysis following joint trauma or a relatively long period of joint immobilization following meniscus injuries or patella injuries or ligament ruptures. They furthermore also include diseases of the connective tissue such as collagenoses, periodontal diseases, wound healing disturbances and chronic diseases of the locomotory apparatus such as inflammatory, immunologically determined or metabolism-determined acute and chronic arthritides, arthropathies, myalgias and disturbances of bone metabolism. The compounds of the formula I are furthermore suitable for the treatment of ulceration, atherosclerosis and stenoses. In addition, the compounds of the formula I are suitable for the treatment of inflammations, cancer diseases, tumor metastases formation, cachexia, anorexia, heart failure and septic shock. The compounds are also suitable for the prophylaxis of myocardial and cerebral infarctions.
The pharmaceuticals according to the invention can be administered by means of oral, inhalative, rectal or transdermal administration or by means of subcutaneous, intraarticular, intraperitoneal or intravenous injection.
Oral administration is preferred.
The invention also relates to a process for producing a pharmaceutical, which comprises bringing at least one compound of the formula I, together with a pharmaceutically suitable and physiologically tolerated excipient and, where appropriate, other suitable active compounds, additives or auxiliary substances, in a suitable form of administration.
Examples of suitable solid or galenic preparation forms are granules, powders, sugar-coated tablets, tablets, (micro)capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions, as well as preparations giving a protracted release of active compound, the production of which makes use of customary adjuvants such as carrier substances, disintegrants, binders, coating agents, swelling agents, glidants, lubricants, flavorings, sweeteners and solubilizers. Frequently employed auxiliary substances which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils, such as cod liver oil, sunflower oil, groundnut oil or sesame oil, polyethylene glycol and solvents such as sterile water and monohydric or polyhydric alcohols, such as glycerol.
The pharmaceutical preparations are preferably produced and administered in dosage units, with each unit containing, as the active constituent, a defined dose of the compound of the formula I according to the invention. This dose can be up to about 1000 mg, preferably, however, from about 50 to 300 mg, in the case of solid dosage units, such as tablets, capsules, sugar-coated tablets or suppositories, and be up to about 300 mg, preferably, however, from about 10 to 100 mg, in the case of injection solutions in ampoule form.
Daily doses of from about 2 mg to 1000 mg of active compound, preferably of from 50 mg to 500 mg, are indicated, in dependence on the activity of the compound of the formula I, for treating an adult patient weighing about 70 kg. However, higher or lower daily doses may sometimes also be appropriate. The daily dose can be administered either by means of a once-only administration in the form of a single dosage unit or of several smaller dosage units or else by means of the multiple administration of subdivided doses at defined intervals.
End products are as a rule determined by means of mass-spectroscopic methods (FAB-MS and ESI-MS) and'H-NMR (400 MHz, in DMSO-D6); the main peak or the two main peaks are given in each case. Temperatures are given in degrees centigrade, RT denotes room temperature (21 °C to 24°C). The abbreviations employed are either explained or in conformity with the customary conventions. The invention is clarified below with the aid of examples.
General protocol 1: Sulfonamide from sulfonyl chloride and carboxylic acid The carboxylic acid (6.45 mmol) was dissolved in 20 ml of dimethylform-amide (DMF), and 3 equivalents of a 3N solution of NaOH (6.45 ml) were added at 0°C. After 10 min, a solution of the arylsulfonyl chloride (1.1 equivalents, 7.1 mmol) in from 10 to 15 ml of DMF was slowly added dropwise; after room temperature (RT) has been reached, the mixture continues to be stirred for a maximum of 12 hours (h) at temperatures between 20°C and 80°C. The precise time depends on when conversion is complete, with this being established by mass spectroscopy. After that, the solvent was removed under reduced pressure. Aqueous working-up (extracting by shaking with 1 N HCI and a saturated solution of NaCI, drying of the organic phase such as ethyl acetate, methylene chloride or chloroform with magnesium sulfate or sodium sulfate, and after that concentrating) subsequently took place. The crude product was either subjected directly to further reaction or purified by chromatography.
General protocol 2: Sulfonamide from sulfonyl chloride and carboxylic acid The carboxylic acid was dissolved in 0.5-2 molar NaOH, where appropriate in the added presence of 10-50% tetrahydrofuran (THF) or DMF. Acid chloride (1-1.2 equivalents, preferably 1.1 ) was dissolved in THF
(concentration, from 0.05 to 1 M) and this solution was slowly added dropwise. 2 N NaOH was automatically added at RT, using an autotitrator, for the purpose of maintaining a constant pH. The set pH was: from 8 to 12, preferably from 9 to 11. After the termination of the reaction, recognizable by no further NaOH being consumed, the organic cosolvent was removed on a rotary evaporator and the aqueous solution or suspension was treated with ethyl acetate and acidified with 1 N HCI. After the organic phase had been separated off, and the aqueous phase had been extracted once again with ethyl acetate, the organic phases were combined and dried over sodium sulfate; the solvent was subsequently removed under reduced pressure. The crude product was either subjected directly to further reaction or purified by chromatography.
General protocol 3: Sulfonamide from sulfonyl chloride and carboxylic acid.
This protocol is particularly suitable for the reaction of biphenylethylsulfonyl chloride with iminocarboxylic acids (see Example 6 and Example 7) or 5 similar, more hydrolysis-labile sulfonyl chlorides.
8 mmol of the imino acid were dissolved or suspended in 30 ml of acetonitrile. 2.3 g (9 mmol) of BSTFA (bis(trimethylsilyl)trifluoroacetamide) were added at RT and under an inert gas (N2) and the mixture was heated 10 for 2 h under reflux. 2.84 g (9 mmol) of 4-chlorobiphenylethanesulfonyl chloride, dissolved in 30 ml of acetonitrile, were added to this solution and the whole was once again heated for 3 h under reflux conditions. After the reaction mixture had cooled down, aqueous 1 N HCI was added and the mixture was stirred for 1 h; the solvent was then removed under reduced 15 pressure on a rotary evaporator, after which ethyl acetate or chloroform was added; the organic phase was then separated off, extracted with a saturated solution of NaCI, dried over sodium sulfate and concentrated under reduced pressure. Depending on its purity, it was either possible to subject the reaction product directly to further reaction or necessary to 20 previously chromatograph it through silica gel.
General protocol 4: Preparing the hydroxamic acid from carboxylic acid by way of chloroformate activation 25 The sulfonated carboxylic acid was dissolved in 10 ml of DMF after which 1.1 equivalents of ethyl chloroformate, 2.2 equivalents of N-ethylmorpholine and, after a preactivation time of from 30 min to 1 h, 3 equivalents of trimethylsilylhydroxylamine were added at 0°C. After the mixture had been heated at 80°C for at least 4 h, the solvent was removed under reduced 30 pressure and the crude product purified using chromatographic methods.
General protocol 5: Preparing the hydroxamic acid by way of the corresponding carbonyl chloride 35 The sulfonated carboxylic acid was initially introduced in dry chloroform (ethanol-free) (about 5 ml for 0.5 mmol) and 3 equivalents of oxalyl chloride were added at RT. The mixture was then heated at 45°C for about 30 min.
In order to monitor the chloride formation, a small sample was removed from the reaction flask and treated with a little benzylamine in THF. It was possible to ascertain when the reaction was complete by the quantitative formation of benzylamide; it was no longer possible to detect the carboxylic acid (monitoring by HPLC-MS). It may be necessary to heat for a longer period or to heat under reflux conditions. The solvent was then distilled off under reduced pressure, after which the residue was taken up repeatedly in dry toluene and once again subjected to rotary evaporation. The acid chloride was now once again taken up in chloroform (10 ml per 0.5 mmol) and this mixture was treated, at RT, with 3 equivalents of O-trimethylsilylhydroxylamine. After a reaction period of at least 30 min (reaction monitored by HPLC-MS), the reaction mixture was evaporated under reduced pressure and the residue was purified directly by chromatography.
Special protocols 4-Chlorobiphenyiethanesulfonyl chloride (intermediate for Example 7) Step 1: 1-(2-Bromoethenone)-4-(4-chlorophenyl)benzene 4-Chlorobiphenyl (23.6 g, 0.125 mol) was introduced, in portions and at 0°C, into a stirred suspension of AICl3 (34.7 g, 0.26 mol) and bromoacetyl bromide (25.2 g, 0.125 mol) in 400 ml of CS2 and the reaction mixture was then heated under reflux for 3 h. After that, it was slowly poured onto ice and subsequently extracted with ethyl acetate; the organic phase was then washed with an aqueous solution of NaHC03 and with water. )t was then dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue which remained was recrystallized from dichloromethane.
Yield: 24.2 g (62% of theory). m.p.: 127 -128°C
'H-NMR: (300 MHz) 5.0 (s, 2H, CH2); 7.5-8.1 (4 d, 8H, ar) MS: 311.1 (M+H) Step 2: 4-Chlorobiphenylethane bromide tert-Butylamineborane (27.5 g, 0.31 mol) was added, at 0°C, to a stirred suspension of AICI3 (20.0 g, 0.15 mol) in dichloromethane (500 ml). After the mixture had been stirred at 0°C for 15 min, a solution of the bromoketone from step 1 (16.0 g, 50 mmol) in dichloromethane (150 mi) was added and the mixture was stirred at 0°C for a further 4 h. Cold dilute HCI (1 N, 30 ml) was added dropwise, after which the mixture was extracted several times with ethyl acetate. The combined organic phases were washed first with dilute HCI and then with a saturated solution of sodium chloride, after which they were evaporated. An oily compound, which was purified by flash chromatography on silica gel, was obtained.
Yield: 15 g (quantitative), m.p.: 142°C
'H-NMR: (300 MHz) 3.2; 3.78 (2t, 4H, CH2); 7.4-7.7 (4 d, 8H, ar) MS: 296.2 (M+H) Step 3: Sodium salt of the 4-chlorobiphenylethanesulfonic acid The compound from step 2 (14.8 g, 50 mmol) was dissolved in a mixture of ethanol and water (1:1, 200 ml). Sodium sulfite (9.5 g, 75 mmol) and tetrabutylammonium iodide (1.8 g, 5 mmol) were added and the mixture was heated under reflux for 16 h. After that, the liquid reaction mixture was decanted off from a small quantity of a solid and the volume of this mixture was reduced by partially evaporating the mixture under reduced pressure.
Then the mixture was cooled, the product crystallized out and was subsequently filtered off and recrystallized from MeOH/H20. It was then dried under reduced pressure.
Yield: 13.9 g (94% of theory).
'H-NMR: (300 MHz) 2.6; 2.95 (2 m, 4 H, CH2); 7.3-7.7 (4 d, 8H, ar) Step 4: 4-Chlorobiphenylethanesulfonyl chloride Phosphorus pentachloride (3.2 g, 15 mmol) was added to a suspension of the compound from step 3 (4.8 g, 15 mmol) in phosphorus oxychloride (50 ml). The mixture was heated at 60°C for 6 h and was subsequently poured onto ice after methylene chloride had been added. This mixture was neutralized with a saturated solution of sodium hydrogen carbonate and the organic phase was separated off, dried and evaporated under reduced pressure.
Yield: 5 g (quantitative) 'H-NMR: (300 MHz) 2.9 (m, 4H, CH2); 7.3-7.7 (4 d, 8H, ar) Using chiral high pressure liquid chromatography (HPLC) to separate the enantiomers of preparation example 3:
Column employed: Chiralpak ADR, 250 x 4.6 mm, 30°C, running time: 30 min, injection volume: 5 NI, flow rate: 1 ml/min, solvent MeOH/EtOH 1:1 isocratic, detection at 277 nm.
isomer 1 (example 14): running time (RT) 6.33 min, 50.48% and isomer 2 (example 15): RT 14.65 min, 49.52%.
Two-dimensional NMR spectroscopy was used to determine the structure of isomer I. The methodology only makes it possible to determine the relative stereochemistry, i.e. the positions of the chiral centers in relation to each other. This means that, when only one single enantiomer is present, as is to be expected after an enantiomer separation, this enantiomer can have either the absolute stereochemistry which is specified or else the absolute stereochemistry which is the mirror image to it. The final structural proof can only be obtained by carrying out X-ray structural analyses. This was done both by means of cocrystallizing with MMP-13 and by means of a single-crystal structural analysis. Both methods showed unambiguously that the stereochemistry which is specified is in accordance with the actual stereochemistry, Chiral HPLC can likewise be used to carry out chiral separations of the other compounds which represent such enantiomeric mixtures, i.e. which have been prepared from the same decahydroisoquinoline derivatives.
Table 1 shows the results:
15 ~6 17 CI
5 7- 9 1 / ~ 14 4 2 1 N~ 10 \
S
3 H18 O~ ~'O
HN O Molecular Weight =448.97 Exact Mass =448 OH Molecular Formula =C22H25CIN204S
Table 1: Chemical shift of isomer 1 at 300 K.
'H C
1 4.12 55.15 2 1.93 35.68 3 1.67/1.41 26.37 4 1.19 21.03 5 1.48/1.16 24.26 6 1.86/1.12 26.06 7 1.52 32.00 8 1.55/1.45 28.88 9 3.75/3.53 38.95 10 - 138.99 11 7.81 127.29 12 7.87 127.26 13 - 142.45 14 - 137.19 15 7.78 128.81 16 7.57 129.05 17 - 133.42 18 - 166.96 18-N H 10.86 -18-NOH 8.88 ~ -Preparation example 2: N-(4-Chlorobiphenylsulfonyl)decahydroiso-quinoline-1-carboxylic acid Decahydroisoquinolinecarboxylic acid was prepared and used as described in US 5,430,023. The resulting imino acid (2.0 g, 9.1 mmol) was dissolved or suspended in THF (20 ml) and the pH was adjusted to 10.5 with 1 molar sodium hydroxide solution using an autotitrator. After that, 4-chlorobiphenylsulfonyl chloride (2.745 g, 9.6 mmol, 1.05 eq.), dissolved in ml of THF, was added dropwise over a period of 2 hours while the pH
was maintained constant. After a further 2 hours, it was not possible to 10 observe any further consumption of sodium hydroxide solution. LC-MS, which was carried out as a reaction control, confirmed this. The solution was then adjusted to a pH of from 3 to 4 with dilute hydrochloric acid;
100 ml of ethyl acetate were then added and the solution was extracted by being shaken. The aqueous phase was extracted a further 2 times with small portions of ethyl acetate and the combined organic phases were dried over sodium sulfate. After the solvent had been removed, there then remained an oily residue which became solid under an oil pump vacuum.
Yield: 2.31 g (58% of theory). Analytical data: see Table 1.
Preparation example 3: N-(4-Chlorobiphenylsulfonyl)decahydroiso-quinoline-1-(N-hydroxy)carboxamide The carboxylic acid from Example 2 (2.3 g, 5.3 mmol) was dissolved in 50 ml of chloroform. Oxalyl chloride (1.345 g, 10.6 mmol, 0.924 ml) was then added dropwise within the space of 10 min and the resulting reaction mixture was heated at 45°C for one hour. After this time, a small sample of the reaction mixture (0.1 ml) was removed, for monitoring the reaction by HPLC-MS, and treated with 0.05 ml of benzylamine. Subsequently, the solvent was distilled off under reduced pressure and the resulting oily residue was entrained with toluene for the purpose of removing any possible oxalyl chloride residues or HCI and left under reduced pressure for 15 min. It was then once again taken up in chloroform (50 ml) after which O-trimethylsilylhydroxylamine (2.23 g, 21.2 mmol, 2.593 ml) was added at RT. After 2 hours, the solvent was removed under reduced pressure and the residue was dissolved in a small quantity of a mixture of acetonitrile/water/0.01 % trifluoroacetic acid for the purpose of direct preparative RP-HPLC. Product fractions were combined, acetonitrile was 5 removed under reduced pressure and the remaining aqueous phase was freeze-dried. Yield: 749 mg (32% of theory; 36 mg of another diastereomer of the same molar mass is obtained in addition). Unreacted acid chloride was reisolated in the form of the carboxylic acid. Analytical data: see Table 1.
The following examples were prepared in analogy with the previously mentioned protocols.
Table 2 shows the results.
Table 2:
Example Struch~re Molecular ES+ 1H-NMR
weight 1 0 459.52 460.2 1.1-2.0 (4 m,12 H);
461.2 3.5-3.9 (m, 2 H); 4.15 \ ~ Q (d, 1 H); 7.88; 8.0;
8.07; 8.35 (4 d, 8 H);
0 0 10.9 (s, 1 H) I
ai 2 a 433.95 433.11 1.2-2.1 (4 m, 12 H);
3.4-3.6 (m, 2 H); 4.2 / ~ (d, 1 H); 7.60; 7.8; (2 w I d, 4 H); 7.9 (m, 4 H);
s ~o ~0 12.8 (s, 1 H) HO" O
3 ci 448.97 449.15 1.1-2.0 (4 m, 12 H);
451.10 3.5-3.9 (m, 2 H); 4.15 i I ~ (d, 1 H); 7.60; 7.7;
oos~~ \ 7.8; 7.9 (4 d, 8 H);
0 10.9 (s, 1 H) OH
4 0 530.52 415.16 N \ \ N I / (ES-) O ~S~~O
H O
O O F
OH
F
0 \ 545.54 ES- 1.1-2.0 (4 m,12 H);
N ~ ~ N I ~ 430.17 3.4-3.8 (2m, 2 H);
~~0 4.08 (d, 1 H); 7.2 (m, "~ ° F 4 H); 7.45 (m, 2 H);
OH OH
F 8,1 (dd, 1 H); 8.45 (s, 1 H); 10.8 (s,1 H) 6 462.01 461.14 1.15-2.05 (4 m,12 H); 2.9-3.5 (mm, about 6 H, 0 overlapping with water); 3.85 (m, 1 H);
4.0 (d, 1 H); 7.48;
7.5;7.61;7.7 (4 d,8 H) 7 I 477.03 477.7 1.15-2.05 (m m, 12 H); 2.9-3.5 (mm, about 6 H, O~ ~~ \ overlapping with 'O water); 4.85 (m, 1 H);
I 7.48; 7.5; 7.65; 7.72 Oi (4d,8H) 8 530.52 416.14 1.2-2.1 (4 m,12 H);
0 2.9.3 (mm, about 3 H, overlapping with ~N
Hp ~o o water); 7.3; 7.45;
F 7.95; 8.70 (4 m, 8 H);
F ~ 12.8 (s, 1 H) F
9 545.54 431.15 1.1-2.0 (4 m, 12 H);
0 3.55 (m, 1 H); 3.8 (m, 1 H); 4.1 (d,1 H);
o '' 7.35; 7.45; 7.9; 8.70 F F (4 d, 8 H); 10.8 (s, 1H) 445.54 446.1 I o _ _ 447.1 N~II
to ~ ~ ~ ~
~o 11 460.55 461.2 1.1-1.95 (4m, 12 H);
_ _ 462.2 3.45 (m, 1 H); 3.7 (m, 1 H); 3.8 (s, 2 H);
\ O 4.05 (d, 1 H); 7.0 (m, I 4 H); 7.1 (m, 2 H);
ai 7.7 (m, 2 H);10.8 (s, 1 H).
12 513.54 514.15 515.2 III \ ~ / °~ F
\ O I F
O F
~ 3 528.55 529.2 1.1-2.0 (4m, 12 H);
I o 530.2 3.45 (m, 1 H); 3.7 (m, o F 1 H); 4.07 (d, 1 H);
o F 7.0 (d, 2 H); 7.17 (s, F
4H);7.7(d,2H);
10.8 (s, 1 H).
14 hemistry 16 8.9726 9.15,4 1.1-2.0 (4 m, 12 H); 3.
1.10 .8 (2m, 2 H); 4.15 (d, 1 a \ ~ H); 7.55-7.9 (3 m, 8 H) H~ mss'' \ ~ 8.9 (s, 1 H); 10.9 (s, 1 NH~ p I O H) HO
15 hemistry 19 8.9726 9.15,4 1.1-2.0 (4 m, 12 H); 3.
H CHIF,AL
1.10 .8 (2m, 2 H); 4.15 (d, 1 a \ / H); 7.55-7.9 (3 m, 8 H) H /
.9 (s, 1 H); 10.9 (s, 1 "° H) 16 hemistry 35 00.6187 01.18 1.25 (d, 6 H); 1.2-1.
(m, 11 H); 2.05 (m, 1 o s° ~ H); 3.44; 4.20; 4.90 Ho o I ~ m, 3-4 H); 7.6; 7.7 (dd N o H); 7.87 (m, 4 H); 9.
(s, 1 H); 12.8 (s, 1 H) 17 hemistry 36 15.6334 16.19 1.25 (d, 6 H); 1.1-1.9 (m, 12 H); 3.55; 3.75 N~
.12;4.91 (4m,4H) o ~ i I ~ o ..6-7.88 (2 dd, 8 H) r a~
18 hemistry 37 512.5524 13.13 1.1-2.0 (m, 12 H); 3.50 .75, 4.11; 4.83 (4 m, H);7.2(d,2H);7.8(m F H); 8.9 (s, 1 H); 10.
I F
(S, 1 H).
Chemistry 38 98.5253 50.08 1.1-2.0 (m, 12 H); 3.50 19 ~ o .75, 4.15 (3 m, 3 H) N~
oS ~ .5(d,2H);7.9(m, o ~ i I ~ F H); 8.9 (s, 1 H); 10.9 (s O' F F
1 H).
0 hemistry 39 8.5174 9.24 1.1-2.0 (m, 12 H); 3.50 .75, 4.10 (3 m, 3 H) N ~~
/ \ o .0-7.7 (4 m. 8 H); 8.
H IOH o / \ s,1 H); 10.9 (s, 1 H).
F
1 hemistry 44 8.5174 9.21 1.1-2.0 (m, 12 H); 3.50 0 ~ ~m 3.75, 4.10 (3 m, 3 H) N\ ~ ~ I / F .0-7.7 (4 m. 8 H); 8.
o (s, 1 H); 10.9 (s, 1 H) i ai hemistry 49 99.51 500.18 1.2-1.7 (m, 11 H); 2.0 / ~ 0 ~ '1 F (m, 1 H); 3.5 (m, +/
N,~ ~ / Jc F H); 4.2 (d, 1 H); 7.1 00'' ~\F
p' '' .80 (4 m ("d"), 8 H) 12.7 (s, 1 H) ~3 hemistry 48 14.5247 15.21 1.1-2.0 (m, 12 H); 3.50 0 \ F 3.75, 4.10 (3 m, 3 H) .1-7.8 (4 m ("d"), 8 H) .9 (s, 1 H); 10.9 (s, 1 0 H) I
24 hemistry 53 99.5129 00.24 1.1-2.0 (4 m, 12 H); 3.
.8 (2m,2H);4.15(d ~ 1 H); 7.4-8.0 (m, 9 H) N~
O~SwO
p pH
Chemistry 52 14.5275 15.26 1.1-2.0 (4 m, 12 H); 3.
.8 (2m,2H);4.15(d 1 H); 7.4-8.0 (m, 9 H) I
ors, ~ .9 (s, 1 H); 10.9 (s, 1 O NH ) OH
6 hemistry 55 55.5368 56.30 1.1-2.0 (m, 12 H); 3.50 O \ .75, 4.10 (3 m, 3 H) 7.2 (m, 4 H); 7.8-8.
~~ 00 ~ N (dd, 4 H); 8.9 (s, 1 H) O 10.9 (s, 1 H) CH
7 / O 13.4963 14.14 1.2-1.7 (m, 11 H); 2.0 (m, 1 H); 3.5 (m, +/-H); 4.3 (d, 1 H); 7.5-7.
O
HO O (6 m, 7 H); 8.7 (s, 1 H) 8 Chemistry 57 28.511 29.21 1.1-2.0 (m, 12 H); 3.60 i ° .75, 4.10 (3 m, 3 H) N~ ~ I ~ ~ 7.5-8.9 (7 m, 8 H); 10.
o' '' HN O (S, 1 H) I I
OH
29 hemistry 62 78.543879.22 1.0-1.95 (m) and 2.6 .05 (m, together 14 H) 0 ~ ~ 0 / ~ .7(s,3H);6.7-7.8( 8 H); S.9 (s, 1 H) 0~ ~~0 10.9 (2 s, 0 1 H) I
OH
Pharmacological examples Determining the enzyme activity of the catalytic domain of human 5 collagenase-1 (MMP-1 ).
This protein is obtained as an inactive proenzyme from Biocol, Potsdam (catalog No. MMP1 ). Activation of the proenzyme:
2 parts by volume of proenzyme are incubated, at 37°C for 1 hour, with 1 part by volume of APMA solution. The APMA solution is prepared from a 10 10 mmol/l solution of p-aminophenylmercuric acetate in 0.1 mmol/I NaOH
by diluting with 3 parts by volume of tris/HCI buffer, pH 7.5 (see below).
The pH is adjusted to between 7.0 and 7.5 by adding 1 mmol/l HCI. After the enzyme has been activated, it is diluted with the tris/HCI buffer to a concentration of 2.5 ~g/ml.
15 In order to measure the enzyme activity, 10 ~I of enzyme solution are incubated for 15 minutes with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide (reaction 1). In order to measure the enzyme inhibitor activity, 10 ~.I of enzyme solution are incubated with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide which contains the enzyme inhibitor 20 (reaction 2).
Both in the case of reaction 1 and in the case of reaction 2, the enzyme reaction is monitored by fluorescence spectroscopy (328 nm (extinction)/
393 nm (emission)) after adding 10 ~,I of a 3% (v/v) aqueous solution of dimethyl sulfoxide which contains 0.3 mmol of the substrate/I.
25 The enzyme activity is presented as increase in extinction/minute.
The inhibitory effect is calculated as percentage inhibition using the following formula: -inhibition = 100 - [(increase in extinction/minute in reaction 2) / (increase in extinction/minute in reaction 1 ) x 100].
30 The IC5o, i.e. the inhibitor concentration which is required for 50%
inhibition of the enzyme activity, is determined graphically by plotting the percentage inhibitions at different inhibitor concentrations.
The buffer solution contains 0.05% Brij (Sigma, Deisenhofen, Germany) and also 0.1 mol of tris/HCl/l, 0.1 mol of NaCl/l, 0.01 mol of CaCl2/l (pH=7.5).
The enzyme solution contains 2.5 ~g of the enzyme domain/ml.
The substrate solution contains 0.3 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2',4'-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2/I (Bachem, Heidelberg, Germany).
Preparation, and determination of the enzyme activity, of the catalytic domain of human stromelysin (MMP-3) and neutrophilic collagenase (MMP-8).
The two enzymes, i.e. stromelysin (MMP-3) and neutrophilic collagenase (MMP-8), were prepared as described by Ye et al. (Biochemistry; 31 (1992) pages 11231-11235). In order to measure the enzyme activity or the inhibitory effect on the enzyme, 10 p.1 of enzyme solution were incubated, for 15 minutes, with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide which contained the enzyme inhibitor, where appropriate. After 10 ~I of a 3% (v/v) aqueous solution of dimethyl sulfoxide which contained 1 mmol of substrate/l had been added, the enzyme reaction was monitored by fluorescence spectroscopy (328 nm (ex)/393 nm(em)).
The enzyme activity is presented as increase in extinction/minute. The ICSo values listed in Table 2 were determined as the inhibitor concentrations which in each case resulted in the enzyme being inhibited by 50%.
The buffer solution contained 0.05% Brij (Sigma, Deisenhofen, Germany) as well as 0.1 mol of tris/HCl/l, 0.1 mol of NaCl/l, 0.01 mol of CaCl2/l and 0.1 mol of piperazine-N,N'-bis[2-ethanesulfonic acidJ/l (pH= 7.5).
The MMP-3 enzyme solution contained 2.3 pg, and the MMP-8 enzyme solution contained 0.6 pg, of one of the enzyme domains/ml prepared as described by Ye et al. The substrate solution contained 1 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2',4'-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2/I (Bachem, Heidelberg, Germany).
Determining the enzyme activity of the catalytic domain of human collagenase-3 (MMP-13).
This protein was obtained as an inactive proenzyme from INVITEK, Berlin (catalog No. 30 100 803). Activation of the proenzyme:
2 parts by volume of proenzyme were incubated, at 37°C for 1.5 hours, with 1 part by volume of APMA solution. The APMA solution was prepared from a 10 mmol/I solution of p-aminophenylmercuric acetate in 0.1 mmol/l NaOH
by diluting the solution with 3 parts by volume of tris/HCl buffer, pH 7.5 (see below). The pH was adjusted to between 7.0 and 7.5 by adding 1 mmol/l HCI. After the enzyme had been activated, it was diluted with the tris/HCI
buffer to a concentration of 1.67 ~g/ml.
In order to measure the enzyme activity, 10 p,1 of enzyme solution were incubated for 15 minutes with 10 p,1 of a 3% (v/v) buffered solution of dimethyl sulfoxide (reaction 1 ). In order to measure the enzyme inhibitor activity, 10 p1 of enzyme solution were incubated with 10 p1 of a 3% (v/v) buffered solution of dimethyl sulfoxide which contained the enzyme inhibitor (reaction 2).
Both in the case of reaction 1 and in the case of reaction 2, the enzyme reaction was monitored by fluorescence spectroscopy (328 nm (extinction)/
393 nm (emission)) after 10 p.1 of a 3% (v/v) aqueous solution of dimethyl sulfoxide which contained 0.075 mmol of the substrate/l had been added.
The enzyme activity was presented as increase in extinction/minute.
The effect of the inhibitor was calculated as a percentage inhibition in accordance with the following formula:
inhibition = 100 - [(increase in extinction/minute in reaction 2) / (increase in extinction/minute in reaction 1 ) x 100].
The ICSO, that is the concentration of inhibitor which is required for 50%
inhibition of the enzyme activity, was determined graphically by plotting the percentage inhibitions at different inhibitor concentrations.
The buffer solution contained 0.05% Brij (Sigma, Deisenhofen, Germany) and also 0.1 mol of tris/HCl/I, 0.1 mol of NaCI/I, 0.01 mol of CaCl2/l (pH=7.5). The enzyme solution contained 1.67 ~g of the enzyme domain/ml. The substrate solution contained 0.075 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2',4'-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2/I (Bachem, Heidelberg, Germany).
Determining the enzyme activity of the catalytic domain of human gelatinase A (MMP-2).
This protein was obtained as an inactive proenzyme from INVITEK, Berlin (catalog No. 30 100 602). Activation of the proenzyme:
2 parts by volume of proenzyme were incubated, at 37°C for 0.5 hour, with 1 part by volume of APMA solution. The APMA solution was prepared from a 10 mmol/l solution of p-aminophenylmercuric acetate in 0.1 mmol/I NaOH
by diluting it with 3 parts by volume of tris/HCI buffer, pH 7.5 (see below).
The pH was adjusted to between 7.0 and 7.5 by adding 1 mmol/l HCI. After the enzyme had been activated, it was diluted with the tris/HCI buffer to a concentration of 0.83 ~g/ml.
In order to measure the enzyme activity, 10 p.1 of enzyme solution were incubated for 15 minutes with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide (reaction 1 ). In order to measure the enzyme inhibitor activity, 10 p.1 of enzyme solution were incubated with 10 ~,I of a 3% (v/v) buffered solution of dimethyl sulfoxide which contained the enzyme inhibitor (reaction 2).
Both in the case of reaction 1 and in the case of reaction 2, the enzyme reaction was monitored by fluorescence spectroscopy (328 nm (extinction)/
393 nm (emission)) after 10 ~I of a 3% (v/v) aqueous solution of dimethyl sulfoxide which contained 0.3 mmol of the substrate/l had been added.
The enzyme activity was presented as increase in extinction/minute.
The effect of the inhibitor was calculated as percentage inhibition in accordance with the following formula:
inhibition = 100 - [(increase in extinction/minute in reaction 2) / (increase in extinction/minute in reaction 1 ) x 100].
The ICSO, that is the concentration of inhibitor which is required for 50%
inhibition of the enzyme activity, was determined graphically by plotting the percentage inhibitions at different inhibitor concentrations.
The buffer solution contained 0.05% Brij (Sigma, Deisenhofen, Germany) and also 0.1 mol of trisIHCl/l, 0.1 mol of NaCl/l, 0.01 mol of CaCl2/l (pH=7.5). The enzyme solution contained 0.83 ~g of the enzyme domain/ml. The substrate solution contained 0.3 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2',4' dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2/I (Sachem, Heidelberg, Germany).
Determining the enzyme activity of the catalytic domain of human gelatinase B (MMP-9).
This protein was obtained as an inactive proenzyme from Roche, Mannheim (catalog No. 1 758 896). Activation of the proenzyme:
2 parts by volume of proenzyme were incubated, at 37°C for 4 hours, with 1 part by volume of APMA solution. The APMA solution was prepared from a 10 mmol/l solution of p-aminophenylmercuric acetate in 0.1 mmol/I NaOH
by diluting it with 3 parts by volume of tris/HCl buffer, pH 7.5 (see below).
The pH was adjusted to between 7.0 and 7.5 by adding 1 mmol/l HCI. After the enzyme had been activated, it was diluted with the tris/HCI buffer to a concentration of 4.2 mU/ml.
In order to measure the activity of the enzyme, 10 ~I of enzyme solution were incubated for 15 minutes with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide (reaction 1 ). In order to measure the enzyme inhibitor activity, 10 ~I of enzyme solution were incubated with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide which contained the enzyme inhibitor (reaction 2).
Both in the case of reaction 1 and in the case of reaction 2, the enzyme reaction was monitored by fluorescence spectroscopy (328 nm (extinction)/393 nm (emission)) after 10 p,1 of a 3% (v/v) aqueous solution of dimethyl sulfoxide, which contained 0.15 mmol of the substrate/I, had been added.
The enzyme activity was presented as increase in extinction/minute.
The inhibitory effect was calculated as percentage inhibition in accordance with the following formula:
inhibition = 100 - [(increase in extinctionlminute in reaction 2)/(increase in extinction/minute in reaction 1 ) X 100].
The ICSO, that is the concentration of inhibitor which is required for 50%
inhibition of the enzyme activity, was determined graphically by plotting the percentage inhibitions at different inhibitor concentrations.
The buffer solution contained 0.05% Brij (Sigma, Deisenhofen, Germany) and also 0.1 mol of tris/HCl/l, 0.1 mol of NaCI/I, 0.01 mol of CaCl2/I
(pH=7.5). The enzyme solution contained 4.2 mU of the enzyme domain/ml. The substrate solution contained 0.15 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2',4'-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2/I (Sachem, Heidelberg, Germany).
Table 3 below shows the results.
Table 3:
ExampleMMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 ICS ICS ICS ICS ICS IC
nnri nnn nm nnn nm nnri 5 70 2 28 2.5 1.2 1.8 11 220 2 25 2.5 2 1.5 13 180 2.6 30 4 2 2 14 400 2 25 2.2 3.5 2 21 21 1.5 23 2.3 0.45 1.3 23 290 2 50 9 2 2.1
Two-dimensional NMR spectroscopy was used to determine the structure of isomer I. The methodology only makes it possible to determine the relative stereochemistry, i.e. the positions of the chiral centers in relation to each other. This means that, when only one single enantiomer is present, as is to be expected after an enantiomer separation, this enantiomer can have either the absolute stereochemistry which is specified or else the absolute stereochemistry which is the mirror image to it. The final structural proof can only be obtained by carrying out X-ray structural analyses. This was done both by means of cocrystallizing with MMP-13 and by means of a single-crystal structural analysis. Both methods showed unambiguously that the stereochemistry which is specified is in accordance with the actual stereochemistry, Chiral HPLC can likewise be used to carry out chiral separations of the other compounds which represent such enantiomeric mixtures, i.e. which have been prepared from the same decahydroisoquinoline derivatives.
Table 1 shows the results:
15 ~6 17 CI
5 7- 9 1 / ~ 14 4 2 1 N~ 10 \
S
3 H18 O~ ~'O
HN O Molecular Weight =448.97 Exact Mass =448 OH Molecular Formula =C22H25CIN204S
Table 1: Chemical shift of isomer 1 at 300 K.
'H C
1 4.12 55.15 2 1.93 35.68 3 1.67/1.41 26.37 4 1.19 21.03 5 1.48/1.16 24.26 6 1.86/1.12 26.06 7 1.52 32.00 8 1.55/1.45 28.88 9 3.75/3.53 38.95 10 - 138.99 11 7.81 127.29 12 7.87 127.26 13 - 142.45 14 - 137.19 15 7.78 128.81 16 7.57 129.05 17 - 133.42 18 - 166.96 18-N H 10.86 -18-NOH 8.88 ~ -Preparation example 2: N-(4-Chlorobiphenylsulfonyl)decahydroiso-quinoline-1-carboxylic acid Decahydroisoquinolinecarboxylic acid was prepared and used as described in US 5,430,023. The resulting imino acid (2.0 g, 9.1 mmol) was dissolved or suspended in THF (20 ml) and the pH was adjusted to 10.5 with 1 molar sodium hydroxide solution using an autotitrator. After that, 4-chlorobiphenylsulfonyl chloride (2.745 g, 9.6 mmol, 1.05 eq.), dissolved in ml of THF, was added dropwise over a period of 2 hours while the pH
was maintained constant. After a further 2 hours, it was not possible to 10 observe any further consumption of sodium hydroxide solution. LC-MS, which was carried out as a reaction control, confirmed this. The solution was then adjusted to a pH of from 3 to 4 with dilute hydrochloric acid;
100 ml of ethyl acetate were then added and the solution was extracted by being shaken. The aqueous phase was extracted a further 2 times with small portions of ethyl acetate and the combined organic phases were dried over sodium sulfate. After the solvent had been removed, there then remained an oily residue which became solid under an oil pump vacuum.
Yield: 2.31 g (58% of theory). Analytical data: see Table 1.
Preparation example 3: N-(4-Chlorobiphenylsulfonyl)decahydroiso-quinoline-1-(N-hydroxy)carboxamide The carboxylic acid from Example 2 (2.3 g, 5.3 mmol) was dissolved in 50 ml of chloroform. Oxalyl chloride (1.345 g, 10.6 mmol, 0.924 ml) was then added dropwise within the space of 10 min and the resulting reaction mixture was heated at 45°C for one hour. After this time, a small sample of the reaction mixture (0.1 ml) was removed, for monitoring the reaction by HPLC-MS, and treated with 0.05 ml of benzylamine. Subsequently, the solvent was distilled off under reduced pressure and the resulting oily residue was entrained with toluene for the purpose of removing any possible oxalyl chloride residues or HCI and left under reduced pressure for 15 min. It was then once again taken up in chloroform (50 ml) after which O-trimethylsilylhydroxylamine (2.23 g, 21.2 mmol, 2.593 ml) was added at RT. After 2 hours, the solvent was removed under reduced pressure and the residue was dissolved in a small quantity of a mixture of acetonitrile/water/0.01 % trifluoroacetic acid for the purpose of direct preparative RP-HPLC. Product fractions were combined, acetonitrile was 5 removed under reduced pressure and the remaining aqueous phase was freeze-dried. Yield: 749 mg (32% of theory; 36 mg of another diastereomer of the same molar mass is obtained in addition). Unreacted acid chloride was reisolated in the form of the carboxylic acid. Analytical data: see Table 1.
The following examples were prepared in analogy with the previously mentioned protocols.
Table 2 shows the results.
Table 2:
Example Struch~re Molecular ES+ 1H-NMR
weight 1 0 459.52 460.2 1.1-2.0 (4 m,12 H);
461.2 3.5-3.9 (m, 2 H); 4.15 \ ~ Q (d, 1 H); 7.88; 8.0;
8.07; 8.35 (4 d, 8 H);
0 0 10.9 (s, 1 H) I
ai 2 a 433.95 433.11 1.2-2.1 (4 m, 12 H);
3.4-3.6 (m, 2 H); 4.2 / ~ (d, 1 H); 7.60; 7.8; (2 w I d, 4 H); 7.9 (m, 4 H);
s ~o ~0 12.8 (s, 1 H) HO" O
3 ci 448.97 449.15 1.1-2.0 (4 m, 12 H);
451.10 3.5-3.9 (m, 2 H); 4.15 i I ~ (d, 1 H); 7.60; 7.7;
oos~~ \ 7.8; 7.9 (4 d, 8 H);
0 10.9 (s, 1 H) OH
4 0 530.52 415.16 N \ \ N I / (ES-) O ~S~~O
H O
O O F
OH
F
0 \ 545.54 ES- 1.1-2.0 (4 m,12 H);
N ~ ~ N I ~ 430.17 3.4-3.8 (2m, 2 H);
~~0 4.08 (d, 1 H); 7.2 (m, "~ ° F 4 H); 7.45 (m, 2 H);
OH OH
F 8,1 (dd, 1 H); 8.45 (s, 1 H); 10.8 (s,1 H) 6 462.01 461.14 1.15-2.05 (4 m,12 H); 2.9-3.5 (mm, about 6 H, 0 overlapping with water); 3.85 (m, 1 H);
4.0 (d, 1 H); 7.48;
7.5;7.61;7.7 (4 d,8 H) 7 I 477.03 477.7 1.15-2.05 (m m, 12 H); 2.9-3.5 (mm, about 6 H, O~ ~~ \ overlapping with 'O water); 4.85 (m, 1 H);
I 7.48; 7.5; 7.65; 7.72 Oi (4d,8H) 8 530.52 416.14 1.2-2.1 (4 m,12 H);
0 2.9.3 (mm, about 3 H, overlapping with ~N
Hp ~o o water); 7.3; 7.45;
F 7.95; 8.70 (4 m, 8 H);
F ~ 12.8 (s, 1 H) F
9 545.54 431.15 1.1-2.0 (4 m, 12 H);
0 3.55 (m, 1 H); 3.8 (m, 1 H); 4.1 (d,1 H);
o '' 7.35; 7.45; 7.9; 8.70 F F (4 d, 8 H); 10.8 (s, 1H) 445.54 446.1 I o _ _ 447.1 N~II
to ~ ~ ~ ~
~o 11 460.55 461.2 1.1-1.95 (4m, 12 H);
_ _ 462.2 3.45 (m, 1 H); 3.7 (m, 1 H); 3.8 (s, 2 H);
\ O 4.05 (d, 1 H); 7.0 (m, I 4 H); 7.1 (m, 2 H);
ai 7.7 (m, 2 H);10.8 (s, 1 H).
12 513.54 514.15 515.2 III \ ~ / °~ F
\ O I F
O F
~ 3 528.55 529.2 1.1-2.0 (4m, 12 H);
I o 530.2 3.45 (m, 1 H); 3.7 (m, o F 1 H); 4.07 (d, 1 H);
o F 7.0 (d, 2 H); 7.17 (s, F
4H);7.7(d,2H);
10.8 (s, 1 H).
14 hemistry 16 8.9726 9.15,4 1.1-2.0 (4 m, 12 H); 3.
1.10 .8 (2m, 2 H); 4.15 (d, 1 a \ ~ H); 7.55-7.9 (3 m, 8 H) H~ mss'' \ ~ 8.9 (s, 1 H); 10.9 (s, 1 NH~ p I O H) HO
15 hemistry 19 8.9726 9.15,4 1.1-2.0 (4 m, 12 H); 3.
H CHIF,AL
1.10 .8 (2m, 2 H); 4.15 (d, 1 a \ / H); 7.55-7.9 (3 m, 8 H) H /
.9 (s, 1 H); 10.9 (s, 1 "° H) 16 hemistry 35 00.6187 01.18 1.25 (d, 6 H); 1.2-1.
(m, 11 H); 2.05 (m, 1 o s° ~ H); 3.44; 4.20; 4.90 Ho o I ~ m, 3-4 H); 7.6; 7.7 (dd N o H); 7.87 (m, 4 H); 9.
(s, 1 H); 12.8 (s, 1 H) 17 hemistry 36 15.6334 16.19 1.25 (d, 6 H); 1.1-1.9 (m, 12 H); 3.55; 3.75 N~
.12;4.91 (4m,4H) o ~ i I ~ o ..6-7.88 (2 dd, 8 H) r a~
18 hemistry 37 512.5524 13.13 1.1-2.0 (m, 12 H); 3.50 .75, 4.11; 4.83 (4 m, H);7.2(d,2H);7.8(m F H); 8.9 (s, 1 H); 10.
I F
(S, 1 H).
Chemistry 38 98.5253 50.08 1.1-2.0 (m, 12 H); 3.50 19 ~ o .75, 4.15 (3 m, 3 H) N~
oS ~ .5(d,2H);7.9(m, o ~ i I ~ F H); 8.9 (s, 1 H); 10.9 (s O' F F
1 H).
0 hemistry 39 8.5174 9.24 1.1-2.0 (m, 12 H); 3.50 .75, 4.10 (3 m, 3 H) N ~~
/ \ o .0-7.7 (4 m. 8 H); 8.
H IOH o / \ s,1 H); 10.9 (s, 1 H).
F
1 hemistry 44 8.5174 9.21 1.1-2.0 (m, 12 H); 3.50 0 ~ ~m 3.75, 4.10 (3 m, 3 H) N\ ~ ~ I / F .0-7.7 (4 m. 8 H); 8.
o (s, 1 H); 10.9 (s, 1 H) i ai hemistry 49 99.51 500.18 1.2-1.7 (m, 11 H); 2.0 / ~ 0 ~ '1 F (m, 1 H); 3.5 (m, +/
N,~ ~ / Jc F H); 4.2 (d, 1 H); 7.1 00'' ~\F
p' '' .80 (4 m ("d"), 8 H) 12.7 (s, 1 H) ~3 hemistry 48 14.5247 15.21 1.1-2.0 (m, 12 H); 3.50 0 \ F 3.75, 4.10 (3 m, 3 H) .1-7.8 (4 m ("d"), 8 H) .9 (s, 1 H); 10.9 (s, 1 0 H) I
24 hemistry 53 99.5129 00.24 1.1-2.0 (4 m, 12 H); 3.
.8 (2m,2H);4.15(d ~ 1 H); 7.4-8.0 (m, 9 H) N~
O~SwO
p pH
Chemistry 52 14.5275 15.26 1.1-2.0 (4 m, 12 H); 3.
.8 (2m,2H);4.15(d 1 H); 7.4-8.0 (m, 9 H) I
ors, ~ .9 (s, 1 H); 10.9 (s, 1 O NH ) OH
6 hemistry 55 55.5368 56.30 1.1-2.0 (m, 12 H); 3.50 O \ .75, 4.10 (3 m, 3 H) 7.2 (m, 4 H); 7.8-8.
~~ 00 ~ N (dd, 4 H); 8.9 (s, 1 H) O 10.9 (s, 1 H) CH
7 / O 13.4963 14.14 1.2-1.7 (m, 11 H); 2.0 (m, 1 H); 3.5 (m, +/-H); 4.3 (d, 1 H); 7.5-7.
O
HO O (6 m, 7 H); 8.7 (s, 1 H) 8 Chemistry 57 28.511 29.21 1.1-2.0 (m, 12 H); 3.60 i ° .75, 4.10 (3 m, 3 H) N~ ~ I ~ ~ 7.5-8.9 (7 m, 8 H); 10.
o' '' HN O (S, 1 H) I I
OH
29 hemistry 62 78.543879.22 1.0-1.95 (m) and 2.6 .05 (m, together 14 H) 0 ~ ~ 0 / ~ .7(s,3H);6.7-7.8( 8 H); S.9 (s, 1 H) 0~ ~~0 10.9 (2 s, 0 1 H) I
OH
Pharmacological examples Determining the enzyme activity of the catalytic domain of human 5 collagenase-1 (MMP-1 ).
This protein is obtained as an inactive proenzyme from Biocol, Potsdam (catalog No. MMP1 ). Activation of the proenzyme:
2 parts by volume of proenzyme are incubated, at 37°C for 1 hour, with 1 part by volume of APMA solution. The APMA solution is prepared from a 10 10 mmol/l solution of p-aminophenylmercuric acetate in 0.1 mmol/I NaOH
by diluting with 3 parts by volume of tris/HCI buffer, pH 7.5 (see below).
The pH is adjusted to between 7.0 and 7.5 by adding 1 mmol/l HCI. After the enzyme has been activated, it is diluted with the tris/HCI buffer to a concentration of 2.5 ~g/ml.
15 In order to measure the enzyme activity, 10 ~I of enzyme solution are incubated for 15 minutes with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide (reaction 1). In order to measure the enzyme inhibitor activity, 10 ~.I of enzyme solution are incubated with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide which contains the enzyme inhibitor 20 (reaction 2).
Both in the case of reaction 1 and in the case of reaction 2, the enzyme reaction is monitored by fluorescence spectroscopy (328 nm (extinction)/
393 nm (emission)) after adding 10 ~,I of a 3% (v/v) aqueous solution of dimethyl sulfoxide which contains 0.3 mmol of the substrate/I.
25 The enzyme activity is presented as increase in extinction/minute.
The inhibitory effect is calculated as percentage inhibition using the following formula: -inhibition = 100 - [(increase in extinction/minute in reaction 2) / (increase in extinction/minute in reaction 1 ) x 100].
30 The IC5o, i.e. the inhibitor concentration which is required for 50%
inhibition of the enzyme activity, is determined graphically by plotting the percentage inhibitions at different inhibitor concentrations.
The buffer solution contains 0.05% Brij (Sigma, Deisenhofen, Germany) and also 0.1 mol of tris/HCl/l, 0.1 mol of NaCl/l, 0.01 mol of CaCl2/l (pH=7.5).
The enzyme solution contains 2.5 ~g of the enzyme domain/ml.
The substrate solution contains 0.3 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2',4'-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2/I (Bachem, Heidelberg, Germany).
Preparation, and determination of the enzyme activity, of the catalytic domain of human stromelysin (MMP-3) and neutrophilic collagenase (MMP-8).
The two enzymes, i.e. stromelysin (MMP-3) and neutrophilic collagenase (MMP-8), were prepared as described by Ye et al. (Biochemistry; 31 (1992) pages 11231-11235). In order to measure the enzyme activity or the inhibitory effect on the enzyme, 10 p.1 of enzyme solution were incubated, for 15 minutes, with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide which contained the enzyme inhibitor, where appropriate. After 10 ~I of a 3% (v/v) aqueous solution of dimethyl sulfoxide which contained 1 mmol of substrate/l had been added, the enzyme reaction was monitored by fluorescence spectroscopy (328 nm (ex)/393 nm(em)).
The enzyme activity is presented as increase in extinction/minute. The ICSo values listed in Table 2 were determined as the inhibitor concentrations which in each case resulted in the enzyme being inhibited by 50%.
The buffer solution contained 0.05% Brij (Sigma, Deisenhofen, Germany) as well as 0.1 mol of tris/HCl/l, 0.1 mol of NaCl/l, 0.01 mol of CaCl2/l and 0.1 mol of piperazine-N,N'-bis[2-ethanesulfonic acidJ/l (pH= 7.5).
The MMP-3 enzyme solution contained 2.3 pg, and the MMP-8 enzyme solution contained 0.6 pg, of one of the enzyme domains/ml prepared as described by Ye et al. The substrate solution contained 1 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2',4'-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2/I (Bachem, Heidelberg, Germany).
Determining the enzyme activity of the catalytic domain of human collagenase-3 (MMP-13).
This protein was obtained as an inactive proenzyme from INVITEK, Berlin (catalog No. 30 100 803). Activation of the proenzyme:
2 parts by volume of proenzyme were incubated, at 37°C for 1.5 hours, with 1 part by volume of APMA solution. The APMA solution was prepared from a 10 mmol/I solution of p-aminophenylmercuric acetate in 0.1 mmol/l NaOH
by diluting the solution with 3 parts by volume of tris/HCl buffer, pH 7.5 (see below). The pH was adjusted to between 7.0 and 7.5 by adding 1 mmol/l HCI. After the enzyme had been activated, it was diluted with the tris/HCI
buffer to a concentration of 1.67 ~g/ml.
In order to measure the enzyme activity, 10 p,1 of enzyme solution were incubated for 15 minutes with 10 p,1 of a 3% (v/v) buffered solution of dimethyl sulfoxide (reaction 1 ). In order to measure the enzyme inhibitor activity, 10 p1 of enzyme solution were incubated with 10 p1 of a 3% (v/v) buffered solution of dimethyl sulfoxide which contained the enzyme inhibitor (reaction 2).
Both in the case of reaction 1 and in the case of reaction 2, the enzyme reaction was monitored by fluorescence spectroscopy (328 nm (extinction)/
393 nm (emission)) after 10 p.1 of a 3% (v/v) aqueous solution of dimethyl sulfoxide which contained 0.075 mmol of the substrate/l had been added.
The enzyme activity was presented as increase in extinction/minute.
The effect of the inhibitor was calculated as a percentage inhibition in accordance with the following formula:
inhibition = 100 - [(increase in extinction/minute in reaction 2) / (increase in extinction/minute in reaction 1 ) x 100].
The ICSO, that is the concentration of inhibitor which is required for 50%
inhibition of the enzyme activity, was determined graphically by plotting the percentage inhibitions at different inhibitor concentrations.
The buffer solution contained 0.05% Brij (Sigma, Deisenhofen, Germany) and also 0.1 mol of tris/HCl/I, 0.1 mol of NaCI/I, 0.01 mol of CaCl2/l (pH=7.5). The enzyme solution contained 1.67 ~g of the enzyme domain/ml. The substrate solution contained 0.075 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2',4'-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2/I (Bachem, Heidelberg, Germany).
Determining the enzyme activity of the catalytic domain of human gelatinase A (MMP-2).
This protein was obtained as an inactive proenzyme from INVITEK, Berlin (catalog No. 30 100 602). Activation of the proenzyme:
2 parts by volume of proenzyme were incubated, at 37°C for 0.5 hour, with 1 part by volume of APMA solution. The APMA solution was prepared from a 10 mmol/l solution of p-aminophenylmercuric acetate in 0.1 mmol/I NaOH
by diluting it with 3 parts by volume of tris/HCI buffer, pH 7.5 (see below).
The pH was adjusted to between 7.0 and 7.5 by adding 1 mmol/l HCI. After the enzyme had been activated, it was diluted with the tris/HCI buffer to a concentration of 0.83 ~g/ml.
In order to measure the enzyme activity, 10 p.1 of enzyme solution were incubated for 15 minutes with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide (reaction 1 ). In order to measure the enzyme inhibitor activity, 10 p.1 of enzyme solution were incubated with 10 ~,I of a 3% (v/v) buffered solution of dimethyl sulfoxide which contained the enzyme inhibitor (reaction 2).
Both in the case of reaction 1 and in the case of reaction 2, the enzyme reaction was monitored by fluorescence spectroscopy (328 nm (extinction)/
393 nm (emission)) after 10 ~I of a 3% (v/v) aqueous solution of dimethyl sulfoxide which contained 0.3 mmol of the substrate/l had been added.
The enzyme activity was presented as increase in extinction/minute.
The effect of the inhibitor was calculated as percentage inhibition in accordance with the following formula:
inhibition = 100 - [(increase in extinction/minute in reaction 2) / (increase in extinction/minute in reaction 1 ) x 100].
The ICSO, that is the concentration of inhibitor which is required for 50%
inhibition of the enzyme activity, was determined graphically by plotting the percentage inhibitions at different inhibitor concentrations.
The buffer solution contained 0.05% Brij (Sigma, Deisenhofen, Germany) and also 0.1 mol of trisIHCl/l, 0.1 mol of NaCl/l, 0.01 mol of CaCl2/l (pH=7.5). The enzyme solution contained 0.83 ~g of the enzyme domain/ml. The substrate solution contained 0.3 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2',4' dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2/I (Sachem, Heidelberg, Germany).
Determining the enzyme activity of the catalytic domain of human gelatinase B (MMP-9).
This protein was obtained as an inactive proenzyme from Roche, Mannheim (catalog No. 1 758 896). Activation of the proenzyme:
2 parts by volume of proenzyme were incubated, at 37°C for 4 hours, with 1 part by volume of APMA solution. The APMA solution was prepared from a 10 mmol/l solution of p-aminophenylmercuric acetate in 0.1 mmol/I NaOH
by diluting it with 3 parts by volume of tris/HCl buffer, pH 7.5 (see below).
The pH was adjusted to between 7.0 and 7.5 by adding 1 mmol/l HCI. After the enzyme had been activated, it was diluted with the tris/HCI buffer to a concentration of 4.2 mU/ml.
In order to measure the activity of the enzyme, 10 ~I of enzyme solution were incubated for 15 minutes with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide (reaction 1 ). In order to measure the enzyme inhibitor activity, 10 ~I of enzyme solution were incubated with 10 ~I of a 3% (v/v) buffered solution of dimethyl sulfoxide which contained the enzyme inhibitor (reaction 2).
Both in the case of reaction 1 and in the case of reaction 2, the enzyme reaction was monitored by fluorescence spectroscopy (328 nm (extinction)/393 nm (emission)) after 10 p,1 of a 3% (v/v) aqueous solution of dimethyl sulfoxide, which contained 0.15 mmol of the substrate/I, had been added.
The enzyme activity was presented as increase in extinction/minute.
The inhibitory effect was calculated as percentage inhibition in accordance with the following formula:
inhibition = 100 - [(increase in extinctionlminute in reaction 2)/(increase in extinction/minute in reaction 1 ) X 100].
The ICSO, that is the concentration of inhibitor which is required for 50%
inhibition of the enzyme activity, was determined graphically by plotting the percentage inhibitions at different inhibitor concentrations.
The buffer solution contained 0.05% Brij (Sigma, Deisenhofen, Germany) and also 0.1 mol of tris/HCl/l, 0.1 mol of NaCI/I, 0.01 mol of CaCl2/I
(pH=7.5). The enzyme solution contained 4.2 mU of the enzyme domain/ml. The substrate solution contained 0.15 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2',4'-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2/I (Sachem, Heidelberg, Germany).
Table 3 below shows the results.
Table 3:
ExampleMMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 ICS ICS ICS ICS ICS IC
nnri nnn nm nnn nm nnri 5 70 2 28 2.5 1.2 1.8 11 220 2 25 2.5 2 1.5 13 180 2.6 30 4 2 2 14 400 2 25 2.2 3.5 2 21 21 1.5 23 2.3 0.45 1.3 23 290 2 50 9 2 2.1
Claims (32)
1. A compound of the formula I
and/or all the stereoisomeric forms of the compound of the formula I
and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, wherein A is -(C0-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(C0-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)n-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1) -C(O)-
and/or all the stereoisomeric forms of the compound of the formula I
and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, wherein A is -(C0-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(C0-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)n-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1) -C(O)-
2) -(C2-C4)-alkenylene,
3) -S(O)o-, where o is the integers zero, 1 or 2,
4) -N(R6)-, in which R6 is hydrogen atom, methyl or ethyl,
5) -N(R6)-C(Y)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above,
6) -C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above,
7) -N(R6)-SO2-, in which R6 is defined as above,
8) -SO2-N(R6)-, in which R6 is defined as above,
9) -N(R6)-SO2-N(R6)-, in which R6 is defined as above,
10) -N(R6)-C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above,
11) -O-C(O)-N(R6)-,
12) -NH-C(O)-O-,
13) -O-,
14) -C(O)-O-,
15) -O-C(O)-,
16) -O-C(O)-O-,
17) -O-CH2-C(O)-,
18) -O-CH2-C(O)-O-,
19) -O-CH2-C(O)-N(R6)-, in which R6 is defined as above,
20) -C(O)-CH2-O-,
21) -O-C(O)-CH2-O-,
22) -N(R6)-C(O)-CH2-O-, in which R6 is defined as above,
23) -O-(CH2)n-O-, in which n is the integer 2 or 3, or
24) -O-(CH2)m-N(R6)-, in which m is the integer 2 or 3 and R6 is defined as above,
25) -N(R6)-(CH2)m-O-, in which m is the integer 2 or 3 and R6 is defined as above,
26) -N(R6)-N(R6)-, in which R6 is defined as above,
27) -N=N-,
28) -N(R6)-CH=N-, in which R6 is defined as above,
29) -N=CH-N(R6)-, in which R6 is defined as above,
30) -N(R6)-C(R7)=N-, in which R6 is defined as above and R7 is -NH-R6,
31) -N=C(R7)-N(R6)-, in which R6 is defined as above and R7 is -NH-R6, or
32) -(C2-C6)-alkynylene, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1) covalent bond, 2) -(C6-C14)-aryl, in which aryl is unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) 4- to 15-membered Het ring, in which Het ring is unsubstituted or substituted, independently of each other, once, twice or three times, by G, ring4 is 1) -(C6-C14)-aryl, in which aryl is unsubstituted or substituted, independently of each other, once, twice or three times, by G, 2) 4- to 15-membered Het ring, in which the Het ring is unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) is one of the following radicals and these radicals are unsubstituted or substituted once by G, G is 1)~hydrogen atom, 2) halogen, 3) =O, 4) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times, by halogen, -(C4-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, 5) -(C6-C14)-aryl, 6) Het ring, 7) -C(O)-O-R10, in which R10 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted once, twice, by -(C3-C6)-cycloalkyl,~
-(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, or~
b) -(C6-C14)-aryl or Het ring, 8) -C(S)-O-R10, in which R10 is defined as above, 9) -C(O)-NH-R11, in which R11 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted once, twice, by -(C3-C6)-cycloalkyl, -(C6-C14)-aryl or Het ring, or b) -(C6-C14)-aryl or Het ring, 10) -C(O)-NH-R11, in which R11 is defined as above, 11) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, c) -(C6-C14)-aryl, d) Het ring, e) -C(O)-O-R13, in which R13 is e)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl, or Het ring, or e)2) -(C6-C14)-aryl or Het ring, f) -C(S)-O-R13, in which R13 is defined as above, g) -C(O)-NH-R14, in which R14 is g)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, or g)2) -(C6-C14)-aryl or Het ring, or h) -C(S)-NH-R14, in which R14 is defined as above, 12) -C(O)-R10, in which R10 is defined as above, 13) -S(O)p-R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 14) -No2, 15) -CN, 16) -N(R15)-R12, in which R15 is 16)1) hydrogen atom, 16)2) -(C1-C6)-alkyl, or 16)3) -SO2-(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, and R12 is defined as above, or 17) -SO2-N(R12)-R1, in which R12 is defined as above and R1 is defined as below, X is -OH or -NH-OH, n1 is the integer zero, 1, 2 or 3, n2 is the integer zero, 1, 2, 3 or 4, with the proviso that the sum of n1 and n2 amounts to 1, 2, 3, 4, 5, 6 or 7, R1, R2, R3, R4 and R5 are identical or different and are, independently of each other, 1) hydrogen atom, 2) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, 3) -C(O)-O-R8, in which R8 is 3)1) hydrogen atom, 3)2) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, or substituted once to five times, by fluorine, or 3)3) -(C6-C14)-aryl or Het ring, 4) -O-R8, in which R8 has the abovementioned meaning, or 5) -(C3-C6)-cycloalkyl.
2. A compound of the formula I as claimed in claim 1, A is -(C0-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(C0-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)n-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1) -C(O)-2) -(C2-C4)-alkenylene, 3) -S(O)o-, where o is the integers zero, 1 or 2, 4) -N(R6)-, in which R6 is hydrogen atom, methyl or ethyl, 5) -N(R6)-C(Y)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 6) -C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 7) -N(R6)-SO2-, in which R6 is defined as above, 8) -SO2-N(R6)-, in which R6 is defined as above, 9) -N(R6)-SO2-N(R6)-, in which R6 is defined as above, 10) -N(R6)-C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 11) -O-C(O)-N(R6)-, 12) -NH-C(O)-O-, 13) -O-, 14) -C(O)-O-, 15) -O-C(O)-, 16) -O-C(O)-O-, 17) -O-CH2-C(O)-, 18) -O-CH2-C(O)-O-, 19) -O-CH2-C(O)-N(R6)-, in which R6 is defined as above, 20) -C(O)-CH2-O-, 21) -O-C(O)-CH2-O-, 22) -N(R6)-C(O)-CH2-O-, in which R6 is defined as above, 23) -O-(CH2)n-O-, in which n is the integer 2 or 3, or 24) -O-(CH2)m-N(R6)-, in which m is the integer 2 or 3 and R6 is defined as above, 25) -N(R6)-(CH2)m-O-, in which m is the integer 2 or 3 and R6 is defined as above, 26) -N(R6)-N(R6)-, in which R6 is defined as above, 27) -N=N-, 28) -N(R6)-CH=N-, in which R6 is defined as above, 29) -N=CH-N(R6)-, in which R6 is defined as above, 30) -N(R6)-C(R7)=N-, in which R6 is defined as above and R7 is -NH-R6, 31) -N=C(R7)-N(R6)-, in which R6 is defined as above and R7 is -NH-R6, or 32) -(C2-C6)-alkynylene, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1) covalent bond, 2) phenyl or naphthyl and are unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) 4- to 15-membered Het ring, in which the Het ring is a radical from the series acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, deca-hydroquinolinyl, dibenzofuranyl, dibenzothiophenyl, dihydrofuran[2,3-b]tetrahydrofuranyl, dihydrofuranyl, dioxolyl, dioxanyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxothiolanyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydro-pyridinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thia-diazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, and these radicals are unsubstituted or substituted, independently of each other, once, twice or three times, by G, ring4 is 1) -(C6-C14)-aryl, in which aryl is a radical from the series phenyl, naphthyl, 1-naphthyl, 2-naphthyl, anthryl and fluorenyl, and these radicals are unsubstituted or substituted, independently of each other, once, twice or three times, by G, 2) 4- to 15-membered Het ring, in which the Het ring is a radical from the series acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, deca-hydroquinolinyl, dibenzofuranyl, dibenzothiophenyl, dihydrofuran[2,3-b]tetrahydrofuranyl, dihydrofuranyl, dioxolyl, dioxanyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolinyl, 2'-methylbiphenyl-2-ol, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxothiolanyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydro-pyridinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thia-diazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, and are unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) is one of the following radicals and these radicals are unsubstituted or substituted once by G, G is 1) hydrogen atom, 2) halogen, 3) =O, 4) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, 5) -(C6-C14)-aryl, where aryl is defined as above, 6) Het ring, where Het ring is defined as above, 7) -C(O)-O-R10, in which R10 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, or b) -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, 8) -C(S)-O-R10, where R10 is defined as above, 9) -C(O)-NH-R11, in which R11 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, or b) -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, 10) -C(S)-NH-R11, in which R11 is defined as above, 11) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, c) -(C6-C14)-aryl, where aryl is defined as above, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C,4)-aryl, or Het ring, where aryl and Het ring are defined as above, or e)2) -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, f) -C(S)-O-R13, in which R13 is defined as above, g) -C(O)-NH-R14, in which R14 is g)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, or g)2) -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, or h) -C(S)-NH-R14, in which R14 is defined as above, 12) -C(O)-R10, in which R10 is defined as above, 13) -S(O)p-R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 14) -NO2, 15) -CN, or 16) -N(R15)-R12, in which R15 is 16)1) hydrogen atom, 16)2) -(C1-C6)-alkyl or 16)3) -SO2-(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, and R12 is defined as above, 17) -SO2-N(R12)-R1, in which R12 is defined as above and R1 is defined as below, X is -OH or -NH-OH, n1 is the integer 1 or 2, n2 is the integer 2 or 3, R1, R2, R3, R4 and R5 are identical or different and are, independently of each other, 1) hydrogen atom, 2) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, 3) -C(O)-O-R8, in which R8 is 3)1) hydrogen atom, 3)2) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, or is substituted once to five times by fluorine, or 3)3) -(C6-C14)-aryl or Het ring, 4) -O-R8, in which R8 has the abovementioned meaning, or 5) -(C3-C6)-cycloalkyl.
3. A compound of the formula I as claimed in claim 1 or 2, wherein A is -(C0-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(C0-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)n-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1) -(C0-C2)-alkylene, 2) ethenylene, 3) ethynylene, 4) -C(O)-5) -N(R6)-C(O)-, in which R6 is hydrogen atom, methyl or ethyl, 6) -C(O)-N(R6)-, in which R6 is defined as above, 7) -O-, or 8) -S-, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1) covalent bond, 2) phenyl or naphthyl and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series dihydrofuranyl, furanyl, pyridinyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl or thiophenyl, and the radicals are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1) phenyl or naphthyl and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dihydrofuranyl, dibenzofuranyl, dibenzothiophenyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical and this radical is unsubstituted or substituted once by G, G is 1) hydrogen atom, 2) Br, Cl or F, 3) -(C1-C4)-alkyl, in which alkyl is unsubstituted or substituted once or twice by F, phenyl, -C3-cycloalkyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH-R11, in which R11 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, -C(S)-O-R13, in which R13 is defined as above, or g) -C(O)-NH-R14, in which R14 is g)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by phenyl or Het ring, where Het ring is defined as above, or g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 10) -S(O)p-R12, in which R12 is defined as above and p is the integers 1 or 2, 11) -NO2, 12) -CN, or 13) -N(R15)-R12, in which R15 is 13)1) hydrogen atom, or 13)2) -(C1-C6)-alkyl and R12 is defined as above, X is -OH or -NH-OH, n1 is the integer 1 or 2, n2 is the integer 2 or 3, R1, R2 and R3 are in each case hydrogen atom, R4 and R5 are identical or different and are, independently of each other, 1) hydrogen atom, 2) methyl, 3) ethyl, or 4) -OH.
4. A compound of the formula I as claimed in one or more of claims 1 to 3, wherein A is -(C0-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(C0-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)n-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1) -(C0-C2)-alkylene, 2) ethenylene, or 3) ethynylene, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1) covalent bond, 2) phenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series dihydrofuranyl, furanyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolyl, thiazolyl or thiophenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1) phenyl, and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dihydrofuranyl, dibenzofuranyl, dibenzothiophenyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical and this radical is unsubstituted or substituted once by G, G is 1) hydrogen atom, 2) Br, Cl or F, 3) -(C1-C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times, by Br, Cl, F, -C3-cycloalkyl, phenyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH-R11, in which R11 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl or naphthyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl, naphthyl, or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, f) -C(S)-O-R13, in which R13 is defined as above, or g) -C(O)-NH-R14, in which R14 is g)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by phenyl or Het ring, where Het ring is defined as above, or g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 10) -S(O)p-R12, in which R12 is defined as above and p is the integers 1 or 2, 11) -NO2, 12) -CN, or 13) -N(R15)-R12, in which R15 is 13)1) hydrogen atom, or 13)2) -(C1-C6)-alkyl and R12 is defined as above, X is -OH or -NH-OH, n1 is the integer 2, n2 is the integer 3, R1, R2, R3, R4 and R5 are in each case hydrogen atom.
5. A compound of the formula I as claimed in one or more of claims 1 to 4, wherein A is a covalent bond or -CH2-CH2-, B, D and E are identical or different and are, independently of each other, -(C0-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)n-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1) -C(O)-2) -(C2-C4)-alkynylene, 3) -S(O)o-, where o is the integers zero or 1, 4) -N(R6)-C(Y)-, in which Y is oxygen atom and R6 is hydrogen atom, 5) -C(Y)-N(R6)-, in which Y is oxygen atom and R6 is hydrogen atom, or 6) -O-, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1) covalent bond, 2) phenyl and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series furanyl, pyridinyl, pyrimidinyl or thiophenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1) phenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dibenzofuranyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical and this radical is unsubstituted or substituted once by G, G is 1) hydrogen atom, 2) Br, Cl or F, 3) -(C1-C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times, by Br, Cl, F, -C3-cycloalkyl, phenyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH-R11, in which R11 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, f) -C(S)-O-R13, in which R13 is defined as above, or g) -C(O)-NH-R14, in which R14 is g)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by phenyl or Het ring, where Het ring is defined as above, or g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 10) -S(O)p-R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 11) -NO2, 12) -CN, or 13) -N(R15)-R12, in which R15 is 13)1) hydrogen atom, or 13)2) -(C1-C6)-alkyl and R12 is defined as above, X is -NH-OH, n1 is the integer 2, n2 is the integer 3, and R1, R2, R3, R4 and R5 are in each case hydrogen atom.
6. A compound of the formula I as claimed in one or more of claims 1 to 5, which is a compound from the series 2-(4'-nitrobiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(4'-chlorobiphenyl-4-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-(4'-chlorobiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(6-phenoxypyridine-3-sulfonyl)decahydroisoquinoline-1-carboxylic acid; trifluoroacetate, 2-(6-phenoxypyridine-3-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide; trifluoroacetate, 2-[2-(4'-chlorobiphenyl-4-yl)ethanesulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-[2-(4'-chlorobiphenyl-4-yl)ethanesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(pyridin-4-yloxy)benzenesulfonyl]decahydroisoquinoline-1-carboxylic acid; trifluoroacetate, 2-[4-(pyridin-4-yloxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide; trifluoroacetate, 2-[4-(4-methoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-[4-(4-methoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-{4-[4-(2,2,2-trifluoroethoxy)phenoxy]benzenesulfonyl}decahydro-isoquinoline-1-carboxylic acid, 2-{4-[4-(2,2,2-trifluoroethoxy)phenoxy]benzenesulfonyl}decahydro-isoquinoline-1-(N-hydroxy)carboxamide, 2-[4'-(2,2,2-trifluoroethoxy)biphenyl-4-sulfonyl]decahydroiso-quinoline-1-carboxylic acid, 2-(4'-isopropoxycarbonylaminobiphenyl-4-sulfonyl)decahydroiso-quinoline-1- carboxylic acid, [4'-(1-hydroxycarbamoyloctahydroisoquinoline-2-sulfonyl)biphenyl-4-yl]carboxamide isopropyl ester, 2-[4'-(2,2,2-trifluoroethoxy)biphenyl-4-sulfonyl]decahydroiso-quinoline-1-(N-hydroxy)carboxamide, 2-(4'-trifluoromethoxybiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-fluorophenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-trifluoromethoxyphenoxy)benzenesulfonyl]decahydroiso-quinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-trifluoromethoxyphenoxy)benzenesulfonyl]decahydroiso-quinoline-1- carboxylic acid, 2-(biphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)car-boxamide, 2-(biphenyl-4-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-[4-(4-cyanophenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(dibenzofuran-2-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-(dibenzofuran-2-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)car-boxamide, or 2-[4-(4-fluorophenoxy)benzenesulfonyl]-6-methoxydecahydroiso-quinoline-1-(N-hydroxy)carboxamide, and also all the isomeric forms of the abovementioned compounds.
7. A process for preparing the compound of the formula I as claimed in one or more of claims 1 to 6, which comprises a) reacting a compound of the formula IV, in which Re is a hydrogen atom or an ester-protecting group, with a compound of the formula V, in which A, B, D, E and ring1, ring2, ring3 and ring4 are defined as in formula I, and in which Rz is chlorine atom, imidazoyl or OH, in the presence of a base or following silylation with a suitable silylating agent, or using a suitable dehydrating agent when Rz =
OH, to give a compound of the formula VI, in which A, B, D, E, Re and ring1, ring2, ring3 and ring4 are defined as above, or b) when Re = ester reacting a compound of the formula VI
prepared as described in a) with a solution of alkali such as NaOH or LiOH, and then treating the product with acid, to give the carboxylic acid according to the invention of the formula I, in which X = OH
(corresponding to VII), with modifications in one of the side chains of the rings ring1-ring4 also having previously been made, where appropriate; or converting said ester, by treating it with a mineral acid, such as hydrochloric acid, into the free carboxylic acid VII
and then converting this into the hydroxamic acid according to the invention, in which X = NH-OH, of the formula I, or c) using salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases, or derivatization with chiral, enantiomerically pure compounds such as amino acids, separation of the resulting diastereomers and elimination of the chiral auxiliary groups, to separate a compound of formula I
prepared as described in procedure a), or a suitable precursor of the formula I, which arises in enantiomeric forms due to its chemical structure, into the pure enantiomers, or d) either isolating the compound of the formula I prepared as described in procedures b) or c) in free form, or, when acid or basic groups are present, converting it into physiologically tolerated salts.
8. A pharmaceutical, which comprises an effective content of at least one compound of the formula I as claimed in one or more of claims 1 to 6 together with a pharmaceutically suitable and physiologically tolerated carrier substance, additive and/or other active compounds and auxiliary substances.
9. The use of the compound of formula I as claimed in one or more of claims 1 to 6 for producing a pharmaceutical for the prophylaxis and therapy of degenerative joint diseases such as osteoarthroses, spondyloses and chondrolysis following joint trauma or a relatively long period of joint immobilization following meniscus injuries or patella injuries or ligament ruptures, diseases of the connective tissue such as collagenoses, periodontal diseases, wound healing disturbances and chronic diseases of the locomotory apparatus such as inflammatory, immunologically determined or metabolism-determined acute and chronic arthritides, arthropathies, myalgias and disturbances of bone metabolism, for the treatment of ulceration, atherosclerosis and stenoses, for the treatment of inflammations, cancer diseases, tumor metastases formation, cachexia, anorexia, heart failure and septic shock, or for the prophylaxis of myocardial and cerebral infarctions.
-(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, or~
b) -(C6-C14)-aryl or Het ring, 8) -C(S)-O-R10, in which R10 is defined as above, 9) -C(O)-NH-R11, in which R11 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted once, twice, by -(C3-C6)-cycloalkyl, -(C6-C14)-aryl or Het ring, or b) -(C6-C14)-aryl or Het ring, 10) -C(O)-NH-R11, in which R11 is defined as above, 11) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, c) -(C6-C14)-aryl, d) Het ring, e) -C(O)-O-R13, in which R13 is e)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl, or Het ring, or e)2) -(C6-C14)-aryl or Het ring, f) -C(S)-O-R13, in which R13 is defined as above, g) -C(O)-NH-R14, in which R14 is g)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, or g)2) -(C6-C14)-aryl or Het ring, or h) -C(S)-NH-R14, in which R14 is defined as above, 12) -C(O)-R10, in which R10 is defined as above, 13) -S(O)p-R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 14) -No2, 15) -CN, 16) -N(R15)-R12, in which R15 is 16)1) hydrogen atom, 16)2) -(C1-C6)-alkyl, or 16)3) -SO2-(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, and R12 is defined as above, or 17) -SO2-N(R12)-R1, in which R12 is defined as above and R1 is defined as below, X is -OH or -NH-OH, n1 is the integer zero, 1, 2 or 3, n2 is the integer zero, 1, 2, 3 or 4, with the proviso that the sum of n1 and n2 amounts to 1, 2, 3, 4, 5, 6 or 7, R1, R2, R3, R4 and R5 are identical or different and are, independently of each other, 1) hydrogen atom, 2) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, 3) -C(O)-O-R8, in which R8 is 3)1) hydrogen atom, 3)2) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, or substituted once to five times, by fluorine, or 3)3) -(C6-C14)-aryl or Het ring, 4) -O-R8, in which R8 has the abovementioned meaning, or 5) -(C3-C6)-cycloalkyl.
2. A compound of the formula I as claimed in claim 1, A is -(C0-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(C0-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)n-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1) -C(O)-2) -(C2-C4)-alkenylene, 3) -S(O)o-, where o is the integers zero, 1 or 2, 4) -N(R6)-, in which R6 is hydrogen atom, methyl or ethyl, 5) -N(R6)-C(Y)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 6) -C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 7) -N(R6)-SO2-, in which R6 is defined as above, 8) -SO2-N(R6)-, in which R6 is defined as above, 9) -N(R6)-SO2-N(R6)-, in which R6 is defined as above, 10) -N(R6)-C(Y)-N(R6)-, in which Y is oxygen atom or sulfur atom and R6 is defined as above, 11) -O-C(O)-N(R6)-, 12) -NH-C(O)-O-, 13) -O-, 14) -C(O)-O-, 15) -O-C(O)-, 16) -O-C(O)-O-, 17) -O-CH2-C(O)-, 18) -O-CH2-C(O)-O-, 19) -O-CH2-C(O)-N(R6)-, in which R6 is defined as above, 20) -C(O)-CH2-O-, 21) -O-C(O)-CH2-O-, 22) -N(R6)-C(O)-CH2-O-, in which R6 is defined as above, 23) -O-(CH2)n-O-, in which n is the integer 2 or 3, or 24) -O-(CH2)m-N(R6)-, in which m is the integer 2 or 3 and R6 is defined as above, 25) -N(R6)-(CH2)m-O-, in which m is the integer 2 or 3 and R6 is defined as above, 26) -N(R6)-N(R6)-, in which R6 is defined as above, 27) -N=N-, 28) -N(R6)-CH=N-, in which R6 is defined as above, 29) -N=CH-N(R6)-, in which R6 is defined as above, 30) -N(R6)-C(R7)=N-, in which R6 is defined as above and R7 is -NH-R6, 31) -N=C(R7)-N(R6)-, in which R6 is defined as above and R7 is -NH-R6, or 32) -(C2-C6)-alkynylene, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1) covalent bond, 2) phenyl or naphthyl and are unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) 4- to 15-membered Het ring, in which the Het ring is a radical from the series acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, deca-hydroquinolinyl, dibenzofuranyl, dibenzothiophenyl, dihydrofuran[2,3-b]tetrahydrofuranyl, dihydrofuranyl, dioxolyl, dioxanyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxothiolanyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydro-pyridinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thia-diazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, and these radicals are unsubstituted or substituted, independently of each other, once, twice or three times, by G, ring4 is 1) -(C6-C14)-aryl, in which aryl is a radical from the series phenyl, naphthyl, 1-naphthyl, 2-naphthyl, anthryl and fluorenyl, and these radicals are unsubstituted or substituted, independently of each other, once, twice or three times, by G, 2) 4- to 15-membered Het ring, in which the Het ring is a radical from the series acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, deca-hydroquinolinyl, dibenzofuranyl, dibenzothiophenyl, dihydrofuran[2,3-b]tetrahydrofuranyl, dihydrofuranyl, dioxolyl, dioxanyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolidinyl, 2-isothiazolinyl, isothiazolyl, isoxazolyl, isoxazolidinyl, 2-isoxazolinyl, 2'-methylbiphenyl-2-ol, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxothiolanyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridothiophenyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydro-pyridinyl, 6H-1,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thia-diazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, and are unsubstituted or substituted, independently of each other, once, twice or three times, by G, or 3) is one of the following radicals and these radicals are unsubstituted or substituted once by G, G is 1) hydrogen atom, 2) halogen, 3) =O, 4) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, 5) -(C6-C14)-aryl, where aryl is defined as above, 6) Het ring, where Het ring is defined as above, 7) -C(O)-O-R10, in which R10 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, or b) -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, 8) -C(S)-O-R10, where R10 is defined as above, 9) -C(O)-NH-R11, in which R11 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, or b) -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, 10) -C(S)-NH-R11, in which R11 is defined as above, 11) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, c) -(C6-C14)-aryl, where aryl is defined as above, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C,4)-aryl, or Het ring, where aryl and Het ring are defined as above, or e)2) -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, f) -C(S)-O-R13, in which R13 is defined as above, g) -C(O)-NH-R14, in which R14 is g)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, or g)2) -(C6-C14)-aryl or Het ring, where aryl and Het ring are defined as above, or h) -C(S)-NH-R14, in which R14 is defined as above, 12) -C(O)-R10, in which R10 is defined as above, 13) -S(O)p-R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 14) -NO2, 15) -CN, or 16) -N(R15)-R12, in which R15 is 16)1) hydrogen atom, 16)2) -(C1-C6)-alkyl or 16)3) -SO2-(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, and R12 is defined as above, 17) -SO2-N(R12)-R1, in which R12 is defined as above and R1 is defined as below, X is -OH or -NH-OH, n1 is the integer 1 or 2, n2 is the integer 2 or 3, R1, R2, R3, R4 and R5 are identical or different and are, independently of each other, 1) hydrogen atom, 2) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, 3) -C(O)-O-R8, in which R8 is 3)1) hydrogen atom, 3)2) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by -(C3-C6)-cycloalkyl, -(C2-C6)-alkynyl, -(C6-C14)-aryl or Het ring, or is substituted once to five times by fluorine, or 3)3) -(C6-C14)-aryl or Het ring, 4) -O-R8, in which R8 has the abovementioned meaning, or 5) -(C3-C6)-cycloalkyl.
3. A compound of the formula I as claimed in claim 1 or 2, wherein A is -(C0-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(C0-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)n-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1) -(C0-C2)-alkylene, 2) ethenylene, 3) ethynylene, 4) -C(O)-5) -N(R6)-C(O)-, in which R6 is hydrogen atom, methyl or ethyl, 6) -C(O)-N(R6)-, in which R6 is defined as above, 7) -O-, or 8) -S-, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1) covalent bond, 2) phenyl or naphthyl and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series dihydrofuranyl, furanyl, pyridinyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl or thiophenyl, and the radicals are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1) phenyl or naphthyl and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dihydrofuranyl, dibenzofuranyl, dibenzothiophenyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical and this radical is unsubstituted or substituted once by G, G is 1) hydrogen atom, 2) Br, Cl or F, 3) -(C1-C4)-alkyl, in which alkyl is unsubstituted or substituted once or twice by F, phenyl, -C3-cycloalkyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH-R11, in which R11 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, -C(S)-O-R13, in which R13 is defined as above, or g) -C(O)-NH-R14, in which R14 is g)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by phenyl or Het ring, where Het ring is defined as above, or g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 10) -S(O)p-R12, in which R12 is defined as above and p is the integers 1 or 2, 11) -NO2, 12) -CN, or 13) -N(R15)-R12, in which R15 is 13)1) hydrogen atom, or 13)2) -(C1-C6)-alkyl and R12 is defined as above, X is -OH or -NH-OH, n1 is the integer 1 or 2, n2 is the integer 2 or 3, R1, R2 and R3 are in each case hydrogen atom, R4 and R5 are identical or different and are, independently of each other, 1) hydrogen atom, 2) methyl, 3) ethyl, or 4) -OH.
4. A compound of the formula I as claimed in one or more of claims 1 to 3, wherein A is -(C0-C4)-alkylene, B, D and E are identical or different and are, independently of each other, -(C0-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)n-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1) -(C0-C2)-alkylene, 2) ethenylene, or 3) ethynylene, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1) covalent bond, 2) phenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series dihydrofuranyl, furanyl, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolyl, thiazolyl or thiophenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1) phenyl, and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dihydrofuranyl, dibenzofuranyl, dibenzothiophenyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical and this radical is unsubstituted or substituted once by G, G is 1) hydrogen atom, 2) Br, Cl or F, 3) -(C1-C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times, by Br, Cl, F, -C3-cycloalkyl, phenyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH-R11, in which R11 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl or naphthyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl, naphthyl, or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, f) -C(S)-O-R13, in which R13 is defined as above, or g) -C(O)-NH-R14, in which R14 is g)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by phenyl or Het ring, where Het ring is defined as above, or g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 10) -S(O)p-R12, in which R12 is defined as above and p is the integers 1 or 2, 11) -NO2, 12) -CN, or 13) -N(R15)-R12, in which R15 is 13)1) hydrogen atom, or 13)2) -(C1-C6)-alkyl and R12 is defined as above, X is -OH or -NH-OH, n1 is the integer 2, n2 is the integer 3, R1, R2, R3, R4 and R5 are in each case hydrogen atom.
5. A compound of the formula I as claimed in one or more of claims 1 to 4, wherein A is a covalent bond or -CH2-CH2-, B, D and E are identical or different and are, independently of each other, -(C0-C4)-alkylene or the radical -B1-B2-B3- in which B1 is -(CH2)n-, in which n is the integer zero, 1 or 2, B3 is -(CH2)m-, in which m is the integer zero, 1 or 2, with the proviso that the sum of n and m amounts to zero, 1 or 2, and B2 is 1) -C(O)-2) -(C2-C4)-alkynylene, 3) -S(O)o-, where o is the integers zero or 1, 4) -N(R6)-C(Y)-, in which Y is oxygen atom and R6 is hydrogen atom, 5) -C(Y)-N(R6)-, in which Y is oxygen atom and R6 is hydrogen atom, or 6) -O-, ring1, ring2 and ring3 are identical or different and are, independently of each other, 1) covalent bond, 2) phenyl and are unsubstituted or substituted, independently of each other, once or twice, by G, or 3) Het ring, in which the Het ring is a radical from the series furanyl, pyridinyl, pyrimidinyl or thiophenyl, and are unsubstituted or substituted, independently of each other, once or twice, by G, ring4 is 1) phenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, 2) Het ring, in which the Het ring is a radical from the series benzofuranyl, dibenzofuranyl, furanyl, 2'-methylbiphenyl-2-ol, morpholinyl, piperazinyl, piperidinyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl and is unsubstituted or substituted, independently of each other, once or twice, by G, or 3) the following radical and this radical is unsubstituted or substituted once by G, G is 1) hydrogen atom, 2) Br, Cl or F, 3) -(C1-C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times, by Br, Cl, F, -C3-cycloalkyl, phenyl or Het ring, where Het ring is defined as above, 4) phenyl, 5) Het ring, where Het ring is defined as above, 6) -C(O)-O-R10, in which R10 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 7) -C(O)-NH-R11, in which R11 is a) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, b) phenyl, or c) Het ring, where Het ring is defined as above, 8) -O-R12, in which R12 is a) hydrogen atom, b) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once, twice or three times, by halogen, cyclopropyl, phenyl or Het ring, where Het ring is defined as above, c) phenyl, d) Het ring, where Het ring is defined as above, e) -C(O)-O-R13, in which R13 is e)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by cyclopropyl, phenyl or Het ring, where Het ring is defined as above, or e)2) phenyl or Het ring, where Het ring is defined as above, f) -C(S)-O-R13, in which R13 is defined as above, or g) -C(O)-NH-R14, in which R14 is g)1) -(C1-C6)-alkyl, in which alkyl is unsubstituted or substituted, once or twice, by phenyl or Het ring, where Het ring is defined as above, or g)2) phenyl or Het ring, where Het ring is defined as above, 9) -C(O)-R10, in which R10 is defined as above, 10) -S(O)p-R12, in which R12 is defined as above and p is the integers zero, 1 or 2, 11) -NO2, 12) -CN, or 13) -N(R15)-R12, in which R15 is 13)1) hydrogen atom, or 13)2) -(C1-C6)-alkyl and R12 is defined as above, X is -NH-OH, n1 is the integer 2, n2 is the integer 3, and R1, R2, R3, R4 and R5 are in each case hydrogen atom.
6. A compound of the formula I as claimed in one or more of claims 1 to 5, which is a compound from the series 2-(4'-nitrobiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(4'-chlorobiphenyl-4-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-(4'-chlorobiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(6-phenoxypyridine-3-sulfonyl)decahydroisoquinoline-1-carboxylic acid; trifluoroacetate, 2-(6-phenoxypyridine-3-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide; trifluoroacetate, 2-[2-(4'-chlorobiphenyl-4-yl)ethanesulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-[2-(4'-chlorobiphenyl-4-yl)ethanesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(pyridin-4-yloxy)benzenesulfonyl]decahydroisoquinoline-1-carboxylic acid; trifluoroacetate, 2-[4-(pyridin-4-yloxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide; trifluoroacetate, 2-[4-(4-methoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-carboxylic acid, 2-[4-(4-methoxyphenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-{4-[4-(2,2,2-trifluoroethoxy)phenoxy]benzenesulfonyl}decahydro-isoquinoline-1-carboxylic acid, 2-{4-[4-(2,2,2-trifluoroethoxy)phenoxy]benzenesulfonyl}decahydro-isoquinoline-1-(N-hydroxy)carboxamide, 2-[4'-(2,2,2-trifluoroethoxy)biphenyl-4-sulfonyl]decahydroiso-quinoline-1-carboxylic acid, 2-(4'-isopropoxycarbonylaminobiphenyl-4-sulfonyl)decahydroiso-quinoline-1- carboxylic acid, [4'-(1-hydroxycarbamoyloctahydroisoquinoline-2-sulfonyl)biphenyl-4-yl]carboxamide isopropyl ester, 2-[4'-(2,2,2-trifluoroethoxy)biphenyl-4-sulfonyl]decahydroiso-quinoline-1-(N-hydroxy)carboxamide, 2-(4'-trifluoromethoxybiphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-fluorophenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-trifluoromethoxyphenoxy)benzenesulfonyl]decahydroiso-quinoline-1-(N-hydroxy)carboxamide, 2-[4-(4-trifluoromethoxyphenoxy)benzenesulfonyl]decahydroiso-quinoline-1- carboxylic acid, 2-(biphenyl-4-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)car-boxamide, 2-(biphenyl-4-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-[4-(4-cyanophenoxy)benzenesulfonyl]decahydroisoquinoline-1-(N-hydroxy)carboxamide, 2-(dibenzofuran-2-sulfonyl)decahydroisoquinoline-1-carboxylic acid, 2-(dibenzofuran-2-sulfonyl)decahydroisoquinoline-1-(N-hydroxy)car-boxamide, or 2-[4-(4-fluorophenoxy)benzenesulfonyl]-6-methoxydecahydroiso-quinoline-1-(N-hydroxy)carboxamide, and also all the isomeric forms of the abovementioned compounds.
7. A process for preparing the compound of the formula I as claimed in one or more of claims 1 to 6, which comprises a) reacting a compound of the formula IV, in which Re is a hydrogen atom or an ester-protecting group, with a compound of the formula V, in which A, B, D, E and ring1, ring2, ring3 and ring4 are defined as in formula I, and in which Rz is chlorine atom, imidazoyl or OH, in the presence of a base or following silylation with a suitable silylating agent, or using a suitable dehydrating agent when Rz =
OH, to give a compound of the formula VI, in which A, B, D, E, Re and ring1, ring2, ring3 and ring4 are defined as above, or b) when Re = ester reacting a compound of the formula VI
prepared as described in a) with a solution of alkali such as NaOH or LiOH, and then treating the product with acid, to give the carboxylic acid according to the invention of the formula I, in which X = OH
(corresponding to VII), with modifications in one of the side chains of the rings ring1-ring4 also having previously been made, where appropriate; or converting said ester, by treating it with a mineral acid, such as hydrochloric acid, into the free carboxylic acid VII
and then converting this into the hydroxamic acid according to the invention, in which X = NH-OH, of the formula I, or c) using salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases, or derivatization with chiral, enantiomerically pure compounds such as amino acids, separation of the resulting diastereomers and elimination of the chiral auxiliary groups, to separate a compound of formula I
prepared as described in procedure a), or a suitable precursor of the formula I, which arises in enantiomeric forms due to its chemical structure, into the pure enantiomers, or d) either isolating the compound of the formula I prepared as described in procedures b) or c) in free form, or, when acid or basic groups are present, converting it into physiologically tolerated salts.
8. A pharmaceutical, which comprises an effective content of at least one compound of the formula I as claimed in one or more of claims 1 to 6 together with a pharmaceutically suitable and physiologically tolerated carrier substance, additive and/or other active compounds and auxiliary substances.
9. The use of the compound of formula I as claimed in one or more of claims 1 to 6 for producing a pharmaceutical for the prophylaxis and therapy of degenerative joint diseases such as osteoarthroses, spondyloses and chondrolysis following joint trauma or a relatively long period of joint immobilization following meniscus injuries or patella injuries or ligament ruptures, diseases of the connective tissue such as collagenoses, periodontal diseases, wound healing disturbances and chronic diseases of the locomotory apparatus such as inflammatory, immunologically determined or metabolism-determined acute and chronic arthritides, arthropathies, myalgias and disturbances of bone metabolism, for the treatment of ulceration, atherosclerosis and stenoses, for the treatment of inflammations, cancer diseases, tumor metastases formation, cachexia, anorexia, heart failure and septic shock, or for the prophylaxis of myocardial and cerebral infarctions.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10344936.1 | 2003-09-27 | ||
DE10344936A DE10344936A1 (en) | 2003-09-27 | 2003-09-27 | Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases |
PCT/EP2004/010248 WO2005030728A1 (en) | 2003-09-27 | 2004-09-14 | Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2539731A1 true CA2539731A1 (en) | 2005-04-07 |
Family
ID=34353126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002539731A Abandoned CA2539731A1 (en) | 2003-09-27 | 2004-09-14 | Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1670766B1 (en) |
JP (1) | JP4861179B2 (en) |
KR (1) | KR20060086367A (en) |
CN (1) | CN1856478B (en) |
AR (1) | AR046165A1 (en) |
AT (1) | ATE550327T1 (en) |
AU (1) | AU2004275937A1 (en) |
BR (1) | BRPI0414594A (en) |
CA (1) | CA2539731A1 (en) |
DE (1) | DE10344936A1 (en) |
IL (1) | IL174040A0 (en) |
MA (1) | MA28075A1 (en) |
ME (1) | MEP33008A (en) |
MX (1) | MXPA06002927A (en) |
MY (1) | MY139830A (en) |
NO (1) | NO20061837L (en) |
NZ (1) | NZ546158A (en) |
PE (1) | PE20050432A1 (en) |
RS (1) | RS20060194A (en) |
RU (1) | RU2335494C2 (en) |
TW (1) | TW200520755A (en) |
UY (1) | UY28539A1 (en) |
WO (1) | WO2005030728A1 (en) |
ZA (1) | ZA200601501B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004031620A1 (en) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-trifluoromethoxyphenoxybenzene-4'-sulphonic acids, process for their preparation and use in medicaments |
DE102004031850A1 (en) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituted tetrahydroisoquinolines as MMP inhibitors, process for their preparation and their use as medicaments |
DE102005002500A1 (en) * | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuran derivatives as inhibitors of matrix metalloproteinases |
DE102005015040A1 (en) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituted tetrahydroisoquinolines as MMP inhibitors, process for their preparation and their use as medicament |
US8790714B2 (en) | 2007-08-03 | 2014-07-29 | Nucitec, S.A. De C.V. | Compositions and methods for treatment and prevention of osteoarthritis |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201303B (en) * | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
FR2701480B1 (en) * | 1993-02-15 | 1995-05-24 | Sanofi Elf | Compounds with a sulfamoyl and amidino group, process for their preparation and pharmaceutical compositions containing them. |
PT861236E (en) * | 1995-11-13 | 2002-07-31 | Hoechst Ag | ALPHA-IMINOHIDOXAMICOS AND N-SUBSTITUTED CARBOXYLIC ACID ACIDS AND HETEROCYCLICS |
NZ334252A (en) * | 1996-08-28 | 2000-11-24 | Procter & Gamble | Heterocyclic metalloprotease inhibitors |
CA2278694C (en) * | 1997-01-23 | 2006-09-26 | F. Hoffmann-La Roche Ag | Sulfamide-metalloprotease inhibitors |
DE10300015A1 (en) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Imino acid derivatives as inhibitors of matrix metal proteinases |
DE102004031620A1 (en) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-trifluoromethoxyphenoxybenzene-4'-sulphonic acids, process for their preparation and use in medicaments |
-
2003
- 2003-09-27 DE DE10344936A patent/DE10344936A1/en not_active Withdrawn
-
2004
- 2004-09-14 CN CN2004800279029A patent/CN1856478B/en not_active Expired - Fee Related
- 2004-09-14 RU RU2006114352/04A patent/RU2335494C2/en not_active IP Right Cessation
- 2004-09-14 AU AU2004275937A patent/AU2004275937A1/en not_active Abandoned
- 2004-09-14 NZ NZ546158A patent/NZ546158A/en unknown
- 2004-09-14 RS YUP-2006/0194A patent/RS20060194A/en unknown
- 2004-09-14 EP EP04786944A patent/EP1670766B1/en active Active
- 2004-09-14 BR BRPI0414594-1A patent/BRPI0414594A/en not_active IP Right Cessation
- 2004-09-14 WO PCT/EP2004/010248 patent/WO2005030728A1/en active Application Filing
- 2004-09-14 KR KR1020067005981A patent/KR20060086367A/en not_active Application Discontinuation
- 2004-09-14 JP JP2006527308A patent/JP4861179B2/en not_active Expired - Fee Related
- 2004-09-14 ME MEP-330/08A patent/MEP33008A/en unknown
- 2004-09-14 CA CA002539731A patent/CA2539731A1/en not_active Abandoned
- 2004-09-14 MX MXPA06002927A patent/MXPA06002927A/en active IP Right Grant
- 2004-09-14 AT AT04786944T patent/ATE550327T1/en active
- 2004-09-21 PE PE2004000918A patent/PE20050432A1/en not_active Application Discontinuation
- 2004-09-23 AR ARP040103437A patent/AR046165A1/en not_active Application Discontinuation
- 2004-09-23 TW TW093128791A patent/TW200520755A/en unknown
- 2004-09-25 MY MYPI20043935A patent/MY139830A/en unknown
- 2004-09-27 UY UY28539A patent/UY28539A1/en unknown
-
2006
- 2006-02-21 ZA ZA200601501A patent/ZA200601501B/en unknown
- 2006-03-01 IL IL174040A patent/IL174040A0/en unknown
- 2006-03-27 MA MA28892A patent/MA28075A1/en unknown
- 2006-04-26 NO NO20061837A patent/NO20061837L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2004275937A1 (en) | 2005-04-07 |
EP1670766B1 (en) | 2012-03-21 |
KR20060086367A (en) | 2006-07-31 |
PE20050432A1 (en) | 2005-07-21 |
MA28075A1 (en) | 2006-08-01 |
UY28539A1 (en) | 2005-04-29 |
NO20061837L (en) | 2006-06-01 |
CN1856478B (en) | 2010-05-26 |
CN1856478A (en) | 2006-11-01 |
ZA200601501B (en) | 2007-04-25 |
JP2007506690A (en) | 2007-03-22 |
RU2006114352A (en) | 2006-08-27 |
DE10344936A1 (en) | 2005-04-21 |
MY139830A (en) | 2009-10-30 |
TW200520755A (en) | 2005-07-01 |
MEP33008A (en) | 2010-10-10 |
AR046165A1 (en) | 2005-11-30 |
NZ546158A (en) | 2008-11-28 |
EP1670766A1 (en) | 2006-06-21 |
MXPA06002927A (en) | 2006-06-14 |
RS20060194A (en) | 2008-08-07 |
ATE550327T1 (en) | 2012-04-15 |
BRPI0414594A (en) | 2006-11-07 |
IL174040A0 (en) | 2006-08-01 |
WO2005030728A1 (en) | 2005-04-07 |
RU2335494C2 (en) | 2008-10-10 |
JP4861179B2 (en) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7399770B2 (en) | Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors | |
AU2007297013B2 (en) | Isoserine derivatives for use as coagulation factor IXa inhibitors | |
US7772270B2 (en) | Imino acid derivatives as inhibitors of matrix metalloproteinases | |
CA2539731A1 (en) | Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases | |
US20100099663A1 (en) | 4-trifluoromethoxyphenoxybenzol-4'-sulfonic acids, method for the production and use thereof in medicaments | |
US7205315B2 (en) | Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases | |
CA2601357C (en) | Tetrahydrofurane derivatives for use as inhibitors of matrix metalloproteinases | |
CA2663332C (en) | Iminoimidazopyridine derivatives having antithrombotic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |